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Chapter 1
General Introduction
1.1 Respiratory disorders in children.
Children differ from adults, and have unique medical needs. It is essential to understand
that the developing child is not only undergoing alveolisation, until the age of two to
four years, and lung growth, but also embodies complex interactions of many
processes, both endogenous, such as genetic background and immune maturation,
as well as exogenous, including environmental influences and influences in utero.1-10
Furthermore, it is equally essential to comprehend that evidence-based medicine has
become the ‘gold standard’ for clinical practice and treatment guidelines.11-12 However,
this concept does not apply to an individual, but to a group of individuals with clinical
features sufficiently distinct from other groups to represent a useful clinical entity or
distinct disease phenotype.13-14 Moreover, evidence-based guidelines do not solve
their problem of inductive reasoning, as the question will always remain to which
extent results are generalisable.14 Nevertheless, disease manifestations in the
developing child, that sound or look similar, may be the expression of distinctly
different underlying mechanisms.15 Most physicians have seen children with wheeze
and/or cough, which become manifest during different time periods in childhood or
adolescence, and persist and progress, or disappear, and sometimes even relapse at
other time periods. 
Wheezing is a common symptom of respiratory disease, and is reported in no less
than 30 per cent of children during the first three years of life, with a prevalence falling
to about half in older children.13,15-16 Especially in young children, wheeze is poorly
characterised, implying a high-pitched sighing or whistling sound that is mainly heard
during expiration.13 Common accompaniments are cough and breathlessness, and
particularly during common viral respiratory tract infections, rattly sounds may mask
wheeze or may be mislabelled as wheeze.13,17 Parental misclassification of noisy
breathing in young children is widespread.18,19 Hence, wheezing phenotypes in
children are hard to classify unequivocally.
In preschool children, exclusively viral wheeze is the most common clinical
phenotype, that accounts for about two-thirds of all wheezers.13 It is characterised by
acute episodes of wheeze, cough and breathlessness in association with viral (upper)
respiratory tract infections, particularly respiratory syncytial virus, rhinovirus and
parainfluenza virus, with few or no interval symptoms.13,20-24 Many of these children
have a good prognosis since 60 per cent will have stopped wheezing by their early
school years.16 This form of transient early wheeze is not related to atopy and allergic
conditions.15 Risk factors associated with transient wheezing are maternal smoking
during pregnancy, premature birth and low birth weight.15 Reduced lung function
after birth, before any wheezing illness has occurred, may contribute to the underlying
mechanism.5,15,25-26 Furthermore, current findings suggest that respiratory syncytial
virus has a similar effect on subsequent wheeze as other confirmed viral infections,
being a mainly nonallergic condition that resolves with age.23-24,27-30 On the other
hand, a preschool persistent wheezing illness resembling classical asthma can be
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distinguished from transient viral wheeze, and is characterised by chronic interval
symptoms between episodes and often an atopic personal and family history.13
By school age, children with the atopic wheezing phenotype are most likely to
develop a chronic course, with exacerbations not only induced by viral infections, but
also by other factors, such as exercise, allergen exposure, irritants and stress.15
Children with atopic wheezing may develop significant impairment in lung function
as well as airway hyperresponsiveness.15 However, there is also a significant number
of children with the nonatopic wheezing phenotype.15 They are thought to have
symptoms triggered by viral infections alone, to lack airway hyperresponsiveness, and
to retain normal lung function in long-term follow-up studies.15,31-33
Allergic asthma is the most persistent and usually the more severe form of recurrent
wheeze, associated with immunoglobulin E-mediated immune responses to food
and/or aeroallergens.15 Most children already have their first symptoms during early
life.16,34-36 The level of allergen exposure has been fiercely discussed as a potential
determinant of the development of asthma, although this is not supported by recent
studies.15,37-39 During and after adolescence, a significant number of children lose
their symptoms, which may in part be attributable to the vanishing disease expression
of the nonatopic wheezing phenotype associated with viral infections.15 On the other
hand, new onset of illness is also seen, particularly among female adolescents and/or
associated with taking up active smoking.15,40 Persistent illness is associated with
severe atopy and airway hyperresponsiveness.15,40
The role of viral infections in exacerbating wheeze and/or inducing wheeze and
asthma-like symptoms is debated extensively.15,24 Recent observations in infants
suggest that the configuration of the immune response prior to any viral infection
determines the risk of virally induced wheeze.41 However, it is also conceivable that a
child’s increased exposure to viral infections through day care can influence the
phenotypic expression and foster a milder form of wheezing by suppressing the atopic
component.24,42-45 Each particular virus will exert an effect depending on its own
specific invasive properties, the elicited immune response, and the interacting host
factors, including genetic factors.24
The hygiene hypothesis, firstly proposed in 1989 by David Strachan, states that
infections and unhygienic contact might actually render protection against the
development of allergic illness.24,45 Interleukin-12 is a dominant mediator that may
skew the T-helper 1 to T-helper 2 balance away from allergy-promoting T-helper 2 cells
towards T-helper 1 cells.24,46 The so-called farm studies suggest that environmental
exposure in the first years of life to nonviable microbial products, such as the
evolutionarily highly conserved endotoxin from gram-negative bacteria, stimulate
immune responses in a way that protects against allergies.24,45,47-48 However, there are
conflicting data regarding the hygiene hypothesis.24,49-57 Alternatively, Holt et al have
recently proposed a theoretical maturation model for the airways (and atopic asthma),
based on common-shared genetic variations in kinetics of postnatal maturation of T-
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helper 1 competence.58 These collectively result in delayed maturation and ‘sluggish’
postnatal T-helper 1 function, and hereby increase susceptibility to both viral infection
and its subsequent spread, as well as programming T-helper 2-polarized memory
against aeroallergens.28,58-60 Nevertheless, to date a truly unifying concept has not yet
emerged, but various pieces of a complex interplay between genetic background,
immune response of the host, characteristics of the invading micro-organism, and the
level and variety of the environmental exposure become apparent.5,8-9,24
Two distinct disease entities also account for various respiratory symptoms in
childhood, in casu ‘new’ bronchopulmonary dysplasia and cystic fibrosis.
Infants with bronchopulmonary dysplasia suffer prolonged (id est more than 28
days) oxygen dependency, troublesome respiratory symptoms, lung function
abnormalities at follow-up, pulmonary and systemic hypertension, and
neurodevelopmental delay.61-63 Risk factors for the development of bronchopulmonary
dysplasia include oxygen toxicity, volutrauma and infection, as well as prematurity.61
Infants described as having ‘new’ bronchopulmonary dysplasia, have abnormal lung
growth with a markedly decreased number of alveoli, which is more prominent in ‘new’
bronchopulmonary dysplasia than the fibrosis and smooth muscle increase of medium-
sized airways as previously seen in classical bronchopulmonary dysplasia.61,64-66
Cystic fibrosis is the most common life-limiting recessive genetic multisystem
disease in Caucasians, caused by a defect in the cystic fibrosis transmembrane
conductance regulator gene.67-70 The phenotype of typical cystic fibrosis includes the
well-known respiratory manifestations, but the hallmark is pancreatic insufficiency.67,69
Diagnosis is established in the majority of patients by one year of age, but in eight
percent not until after ten years of age.69,71 Often, the problem is remembering to do
the sweat test.67,72 Although newborn screening becomes more widely introduced, it
does not preclude the need to consider cystic fibrosis in many differential
diagnoses,67,73-74 and the difficulty will be classifying and/or diagnosing patients with
atypical, difficult, subclinical or pre-cystic fibrosis.67,75-77
There are less frequent or even rare but specific disorders, such as congenital
airway disorders, obliterative bronchiolitis and primary ciliary dyskinesia, that may also
have a wheezy component. However, they fall beyond the scope of this general
introduction. 
Finally, overlap or coincidental occurrence of two independent disorders in an
individual creates a wide potential spectrum and at the same time it creates the sort
of uncertainty that makes clinical paediatric medicine such a challenge.13
1.2 Chronic respiratory inflammation in children.
Having explored to some extent a wide clinical diversity of respiratory disorders from
infancy to adolescence, and having designated their complex and multi-dimensional
nature, comprising at least the affected phenotype, time, environment and genetic
13
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susceptibility, it now seems appropriate to attempt to address the featuring phenotypes
of chronic respiratory inflammation in children. 
Asthma is characterised by a variable degree of airflow obstruction, bronchial
hyperresponsiveness, and airway inflammation.78 At autopsy, patients with fatal
asthma have shown a cellular infiltrate of neutrophils and eosinophils, degranulated
mast cells, reticular basement membrane thickening, loss of epithelial cell integrity,
occlusion of the bronchial lumen by mucus, and hyperplasia and hypertrophy of
bronchial smooth muscle and hyperplasia of goblet cells.78 In patients with mild to
moderate asthma, infiltration by lymphocytes and eosinophils can occur throughout
the central and peripheral airways, often varying with disease severity.78 In airways,
resident mast cells, macrophages and epithelial cells, and recruited inflammatory cells
generate chemotactic chemokines and cytokines, which activate transcription factors,
such as nuclear factor-κB, that bind to the promoter region of genes that encode
inflammatory cytokines, chemokines, adhesion molecules and other proteins that
induce and perpetuate inflammation.78-79
To initiate immunoglobulin E-mediated inflammation in allergic asthma, inhaled
allergens must encounter dendritic cells that line the airways and then migrate to
draining lymph nodes, where they present processed antigen to T and B cells.78,80
Interactions among these cells elicit responses that are influenced by cytokines. T-
helper 2-mediated interleukin-4 and interleukin-13 promote B cells to switch to
synthesise, and to release specific immunoglobulin E.24,78,81 This immunoglobulin
binds to high-affinity immunoglobulin E receptors on the surface of mast cells in tissue
or peripheral-blood basophils, and to low-affinity immunoglobulin E receptors on the
surface of lymphocytes, eosinophils, platelets and macrophages.24,78,81 Subsequently
inhaled allergen interacts with receptor-bound immunoglobulin E (cross-linking), and
causes activation of the cell membrane and cytosolic pathways of mast cells and T-
helper 2 cells in the airways.78,82-83 This causes the release of preformed mediators
such as histamine, and initiates the synthesis of arachidonic acid metabolites and T-
helper 2 cytokines, including interleukin-4 and interleukin-5.78,82-83
However in childhood asthma, data from mucosal biopsy studies and
bronchoalveolar lavage studies are inconsistent and often not in accordance with
studies in adults.84 In fact, the presence and nature of airway inflammation in common
clinical expressions of childhood asthma is largely unknown, and it is quite likely that
it differs considerably from the findings in adults.84 The only really consistent finding
is thickening of the reticular basement membrane, a key feature of airway wall
remodelling, which was observed in almost all biopsy studies, even in young
children.60,84-95 It is not clear whether these structural changes precede, or occur early
and in parallel with, or develop as a result of airway inflammation.60,89,93,95-97
Nevertheless, interference with normal airway growth and lung development at
crucial time periods may have particularly long-term effects and cannot be
overstated.93,98
14
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Inhaled corticosteroids have become the cornerstone of maintenance therapy in
childhood asthma, although it is not clear at what point such treatment should begin
and indeed whether anti-inflammatory therapy can influence the natural course of the
disease.32,78,84,99-108 A further complication is the fact that, idealised asthma guidelines
do not reflect the reality of individual asthma management.84,109-116
There is good evidence to show that preschool children with exclusively viral-
triggered wheeze do not have chronic eosinophilic airway inflammation, and that
during an acute viral-triggered attack, neutrophilic inflammation predominates.13,117-
121 However, a minority of preschool wheezers have eosinophilic airways inflammation
between viral-triggered attacks.13,122-126 On the other hand, it is possible that
exclusively viral wheeze is atopic asthma but without the propensity to develop
chronic inflammation.13,127-128 Furthermore, it currently remains unclear whether
respiratory syncytial virus infections directly damage the infant’s respiratory system and
promote the development of later recurrent wheezing, or if bronchiolitis unmasks
some inherent susceptibility or pre-existing lung function abnormalities, or even
both.23 The T-helper 1 to T-helper 2 paradigm is not necessarily followed,23,129-133 and
it is plausible that small infants with a less mature immune response are unable to
mount a strong antiviral T-helper 1 response, making them most vulnerable to severe
disease.58-59,134
In bronchopulmonary dysplasia, neutrophilic lung inflammation is a key
feature.61,135-136 The inflammatory phase may commence antenatally, with infection
being the most likely initiator.137 Alveolar macrophages appear to mediate resolution
of the acute lung injury, and are likely responsible for dysregulated lung growth, as
they release growth factors.61 Alternatively, the capillary network may fail to expand,
as vascular endothelial growth factor is significantly decreased in bronchopulmonary
dysplasia.138
In cystic fibrosis, there is no dispute that the two main components of airway
disease are chronic infection and an exuberant host inflammatory response.67 What
is not clear is their relationship.67,139-145 New data are strongly suggestive that the
dysregulated inflammatory response in cystic fibrosis is not related to the underlying
cystic fibrosis transmembrane conductance regulator defect, but is a secondary
response to prolonged and chronic infection.146-147 It would seem likely that early on
in cystic fibrosis, the inflammatory response is beneficial and wards off early infection
with Pseudomonas aeruginosa, but that in late-stage cystic fibrosis, it is clearly both
ineffectual and harmful.67 What is not known is when the transition to harm occurs,
which is important, as steroids are definitely beneficial in late disease, but may not be
helpful early on.67,148 Moreover, it is also not clear why there is persistent acute
(neutrophilic), rather than chronic infection in the cystic fibrosis airway.67
In summary, common respiratory symptoms, such as wheezing, coughing,
shortness of breath, chest tightness and fatigue, in the developing child, with its
specific genetic background, and undergoing alveolisation, lung growth, immune
15
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maturation as well as environmental influences, may be attributed to different
pulmonary diseases, ranging from transient viral wheeze to life-limiting cystic fibrosis,
all featuring some phenotype of respiratory inflammation. Although our theoretical
and clinical knowledge is increasing, and several global concepts or hypotheses have
been proposed, many questions still remain unanswered and await disentanglement.
The practical need for tailored individual monitoring of the natural course of disease
or response to treatment, as well as the need for accurate, objective and early
assessment of respiratory inflammation, in little or non-cooperative children is obvious. 
1.3 Assessment of chronic respiratory disease in children. 
The key question is how to identify those children with an underlying disease and
separate them from the large group of children with benign and self-limiting
problems.149
Medical advice often relies on gathered information on symptoms and quality of
life as perceived by the child or her/his parents. Each physician should balance, on one
hand, his own professional findings and misunderstandings, and, on the other hand,
potential parental or patient’s misclassification of noisy breathing, mismatched
prevalence of symptoms, poor adherence to treatment, and perception of quality of
life and disease control.18-19,84,109-110,113,150-159 Also, disease outcomes are influenced
by emotional characteristics, disease management behaviours and psychological
factors.160 It has become obvious that poor disease control is not only a problem of
education, both for patients and providers, but also a problem of mutual
communication between patients and providers.84,110,113
Pulmonary function tests, mainly spirometry, are generally considered the standard
criterion for objective assessment of paediatric lung disease.99-100,149,161 The poor
cooperation of children under six years of age in performing the required manoeuvres
has limited lung function evaluation.149 In the ‘cooperative’ child (id est more than six
years old) spirometry is the most used pulmonary function test, as, in these children,
it is relatively not difficult to perform and it is repeatable.84,149 Paediatric guidelines
have recently been published.162 In asthmatic children, spirometric parameters detect
airflow limitation and help to diagnose and monitor the disease.107 Forced expiratory
volume in one second is the most reliable spirometric parameter and is used, along
with symptom frequency and medication usage, to classify the severity of airway
disease.108 However, asthma is a condition with intermittent airway obstruction, and
in 5 to 18 year old asthmatic children forced expiratory volume in one second is
generally normal, which does not exclude disease, however.149,152,163-164 Whereas
guidelines recommend that the monitoring of asthma should be based on symptoms
and lung function tests, often insufficient attention has been paid to the underlying
airway inflammation.84 Additional markers of airway inflammation may be helpful to
improve disease outcome.84,165-166
The main pathological factors that underlie bronchial hyperreactivity are
presumably airway inflammation and bronchial remodeling.149,167 Guidelines for
16
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bronchial challenge tests have been published.168-169 However, the relationship
between bronchial hyperreactivity and asthma is complex in children. While asthmatic
children have bronchial hyperreactivity, bronchial hyperreactivity is not the same as
asthma.149,170 It has also been reported in children with cystic fibrosis, allergic rhinitis
and even in asymptomatic children.171 Indirect stimuli, such as exercise and cold air,
correlate better with airway inflammation than direct stimuli, such as metacholine and
histamine.167-168,172 Bronchial hyperreactivity may be important in difficult cases: a
direct challenge will be very helpful in ruling out asthma (when negative), while it will
not be able to confirm it (when positive), and conversely, an indirect challenge will be
more helpful in confirming a diagnosis of asthma (when positive), than ruling it out
(when negative).167
Sputum induction may directly assess airway inflammation in children.173 It implies
a semi-invasive induction procedure through inhalation of an ultrasonic aerosol of
hypertonic saline, and allows examination of the cellular and soluble content.174-176
Although methodological guidelines have been published, a wide variety of sputum
induction and processing protocols have been used.175,177-180 In children, reported
side-effects include not only minor symptoms and discomfort in 6 to 26 per cent, but
also airway obstruction, even after beta-2-agonist-pretreatment, in 10 and 19 per
cent, respectively, of children with mild and severe disease.173,175,181-187 In children, the
reported success rate depends on disease severity and age (id est few children aged
less than seven years), and varies from 61 to 100 per cent.166,173,175,181-185,188-189 All
studies report high requirements for technical support and expertise to process, stain
and interpret induced sputum samples, hereby limiting its use to tertiary centers.176 In
asthmatic children, sputum induction can provide information on eosinophilic
inflammation and treatment response and is associated with several measures of
asthma control.166,173,190-192 In children with difficult asthma, abnormal sputum
cytology is only present in a minority, whereas it has been suggested recently that
sputum eosinophilia in these children may predict their response to systemic
corticosteroids.181,193 Also, in children with cystic fibrosis, limited data suggest that
induced sputum may provide useful markers of inflammation and infection.192,194-197
To date, endobronchial biopsy remains the ‘golden standard’ by which to determine
airway inflammation. This invasive diagnostic procedure is safe, even in children with
severe asthma, if it is performed by experienced operators with back-up from doctors
skilled in airway management and the monitoring of sick children.93,198-202 Moreover,
there is no reason not to use the opportunities afforded by clinically indicated
bronchoscopy to carry out research, if sound ethical principles are followed.89,93,95,203-
205 However, bronchoscopy has considerable limitations: (i) it is an invasive procedure
for specific indications only and not suitable for repeated use;199,201 (ii) data are lacking
on the reproducibility of several parameters in children;206 (iii) specimens are small and
vulnerable to damage during the biopsy procedure, and can only be obtained from
the larger airways; and (iv) many physiological, infectious and mechanical
complications are associated with the procedure.174,198,201,207-208
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During bronchoscopy, bronchoalveolar lavage fluid can be obtained for microbiological
and cytological analysis.93,117,201,209 However, there are many difficulties in the
interpretation of findings: (i) bronchoalveolar lavage does not sample a static space or
volume of airway surface fluid, as there is a constant exchange of fluid, electrolytes
and other soluble constituents across the airway and alveolar epithelium, and as there
is no practical way to obtain a pure bronchial or alveolar fraction; (ii) the concentration
of any material or cell type in the bronchoalveolar lavage fluid depends on the volume
of fluid used for the lavage, the efficiency of mixing and recovery (id est usually 40 to
60 per cent fluid return), the initial concentration in the epithelial lining fluid, and the
rate of flux of the material or fluid into the bronchoalveolar lavage fluid during the
procedure; and (iii) available normal values are poly-interpretable.174
In summary, it may be clear that there exist many limitations of, and discrepancies
between: (i) subjectively reported and objectively assessed airway symptoms; (ii)
pulmonary function tests reflecting airflow limitation; and (iii) direct or indirect markers
of airway inflammation. Moreover, endobronchial biopsy, bronchoalveolar lavage and
sputum induction are relatively difficult direct measures of inflammation and not
suitable for routine use in clinical practice, whereas it should be stressed again that
these are highly valuable basic and clinical research tools.84 Obviously, pulmonary
function tests and sputum induction require more than minimal cooperation of a child,
and thus, success rate substantially declines in children aged six to seven years or less.
In general, procedures in favour of children should be suitable at any age, rapid and
easy to perform, requiring only minimal cooperation, as well as harmless and painless,
and thus, by definition, should never be invasive or semi-invasive. Furthermore, as there
is such heterogeneity in chronic respiratory disease expression, it seems only logical
that: (i) noninvasive specific single markers, indicating diagnosis, disease control and
airway inflammation, have to be assessed at an individual level; and that (ii) if generally
applied, a set of various markers is more likely to be useful in larger populations.84,116,210
Hence, the leitmotif being the development of novel individualised therapeutical
strategies that may replace the current paradigm of strategies aimed at the whole of
a certain population.84 Therefore, it is crucial to attempt to define additional noninvasive
markers that can be applied in clinical practice over a wide range, that may be specific
for the evaluation and monitoring of certain disease patterns, including early disease
events, and/or response to treatment, and that may give relevant information on the
individual child.84,149,211
1.4 Noninvasive inflammometry in children.
Having explored, in the previous chapter, the various reasons why there is a need for
additional noninvasive markers of various phenomena associated with chronic
respiratory diseases, especially in the growing child, we will now explore some
possibilities that may address this issue. Ideally, we need a noninvasive, rapid and easy
to perform method that can be used repeatedly to obtain direct samples of the
airways without any risk, that is standardised and successful at any age, that requires
no cooperation, and that offers direct measures that are not only sensitive and specific
but also reproducible.212 Clearly, such a well-defined ideal does not exist in the realities
18
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of life. Nevertheless, we may unremittingly pursue amelioration, while learning from
the past. When Antoine Laurent de Lavoisier published in Paris his ‘Traité Elémentaire
de Chimie’ in 1789, not only the French Revolution was imminent, but also modern
chemistry was born by demonstrating that air is not a simple element but actually a
composite.213 This principle is the basis of this thesis. Indeed, exhaled air or breath
potentially has many advantages that approximate the characteristics of an ideal
marker of the airways. Analysis of exhaled air shows the presence of volatile
substances, such as nitric oxide.207,212 Furthermore, exhalation against a cold surface
or condenser yields exhaled breath condensate (EBC) that in turn may be collected
and analysed for volatile and nonvolatile macromolecules.212,214
Nitric oxide, biosynthesised from arginine and oxygen by various nitric oxide
synthase enzymes, is now known as a widespread signalling molecule in various organ
systems. In 1987, Salvador Moncada (married to Her Royal Highness Princess Maria-
Esmeralda of Belgium) et al showed unambiguously that nitric oxide was made by
endothelial cells and that the actions of nitric oxide (id est full relaxant response of
blood vessels) could explain the actions of the formerly known endothelium-derived
relaxing factor.215 In 1991, Lars Gustafsson et al first described the presence of
endogenous nitric oxide in exhaled breath of animals and humans.216 In 1998, Robert
F Furchgott, Louis J Ignarro and Ferid Murad were jointly awarded the Nobel Prize in
Physiology or Medicine for their discoveries concerning nitric oxide as a signalling
molecule of the cardiovascular system.217
Since the 1990s, the exhaled nitric oxide fraction has been extensively studied and
validated as a noninvasive marker in asthma that reflects eosinophilic airway
inflammation in the bronchial mucosa and shows a rapid, dose-dependent response
to corticosteroids.149,207,212,218 Exhaled nitric oxide has been standardised for use in
clinical practice, and there are detailed guidelines for the online and offline
measurement of exhaled nitric oxide in children aged four to five years and more.219-
220 Normative values have been published for children aged four years and more.221
In these cooperative children, the single-breath online measurement method using a
chemiluminescence analyser is the preferred technique.149,219-220 Results are
immediately available.149 Recently, compact hand-held analysers have been developed
and will facilitate more widespread introduction.149 Possible applications of exhaled
nitric oxide inflammometry include diagnosis of asthma, prediction of steroid response,
monitoring of steroid treatment and treatment compliance, steroid dose titration,
prediction of exacerbation or relapse, and screening for asthma.149,207,212,222 Recently,
several studies have shown not only the feasibility of exhaled nitric oxide measurement
in paediatric clinical practice, but also suggested a significant benefit of additionally
monitoring exhaled nitric oxide in childhood asthma, as treatment with inhaled
corticosteroids can be adjusted individually to prevent under- or over-treatment.207,223-
226 In children and adolescents, elevated exhaled nitric oxide has been shown to
correlate well with induced sputum eosinophil counts,219,227-229 but not with bronchial
hyperrresponsiveness.229-231 However, in adolescents in clinical remission of atopic
asthma, exhaled nitric oxide and airway responsiveness were significantly correlated
19
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with each other, as well as with eosinophil counts in bronchial biopsies.85,232 Also, in
children with difficult asthma, after treatment with oral steroids, a correlation was
seen between biopsy eosinophil score and exhaled nitric oxide.233
On the other hand in infants and preschool children, although suggestions for the
measurement of exhaled nitric oxide have been published, more research is needed
to resolve various confounding methodological issues related to spontaneous
breathing with or without controlled flow rate, contamination from the upper airways,
and forced exhalation.149,219-220,234-245
Various other diseases have been associated with high exhaled nitric oxide
values,246-258 variable exhaled nitric oxide values,259-275 and low levels of exhaled nitric
oxide.276-288 In children with cystic fibrosis, low exhaled nitric oxide levels may be
explained by deficient or reduced inducible nitric oxide synthase expression, and/or by
trapping and metabolisation of nitric oxide in airways secretions and mucus.278-282,289
Children with primary ciliary dyskinesia, characterized by chronic airway infection and
bronchiectasis due to a genetic defect leading to reduced ciliary function and impaired
mucociliary clearance, have not only abnormally low exhaled nitric oxide values, but
also low nasal nitric oxide that is even more discriminative and is now recommended
as the screening tool of choice for primary ciliary dyskinesia.149,219,290
EBC represents a bi-phasic technique, implicating at first the cooling of exhaled
breath to collect the condensate, and subsequently its analysis.212 There is strong
evidence that abnormalities in EBC composition may reflect biochemical changes of
the airway lining fluid, and thus may constitute an alternative approach for noninvasive
inflammometry.214
Although the EBC procedure is experimental, the guiding and cooling of exhaled
breath into a breath condenser system appears to be noninvasive, rapid and relatively
easy to perform, as well as being a technique that may be used repeatedly as it does
not interact with the ongoing processes in the airways, which, by consequence, may
guarantee a high degree of safety to the subjected individual.
Moreover, the bi-phasic nature of the EBC technique may even offer some
advantages compared with exhaled nitric oxide: (i) the collection of EBC requires only
minimal cooperation of a normal (id est tidal) breathing subject; (ii) therefore, the
potential to improve the feasibility of EBC collection, especially in the younger child;
(iii) the analysis of EBC may reveal the presence of multiple biomarkers, instead of only
one specific volatile substance; and (iv) hence, EBC analysis may prove to be useful in
discriminating and/or monitoring more than one inflammatory lung disease.
1.5 Objectives of the thesis.
As stated previously, this thesis is based on the principle that air is a composite, and
hence, analysis of breath condensate may offer new perspectives in monitoring lung
inflammation.213 In this thesis, we hypothesise that the noninvasive methodology of
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EBC collection and analysis can be improved and adapted based on objective
experimental findings, in order to evolve from a simple home made experimental
research tool into a new and potentially useful means of assessing inflammatory
disease status, especially in preschool children with chronic respiratory disorders. By
consequence, the scope of this thesis is the further development of EBC methodology.
In chapter 1.6 we present a state of the art on the collection and analysis of EBC
in children, corresponding to our knowledge in the early years of the new millennium. 
In order to facilitate future comparison and interpretation of data on this rapidly
growing field of research, we proceed in chapter 2 with an elaboration, from a
paediatric point of view, of the pearls and pitfalls of each single aspect of EBC
collection and preservation, and, of the markers that yet have been detected in
condensate in children. 
In chapter 3 we compare new exhaled markers, comprising exhaled nitric oxide,
exhaled carbon monoxide, condensate acidity, and cytokines in EBC, with conventional
asthma measures, such as lung function parameters and the asthma control
questionnaire of Juniper, in a cross sectional study in 32 children. 
Triggered by the previous study results, we discuss in chapter 4.1 our increasing
awareness of the confounding factors due to the bi-phasic nature of EBC methodology
(id est standardisation of collection versus reproducibility of analysis). Consequently,
this leads us to proceed with research that intends to integrate more consistently the
following three equivalent key issues: (i) engineering of an optimal condensate
collection device, (ii) using improved or new techniques suitable to analyse the
resulting condensate, and (iii) clinical application in subsets of patients with chronic
respiratory disease. 
In chapter 4.2 we investigate, both in vitro and in vivo, our hypothesis that the
adhesive properties of different condenser coatings interfere with the detection and
measurements of eicosanoids and proteins in EBC, as this may prove to be a crucial
factor to the further development of a standardised condensate collection system.
In chapter 5 we study the reproducibility of different condensate markers, such as
hydrogen peroxide, 8-isoprostane, and cytokines, using different condenser coating
systems, including a newly developed glass condenser, in order to find a more reliable
condenser. Furthermore, we describe the use of xMAP® technology, a liquid bead
array multiplexing system to simultaneously measure multiple cytokines within a small,
single condensate sample.
In chapter 6 we investigate the use of electron paramagnetic resonance
spectroscopy to directly detect the presence of free radicals, and thus directly assessing
oxidative stress, in EBC in 21 children with cystic fibrosis and healthy controls. Secondly,
we examine the possible source of these free radicals.
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In chapter 7 we explore, in a cross sectional design, the ability of exhaled inflammatory
markers, including exhaled nitric oxide, condensate acidity, nitrite, nitrate, hydrogen
peroxide, 8-isoprostane, interferon-gamma, tumor necrosis factor-alpha, interleukin-
2, interleukin-4, interleukin-5 and interleukin-10 in EBC, to discriminate between
cystic fibrosis and healthy controls, and to indicate disease exacerbation and severity,
in a large cohort of 98 children. 
In chapter 8 we investigate the feasibility of EBC collection in 70 preschool children,
with and without wheezing illness, using a newly modified glass condenser system with
breath recirculation system. Furthermore, we study the profiles of interleukin-4,
interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-12p70, interleukin-
13, and tumor necrosis factor-alpha in EBC, measured by multiplexed xMAP® technology,
in different preschool wheezing phenotypes.
Finally, in chapter 9 we present the general discussion of this thesis.
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1.6 New perspectives in monitoring lung inflammation: analysis of
exhaled breath condensate in children.
Airway inflammation plays an important role in various respiratory disorders of
childhood, including recurrent wheezing, asthma, cystic fibrosis, bronchopulmonary
dysplasia, and respiratory distress syndrome.291-294 In daily clinical practice, indirect
indices of airway inflammation like symptoms and lung function measurements are
routinely used for diagnosis and follow-up of inflammatory respiratory disorders.
Especially in young children, these indirect indices of disease severity are less valuable
than in adults; lung function studies in young children are often not possible because
of lack of cooperation. Furthermore, reporting of symptoms by parents is much
dependent on perception of symptoms with the potential risk for both under or
overperception. Therefore in children, there is a strong need for objective and early
criteria to detect and monitor airway inflammation in order to prevent or minimize the
irreversible changes which are described in various chronic respiratory disorders
including asthma, cystic fibrosis and bronchopulmonary dysplasia.291-295 The analysis
of airway inflammatory cells and mediators has traditionally been performed by
bronchoscopy on samples of bronchial mucosal biopsies or on bronchoalveolar lavage
fluid samples. In children both methods are limited in their applicability because of the
invasive procedure of bronchoscopy. It is clear that in daily clinical practice, (serial)
measurements of airway inflammation is not feasible using such invasive methods. A
less invasive procedure to assess the presence and activity of airway inflammation
would be of great benefit for early diagnosis and monitoring of inflammatory airway
diseases in children.296
Inflammatory markers can be measured in blood or in urine.296 The noninvasiveness
of these methods is an advantage, but their indirect nature is a limitation.
Measurements of certain inflammatory markers in blood and urine represents whole
body production and does not necessarily reflect production of these inflammatory
markers in the respiratory tract. It is reasonable to assume that the composition of
respiratory tract secretions might closer reflect airway inflammation than substances
in blood or urine. Sputum is one of the respiratory secretions which can be used in
the assessment of airway inflammation.297-298 Sputum can be obtained noninvasively,
spontaneously or during chest physiotherapy. Sputum examination has been limited
by difficulties in obtaining adequate samples. When sputum can not be produced
spontaneously, it can be induced by inhalation of an aerosol of hypertonic saline. With
this technique, sputum samples can be obtained in up to 75 to 100 per cent of
asthmatic and healthy adults.298 In children, the succes rate in obtaining adequate
samples is definitely lower.188 In general sputum induction in children aged less than
6 years is not feasible. Other practical considerations of sputum induction include an
inevitability of pretreatment with short acting beta-2-agonists in order to prevent an
obstructive airway response provoked by inhalation of hypertonic saline, and the time-
consuming procedure for inducing sputum and processing induced sputum samples.
Furthermore, several studies have shown that repeated sputum induction in itself
induces changes in airway inflammation within 8 to 24 hours after sputum induction,
which limits the usefulness of this method for serial measurements.299-300
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EBC is a recently rediscovered vehicle of substances from the respiratory tract, in which
several potential markers of airway inflammation can be detected. In contrast with the
other sampling methods mentioned above, EBC offers the advantage that it can be
obtained completely noninvasively. Exhaled air carries components from the lower
respiratory airways, and does not disturb the airways, in contrast to bronchial biopsies,
bronchoalveolar lavage and induced sputum, and it can be obtained with minimal risk
and inconvenience from both adults and children.
1.6.1 Collection of EBC in children
In children from the age of 4 years and over the EBC collection method(s) as used in
adults, can be applied in almost the same way. There is a variety of condensor systems
to collect EBC, altough they are fundamentally similar, based on condensation of
exhaled air on a cold surface. In general, EBC is collected from adults and children
from the age of 4 years by tidal breathing through a mouthpiece and a two-way
nonrebreathing valve, which can also serve as a saliva trap, connected to a cooled
condensing system. Minimal co-operation from the child is required for this technique
of EBC collection. In children, the main issue for success of EBC sampling is if they are
able to use a mouthpiece properly for approximatly 10 to 15 minutes. Adequate
instruction of the procedure and distraction of the child, for example by using video
cartoons, increases the success rate of EBC collection in children. Collecting EBC in
children is not only a simple non-invasive procedure, but it is also a safe and feasible
method of sampling substances from the respiratory tract. No adverse effects were
seen in an EBC collection study in 93 healthy children aged 8 to 13 years, and all the
children were able to complete the EBC collection procedure successfully.301 In a study
of 91 children with asthma of varying severity, the EBC procedure proved to be safe
even in children with an asthma exacerbation.302 No significant changes in forced
expiratory volume in one second were found after the EBC collection. The success rate
was 100 per cent starting from 4 years of age. The volume of collected condensate
depends on different variables, like minute ventilation or total respired volume,
condensor material and temperature, and turbulence characteristics.303 Minute
ventilation seems to be the most important determinant of the condensate volume
over time. So, in children it will take more time to collect the same amount of
condensate as in adults. In general, a collection time of 15 to 20 minutes will yield 1
to 3 mL of EBC in children aged 4 years and over. It has been shown that the collected
condensate volume significantly correlates with the age of children.302
In infants and young children, who are not able to use a mouthpiece properly, a
facemask can be used. In a small number of infants, who are preferential nasal
breathers, it was shown that collection of EBC through a facemask was feasible.304-
305 In a sampling time of almost 30 minutes a mean condensate volume of 101.6 µL
was recovered.304 In the condensate of healthy infants and cystic fibrosis infants nitrite
and nitrate was detected. However, significant nasal contribution to the total nitrite
to nitrate was found, suggesting to limit EBC analysis in infants to compounds not
affected by nasal contribution, or to limit EBC collection to sedated infants with
induced oral breathing.305
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Nasal collection of EBC is reported in minimal co-operative patients like healthy infants
from 4 weeks of age for the analysis of hydrogen peroxide.306 Nasal prongs are serially
connected to two polypropylene tubes, submerged in a cold trap, and in turn
connected to an electric air suction pump. The condensate volume obtained, increased
significantly with age, up to 18 years, and was about 45 per cent less in 1 to 6 year
old children. It averaged about 20 to 30 per cent of the exhaled breath water vapour.
However, contamination with nasal secretions may interfere with the actual
concentration of inflammatory mediators in the lower respiratory tract.
1.6.2 Inflammatory mediators detected in EBC of children
EBC is presently an active research area. Over the last years an increasing number of
EBC data are being presented. However, most data are obtained in adults. For the
results of inflammatory mediators in EBC of children we will focus on data published
in the international literature as peer-reviewed full articles. 
A variety of inflammatory markers have been detected in EBC of children. In
contrast to the condensate volume, the studied inflammatory marker levels in EBC are
not age dependent.
The most commonly studied mediator is hydrogen peroxide, a marker of oxidative
stress. The concentration of hydrogen peroxide in EBC of stable asthmatic children is
significantly increased compared to healthy children.307 In stable asthmatic children the
hydrogen peroxide concentrations were lower in those who used inhaled corticosteroids.
In children with unstable asthma higher concentrations have been reported than in
stable asthmatic children.308 Reference values on hydrogen peroxide have been described
in a group of 93 healthy children with a mean age of 10 years.301 Hydrogen peroxide
was not age-dependent, nor was there a correlation with sex or lung function.301 In
children, it was demonstrated that atmospheric nitric oxide influenced exhaled hydrogen
peroxide levels.309 Besides asthma, hydrogen peroxide concentration has also been
detected in EBC of cystic fibrosis children with an acute infectious pulmonary
exacerbation, and significantly decreased during intravenous antbiotic treatment.310
Another marker of oxidative stress which can be measered in the EBC of children
is 8-isoprostane. Children with stable asthma had higher exhaled 8-isoprostane
concentrations than healthy children.311 In the asthmatic group, treatment with
inhaled corticosteroids showed no difference in exhaled 8-isoprostane concentrations.
The same study also showed, in contrast to the 8-isoprostane results, no significant
difference in exhaled prostaglandin E2 concentrations between asthmatic and healthy
children. In children with an asthma exacerbation there is a significant reduction of
exhaled 8-isoprostane after a 5 day course of oral prednisone.312
Leukotrienes can also be measured in EBC. In asthmatic children cysteinyl
leukotrienes and leukotriene B4 were significantly increased compared with healthy
children.313 After a course of oral corticosteroid therapy, a reduction was seen in
cysteinyl-leukotrienes in children with an asthma exacerbation.312
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In children with asthma and cystic fibrosis higher levels of nitrite in EBC have been
found compared to children with non-asthmatic episodic cough and healthy
children.314 No significant differences were noted between the asthmatic and cystic
fibrosis children, nor the episodic cough and healthy groups. In cystic fibrosis, there
was no significant correlation between condensate nitrite levels and age, lung function
or use of inhaled corticosteroids.315 Children with primary ciliary dyskinesia have been
shown to have very low levels of exhaled oral and nasal nitric oxide.283 However, no
differences were found in the EBC levels of nitric oxide metabolites such as nitrite,
nitrate, and S-nitrosothiol between children with primary ciliary dyskinesia and healthy
children, despite the marked decrease in exhaled nitric oxide levels in primary ciliary
dyskinesia patients.316
Cytokines reported in EBC of children include interleukin-8, interleukin-4 and
interferon-gamma. In cystic fibrosis, interleukin-8 could only be detected in 33 per
cent of the condensate samples.315 Altough the interleukin-8 values were higher in
cystic fibrosis children than in healthy controls, there was no statistically significant
difference. Increased levels of interleukin-4 and decreased levels of interferon-gamma
were detected in EBC of stable asthmatic children.317 The use of inhaled corticosteroids
was associated with a significant change in interleukin-4 concentration, in contrast to
interferon-gamma concentration. Interferon-gamma was detectable in all EBC
samples, whereas interleukin-4 was detectable in 92 per cent of the samples.
Aldehydes and glutathione are biomarkers of oxidant induced damage and
antioxidant status, respectively. Malondialdehyde and glutathione are detectable in EBC
of children.318 In children with an asthma exacerbation, malondialdehyde levels were
higher and glutathione levels were lower compared to healthy children.318 After a 5 day
course of oral prednisone malondialdehyde decraesed to values no longer different from
those of the healthy control children, whereas glutathione levels increased. In healthy
subjects as well as in asthmatic children, malondialdehyde and glutathione were negatively
correlated. Malondialdehyde and glutathione concentrations were not dependent of
exhaled flow rate (200, 150, 100, and 50 mL/second), and no correlation was found
between spirometric values and these oxidant versus antoxidant levels in EBC. 
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Table 1 summarizes paediatric results of inflammatory markers in EBC of children
with asthma or cystic fibrosis. 
1.6.3 Conclusion
Assesment of inflammatory mediators in EBC is a challenging new technique for the
diagnosis and management of various inflammatory lung diseases. Because of the
non-invasive character of EBC and the general lack of appropiate other techniques  to
characterize airway inflammation in children, it is particularly interesting for paediatric
respiratory medicine. EBC is not only a simple and noninvasive procedure, but it is also
a safe and feasible method of sampling inflammatory mediators from the respiratory
tract in children from the age of 4 years and over. A variety of inflammatory markers
have been detected in EBC of children. Potentially, this noninvasive method will allow
early and appropriate anti-inflammatory treatment in children, which hopefully will
prevent, or at least limit, the later development of chronic respiratory diseases in
adults. However, the clinical relevance of exhaled inflammatory markers first needs to
be established in longitudinal studies in various respiratory disorders, with repeated
measurements in individual patients.
27
General Introduction
Table 1. Inflammatory markers in EBC of children with asthma or cystic fibrosis
Asthma Cystic Fibrosis References
hydrogen peroxide ⇑ ⇑ 307, 308, 310
8-isoprostane ⇑ (-) 311, 312
prostaglandin E2 = (-) 311
cysteinyl leukotrienes ⇑ (-) 312, 313
leukotriene B4 ⇑ (-) 313
nitrite ⇑ ⇑ 314, 315
interleukin-4 ⇑ (-) 317
interleukin-8 (-) = 315
interferon-gamma ⇓ (-) 317
aldehyde ⇑ (-) 318
glutathione ⇓ (-) 318
EBC exhaled breath condensate
⇑ significantly increased compared to healthy children
⇓ significantly decreased compared to healthy children
= no significant difference compared to healthy children
(-) no paediatric data
28
Chapter 1
References
1. Merkus PJFM, Hislop AA. Lung development from infancy to adulthood. In: Frey U,
Gerritsen J, eds. Respiratory diseases in infants and children. Eur Respir Mon 2006;
37: 8-21.
2. Hislop A, Wigglesworth JS, Desai R. Alveolar development in the human fetus and
infant. Early Hum Dev 1986; 13: 1-11.
3. Mead J. Dysanapsis in normal lungs assessed by the relationship between maximal
flow, static recoil, and vital capacity. Am Rev Respir Dis 1980; 121: 339-342.
4. LeSouëf P, Kabesch M. Impact of genetic factors on lung development in health and
disease. In: Frey U, Gerritsen J, eds. Respiratory diseases in infants and children. Eur
Respir Mon 2006; 37: 93-107.
5. Gerritsen J, Reijmerink NE, Kerkhof M, Postma DS. Gene-environment interaction
and respiratory disease in children. In: Frey U, Gerritsen J, eds. Respiratory diseases
in infants and children. Eur Respir Mon 2006; 37: 108-119.
6. Darwin C. On the origin of species by means of natural selection, or the preservation
of favoured races in the struggle for life. London, John Murray, ed., 1859.
7. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome
integrates intrinsic and environmental signals. Nat Genet 2003; 33: 245-254.
8. Schaub B, Lauener R, Prescott SL. Immunology and defence mechanism of the
developing lung. In: Frey U, Gerritsen J, eds. Respiratory diseases in infants and
children. Eur Respir Mon 2006; 37: 60-78.
9. Custovic A, Lødrup Carlsen KC, Håkon Carlsen K. Allergy and the paediatric lung
during development. In: Frey U, Gerritsen J, eds. Respiratory diseases in infants and
children. Eur Respir Mon 2006; 37: 79-92.
10. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
11. Cochrane AL. Effectiveness and efficiency: random reflections on Health services.
London 1972, Nuffield Provincial Hospitals Trust.
12. Centre for Evidence-Based Medicine. What is EBM? www.cebm.net/?o=1014. Date
last accessed: May 28 2007.
13. Grigg J, Silverman M. Wheezing disorders in young children: one disease or several
phenotypes? In: Frey U, Gerritsen J, eds. Respiratory diseases in infants and children.
Eur Respir Mon 2006; 37: 153-169.
14. Tonelli MR. The limits of evidence-based medicine. Respir Care 2001; 46: 1435-1440.
15. von Mutius E. Epidemiology of respiratory diseases in infants and children. In: Frey
U, Gerritsen J, eds. Respiratory diseases in infants and children. Eur Respir Mon 2006;
37: 1-7.
16. Martinez FD, Wrigth AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma 
and wheezing in the first six years of life. N Engl J Med 1995; 332: 133-138.
17. Elphick HE, Ritson S, Rodgers H, Everard ML. When a “wheeze” is not a wheeze:
acoustic analysis of breath sounds in infants. Eur Respir J 2000; 16: 593-597.
18. Cane RS, Ranganathan SC, McKenzie SA. What do parents of wheezy children
understand by “wheeze”? Arch Dis Child 2000; 82: 327-332.
19. Chauliac ES, Silverman M, Zwahlen M, Strippoli M-PF, Brooke AM, Kuehni CE. The
therapy of preschool wheeze: appropriate and fair? Pediatr Pulmonol 2006; 41: 829-838.
29
General Introduction
20. Silverman M, Wang M, Hunter G, Taub N. Episodic viral wheeze in preschool children:
effect of topical nasal corticosteroid prophylaxis. Thorax 2003; 58: 431-434. 
21. Johnston SL. Overview of virus-induced airway disease. Proc Am Thorac Soc 2005;
2: 150-156.
22. Lemanske RF Jr, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, Kirk CJ, Reisdorf
E, Roberg KA, Anderson EL, Carlson-Dakes KT, Adler KJ, Gilbertson-White S, Pappas
TE, Dasilva DF, Tisler CJ, Gern JE. Rhinovirus illnesses during infancy predict
subsequent childhood wheezing. J Allergy Clin Immunol 2005; 116: 571-577.
23. Kimpen JLL, Hammer J. Bronchiolitis in infants and children. In: Frey U, Gerritsen J,
eds. Respiratory diseases in infants and children. Eur Respir Mon 2006; 37: 170-190.
24. Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J
Allergy Clin Immunol 2006; 117: 969-977.
25. Tager I, Ngo L, Hanrahan J. Maternal smoking during pregnancy. Effects on lung
function during the first 18 months of life. Am J Respir Crit Care Med 1995; 152:
977-983.
26. Hanrahan J, Tager IB, Segal MR, Tosteson TD, Castile RG, Van Vunakis H, Weiss ST,
Speizer FE. The effect of maternal smoking during pregnancy on early infant lung
function. Am Rev Respir Dis 1992; 145: 1129-1135.
27. Nafstad P, Brunekreef B, Skrondal A, Nystad W. Early respiratory infections, asthma, and
allergy: 10 year follow-up of the Oslo Birth Cohort. Pediatrics 2005; 116: e255-e262.
28. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL,
Martinez FD. Respiratory syncytial virus in early life and risk of wheeze and allergy by
age 13 years. Lancet 1999; 354: 541-545.
29. Bont L, Steijn M, Van Aalderen WMC, Brus F, Draaisma JMTh, Van Diemen-
Steenvoorde RA, Pekelharing-Berghuis M, Kimpen JL. Seasonality of long term
wheezing following respiratory syncytial virus lower respiratory tract infection.
Thorax 2004; 59: 512-516.
30. Korppi M, Piippo-Savolainen E, Korhonen K, Remes S. Respiratory morbidity 20 years
after RSV infection in infancy. Pediatr Pulmonol 2004; 38: 155-160.
31. Phelan P, Robertson C, Olinsky A. The Melbourne Asthma Study: 1964-1999. J
Allergy Clin Immunol 2002; 109: 189-194.
32. Sears MR, Greene JM, Willian AR. A longitudinal, population-based, cohort study of
childhood asthma followed to adulthood. N Eng J Med 2003; 349: 1414-1422.
33. Kurukulaaratchy RJ, Matthews S, Arshad SH. Defining childhood atopic phenotypes
to investigate the association of atopic sensitization with allergic disease. Allergy
2005; 60: 1280-1286.
34. Halonen M, Stern DA, Wright AL, Taussig LM, Martinez FD. Alternaria as a major
allergen for asthma in children raised in a desert environment. Am J Respir Crit Care
Med 1997; 155: 1356-1361.
35. Illi S, von Mutius E, Lau S, Nickel R, Niggemann B, Sommerfeld C, Wahn U; Multicenter
Allergy Study Group. The pattern of atopic sensitization is associated with the
development of asthma in childhood. J Allergy Clin Immunol 2001; 108: 709-714.
36. Wahn U, Bergmann R, Kulig M, Forster J, Bauer CP. The natural course of sensitisation
and atopic disease in infancy and childhood. Pediatr Allergy Immunol 1997; 8:
Suppl.10, 16-20.
30
Chapter 1
37. Lau S, Illi S, Sommerfeld C, Niggemann B, Bergmann R, von Mutius E, Wahn U. Early
exposure to house dust mite and cat allergens and the development of childhood
asthma. Lancet 2000; 356: 1392-1397.
38. Brussee JE, Smit HA, van Strien RT, Corver K, Kerkhof M, Wijga AH, Aalberse RC,
Postma D, Gerritsen J, Grobbee DE, de Jongste JC, Brunekeef B. Allergen exposure
in infancy and the development of sensitization, wheeze, and asthma at 4 years. J
Allergy Clin Immunol 2005; 115: 946-952.
39. Woodcock A, Lowe LA, Murray CS, Simpson BM, Pipis SD, Kissen P, Simpson A,
Custovic A; NAC Manchester Asthma and Allergy Study Group. Early life
environmental control: effect on symptoms, sensitization, and lung function at age
of 3 years. Am J Respir Crit Care Med 2004; 170: 433-439.
40. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and
wheezing illness from early childhood to age 33 in a national British cohort. BMJ
1996; 312: 1195-1199.
41. Gern JE, Brooks GD, Meyer P, Chang A, Shen K, Evans MD, Tisler C, Dasilva D,
Roberg KA, Mikus LD, Rosenthal LA, Kirk CJ, Shult PA, Bhattacharya A, Li Z, Gangnon
R, Lemanske RF Jr. Bidirectional interactions between viral respiratory illnesses and
cytokine responses in the first year of life. J Allergy Clin Immunol 2006; 117: 72-78.
42. Celedon JC, Wright RJ, Litonjua AA, Sredl D, Ryan L, Weiss ST, Gold DR. Day care
attendance in early life, maternal history of asthma, and asthma at the age of 6
years. Am J Respir Crit Care Med 2003; 167: 1239-1243.
43. Ball TM, Castro-Rodriguez JA, Griffith KA, Holberg CJ, Martinez FD, Wright AL.
Siblings, day-care attendance, and the risk of asthma and wheezing during childhood.
N Eng J Med 2000; 343: 538-543.
44. Kramer U, Heinrich J, Wjst M, Wichmann HE. Age of entry to day nursery and allergy
in later childhood. Lancet 1999; 353: 450-454.
45. Strachan DP. Hay fever, hygiene and household size. BMJ 1989; 299: 1259-1260.
46. Martinez FD, Holt PG. Role of microbial burden in aetiology of allergy and asthma.
Lancet 1999; 354 (suppl.2): II12-15.
47. Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Waser M, Maisch S, Carr D,
Schierl R, Nowak D, von Mutius E; ALEX Study Team. Exposure to farming in early
life and development of asthma and allergy: a cross-sectional survey. Lancet 2001;
358: 1129-1133.
48. Radon K, Ehrenstein V, Praml G, Nowak D. Childhood visits to animal buildings and
atopic diseases in adulthood: an age-dependent relationship. Am J Ind Med 2004;
46: 349-356.
49. Platts-Mills TA, Woodfolk JA, Sporik RB. Con: the incresase in asthma cannot be
ascribed to cleanliness. Am J Respir Crit Care Med 2001; 164: 1107-1109.
50. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases.
N Eng J Med 2002; 347: 911-920.
51. Yazdanbakhsh M, van den Biggelaar A, Maizels RM. Th2 responses without atopy:
immunoregulation in chronic helminthic infections and reduced allergic disease.
Trends Immunol 2001; 22: 372-377.
31
General Introduction
52. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K.
Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2
responses to inhaled antigen. J Exp Med 2002; 196: 1645-1651.
53. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L, Maisch S, Carr D,
Gerlach F, Bufe A, Lauener RP, Schierl R, Renz H, Nowak D, von Mutius E; Allergy and
Endotoxin Study Team. Environmental exposure to endotoxin and its relation to
asthma in school-age children. N Eng J Med 2002; 347: 869-877.
54. Akdis CA, Blaser K, Akdis M. Genes of tolerance. Allergy 2004; 59: 897-913.
55. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T
cells control Leishmania major persistence and immunity. Nature 2002; 420: 502-
507.
56. Beeson PB. Tolerance to bacterial pyrogens. J Exp Med 1947; 86: 29.
57. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res
2004; 10: 71-84. 
58. Holt PG, Upham JW, Sly PD. Contemporaneous maturation of immunologic and
respiratory functions during early childhood: implications for development of asthma
prevention strategies. J Allergy Clin Immunol 2005; 116: 16-24.
59. Culley FJ, Pollot J, Openshaw PJM. Age at first viral infection determines the pattern
of T-cell-mediated disease during reinfection in adulthood. J Exp Med 2002; 196:
1381-1386.
60. Pohunek P, Warner JO, Turzikova J, Kudrmann J, Roche WR. Markers of eosinophilic
inflammation and tissue re-modelling in children before clinically diagnosed bronchial
asthma. Pediatr Allergy Immunol 2005; 16: 43-51.
61. Greenough A, Kotecha S, Vrijlandt E. Bronchopulmonary dysplasia: current models
and concepts. In: Frey U, Gerritsen J, eds. Respiratory diseases in infants and children.
Eur Respir Mon 2006; 37: 217-233.
62. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, Calvert SA;
United Kingdom Oscillation Study Group. High-frequency oscillatory ventilation for the
prevention of chronic lung disease of prematurity. N Eng J Med 2002; 347: 633-642.
63. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;
163: 1723-1729.
64. Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in
post-surfactant bronchopulmonary dysplasia. Hum Pathol 1998; 29: 710-717.
65. Kotecha S. Lung growth: implications for the newborn infant. Arch Dis Child Fetal
Neonatal Ed 2000; 82: F69-F74.
66. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator
therapy of hyaline-membrane disease: bronchopulmonary dysplasia. N Eng J Med
1967; 276: 357-368.
67. Bush A, Götz M. Cystic Fibrosis. In: Frey U, Gerritsen J, eds. Respiratory diseases in
infants and children. Eur Respir Mon 2006; 37: 234-290.
68. Bush A. Cystic Fibrosis. In: European Respiratory Society /  European Lung Foundation.
Lung Health in Europe Facts and Figures. Loddenkemper R, Gibson GJ, Sibille Y, eds.
Sheffield, UK, ERSJ, 2003: pp.89-95.
69. Rosenstein BJ, Cutting GR, for the Cystic Fibrosis Foundation Consensus Panel. The
diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998; 132: 589-595.
32
Chapter 1
70. Rowe SM, Miller S, Sorscher EJ. Cystic Fibrosis. Mechanisms of disease. N Eng J Med
2005; 352: 1992-2001.
71. Cystic Fibrosis Foundation. Patient Registry 1995 Annual Data Report. Bethesda,
Cystic Fibrosis Foundation 1996.
72. Guidelines for the performance of the sweat test for the investigation of cystic fibrosis in
the UK www.guideline.gov/summary/summary.aspx?ss=15&doc_id=5059&nbr=3543.
Date last accessed: May 28 2007.
73. Massie J, Olzen M, Glazner J, Robertson C, Francis I. Newborn screening for cystic
fibrosis in Victoria : 10 years’ experience (1989-1998). Med J Aust 2000; 172: 584-
587.
74. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis
phenotypes in the absences of CFTR mutations. N Eng J Med 2002; 347: 401-407.
75. Bishop MD, Freedman SD, Zielenski J, et al. The cystic fibrosis transmembrane
conductance regulator gene and ion channel function in patients with idiopathic
pancreatitis. Hum Genet 2005; 118: 372-381.
76. Eaton TE, Weiner Miller P, Garrett JE, Cutting GR. Cystic fibrosis transmembrane
conductance regulator gene mutations: do they play a role in the aetiology of allergic
bronchopulmonary aspergillosis? Clin Exp Allergy 2002; 32: 756-761.
77. Bush A, Wallis C. Time to think again: cystic fibrosis is not an “all or none” disease.
Pediatr Pulmonol 2000; 30: 139-144.
78. Busse WW, Lemanske RF Jr. Advances in immunology: asthma. N Eng J Med 2001;
344: 350-362.
79. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825-857.
80. Noah TL, Becker S. Chemokines in nasal secretions of normal adults experimentally
infected with respiratory syncytial virus. Clin Immunol 2000; 97: 43-49.
81. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch
recombination. Nat Rev Immunol 2003; 3: 721-732.
82. Bacharier LB, Jabara H, Geha RS. Molecular mechanisms of immunoglobulin E
regulation. Int Arch Allergy Immunol 1998; 115: 257-269.
83. Lane SJ, Lee TH. Mast cell effector mechanisms. J Allergy Clin Immunol 1996; 98:
S67-S72.
84. Wildhaber JH, Sennhauser FH, Brand PLP. Asthma in school-aged children and
adolescents. In: Frey U, Gerritsen J, eds. Respiratory diseases in infants and children.
Eur Respir Mon 2006; 37: 191-216.
85. van den Toorn LM, Overbeek SE, de Jongste JC, Leman K, Hoogsteden HC, Prins JB.
Airway inflammation is present during clinical remission of atopic asthma. Am J
Respir Crit Care Med 2001; 164: 2107-2113.
86. Cokugras H, Akcakaya N, Seckin, Camcioglu Y, Sarimat N, Aksoy F. Ultrastructural
examination of bronchial biopsy specimens from children with moderate asthma.
Thorax 2001; 56: 25-29.
87. Payne DN, Rogers AV, Ädelroth E, Bandi V, Guntupalli KK, Bush A, Jeffery PK. Early
thickening of the reticular basement membrane in children with difficult asthma. Am
J Respir Crit Care Med 2003; 167: 78-82.
88. Jenkins HA, Cool C, Szefler SJ, Covar R, Brugman S, Gelfand EW, Spahn JD.
Histopathology of severe childhood asthma: a case series. Chest 2003; 124: 32-41.
33
General Introduction
89. Barbato A, Turato G, Baraldo S, Bazzan E, Calabrese F, Tura M, Zuin R, Beghe B,
Maestrelli P, Fabbri LM, Saetta M. Airway inflammation in childhood asthma. Am J
Respir Crit Care Med 2003; 168: 798-803.
90. Payne DN, Qiu Y, Zhu J, Peachey L, Scallan M, Bush A, Jeffery PK. Airway inflammation
in children with difficult asthma: relationships with airflow limitation and persistent
symptoms. Thorax 2004; 59: 862-869.
91. de Blic J, Tillie-Leblond I, Tonnel AB, Jaubert F, Scheinmann P, Gosset P. Difficult
asthma in children: an analysis of airway inflammation. J Allergy Clin Immunol 2004;
113: 94-100.
92. Saglani S, Malmstrom K, Pelkonen AS, Malmberg LP, Lindahl H, Kajosaari M,
Turpeinen M, Rogers AV, Payne DN, Bush A, Haahtela T, Makela MJ, Jeffery PK.
Airway remodeling and inflammation in symptomatic infants with reversible airflow
obstruction. Am J Respir Crit Care Med 2005; 171: 722-727.
93. Payne DN, Saglani S, Bush A. Remodelling in paediatric respiratory disease and
impact on growth and development. In: Frey U, Gerritsen J, eds. Respiratory diseases
in infants and children. Eur Respir Mon 2006; 37: 41-59.
94. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma, from
bronchoconstriction to airways inflammation and remodelling. Am J Respir Crit Care
Med 2000; 161: 1720-1745.
95. Fedorov IA, Wilson SJ, Davies DE, Holgate ST. Epithelial stress and structural
remodelling in childhood asthma. Thorax 2005; 60: 389-394.
96. Holgate ST. Inflammation and remodelling in asthma and allied disorders. Summary
and conclusions. Clin Exp Allergy Rev 2001; 1: ix-xiii.
97. Baldwin L, Roche WR. Does remodelling of the airway wall precede asthma? Paediatr
Respir Rev 2002; 3: 315-320.
98. Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, Taussig LM,
Wright AL, Martinez FD. Outcome of asthma and wheezing in the first six years of
life: follow-up through adolescence. Am J Respir Crit Care Med 2005; 172: 1253-
1258.
99. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline
on the management of asthma. Thorax 2003; 58: Suppl.1, i1-i94.
100. NAEPP Expert Panel. Guidelines for the diagnosis and management of asthma –
update on selected topics 2002. NIH publication no. 02-5075. 2002. Bethesda,
National Institutes of Health, 2002.
101. Childhood Asthma Management Program Research Group. Long-term effects of
budesonide or nedocromil in children with asthma. N Eng J Med 2000; 343: 1054-1063.
102. Merkus PJ, van Pelt W, van Houwelingen JC, van Essen-Zandvliet LE, Duiverman EJ,
Kerrebijn KF, Quanjer PH. Inhaled corticosteroids and growth of airway function in
asthmatic children. Eur Respir J 2004; 23: 861-868.
103. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm
CJ, O’Byrne PM; START Investigators Group. Early intervention with budesonide in mild
persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071-1076.
104. Martinez FD. Towards asthma prevention – does all that really matters happen before
we learn to read? N Eng J Med 2003; 349: 1473-1475.
34
Chapter 1
105. Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP, Sears MR.
Risk factors for airway remodelling in asthma manifested by a low postbronchodilator
FEV1/vital capacity ratio: a longitudinal population study from childhood to
adulthood. Am J Respir Crit Care Med 2002; 165: 1480-1488.
106. Kamps AW, Brand PL, Kimpen JL, Maille AR, Overgoor-van de Groes AW, van
Helsdingen-Peek LC, Roorda RJ. Outpatient management of childhood asthma by
paediatrician or asthma nurse: randomised controlled study with one year follow up.
Thorax 2003; 58: 968-973.
107. NHLBI/WHO. NHLBI/WHO Workshop Report. Global strategy for asthma mangement
and prevention. Publication no. 02-3659, issued 1995 and revised 2002. Bethesda,
Maryland, USA, National Institute of Health.
108. NAEPP Expert Panel Report 2. Guidelines for the diagnosis and management of
asthma. Publication no. 97-4051, issued 1997 and revised 2002. Bethesda, Maryland,
USA, National Institute of Health.
109. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST. Worldwide
severity and control of asthma in children and adults: the global asthma insights and
reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.
110. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in
1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16:
802-807.
111. Kaur B, Anderson HR, Austin J, Burr M, Harkins LS, Strachan DP, Warner JO. Prevalence
of asthma symptoms, diagnosis, and treatment in 12-14 year old children across
Great Britain (international study of asthma and allergies in childhood, ISAAC UK).
BMJ 1998; 316: 118-124.
112. Paterson NAM, Peat JK, Mellis CM, Xuan W, Woolcock AJ. Accuracy of asthma
treatment in schoolchildren in NSW, Australia. Eur Respir J 1997; 10: 658-664.
113. Kuehni CE, Frey U. Age-related differences in perceived asthma control in childhood:
guidelines and reality. Eur Respir J 2002; 20: 880-889.
114. Balfour-Lynn IM. Difficult asthma: beyond the guidelines. Arch Dis Child 1999; 80:
201-206.
115. Milgrom H, Bender B, Ackerson L, Bowry P, Smit B, Rand C. Noncompliance and
treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98: 1051-1057.
116. Custovic A, Simpson A. Environmental allergen exposure, sensitisation and asthma:
from whole populations to individuals at risk. Thorax 2004; 59: 825-827.
117. Stevenson EC, Turner G, Heaney LG, Schock BC, Taylor R, Gallagher T, Ennis M,
Shields MD. Bronchoalveolar lavage findings suggest two different forms of childhood
asthma. Clin Exp Allergy 1997; 27: 1027-1035.
118. Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ. Airway
inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol
2006; 41: 577-583.
119. Le Bourgeois M, Goncalves M, Le Clainche L, et al. Bronchoalveolar cells in children
<3 years old with severe recurrent wheezing. Chest 2002; 122: 791-797.
120. Krawiec ME, Westcott JY, Chu HW, et al. Persistent wheezing in very young children
is associated with lower respiratory inflammation. Am J Respir Crit Care Med 2001;
163: 1338-1343.
35
General Introduction
121. McKean MC, Hewitt C, Lambert PC, Myint S, Silverman M. An adult model of
exclusively viral wheeze: inflammation in the upper and lower respiratory tracts. Clin
Exp Allergy 2003; 33: 912-920.
122. Saglani S, Nicholson AG, Scallan M, Balfour-Lynn I, Rosenthal M, Payne DN, Bush A.
Investigation of young children with severe recurrent wheeze: any clinical benefit?
Eur Respir J 2006; 27: 29-35.
123. Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH. Airway inflammation,
basement membrane thickening and bronchial hyperresponsiveness in asthma.
Thorax 2002; 57: 309-316.
124. Oommen A, McNally T, Grigg J. Eosinophil activation and preschool viral wheeze.
Thorax 2003; 58: 876-879.
125. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral
prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial.
Lancet 2003; 362: 1433-1438.
126. Oommen A, Patel R, Browning M, Grigg J. Systemic neutrophil activation in acute
preschool viral wheeze. Arch Dis Child 2003; 88: 529-531.
127. Grissell TV, Powell H, Shafren DR, Boyle MJ, Hensley MJ, Jones PD, Whitehead BF,
Gibson PG. Interleukin-10 gene expression in acute virus-induced asthma. Am J
Respir Crit Care Med 2005; 172: 433-439.
128. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and
possible mechanisms. Thorax 2002; 57: 643-648.
129. Lindemans CA, Coffer PJ, Schellens I, de Graaf PM, Kimpen JLL, Koenderman L.
Respiratory syncytial virus prolongs granulocytes survival. Proc Am Thorac Soc 2005;
2: A683.
130. Beyer M, Bartz H, Hörner K, Doths S, Koerner-Rettberg C, Schwarze J. Sustained
increases in numbers of pulmonary dendritic cells after respiratory syncytial virus
infection. J Allergy Clin Immunol 2004; 113: 127-133.
131. Gill MA, Palucka AK, Barton T, Ghaffar F, Jafri H, Banchereau J, Ramilo O. Mobilization
of plasmacytoid and myeloid dendritic cells to mucosal sites in children with
respiratory infections. J Infect Dis 2005; 191: 1105-1115.
132. de Graaff PM, de Jong EC, van Capel TM, van Dijk ME, Roholl PJ, Boes J, Luytjes W,
Kimpen JL, van Bleek GM. Respiratory syncytial virus infection of monocyte-derived
dendritic cells decreases their capacity to activate CD4 T cells. J Immunol 2005; 175:
5904-5911.
133. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JT, Geelen SM,
Kimpen JL. Monocyte IL-10 production during respiratory syncytial virus bronchiolitis
is associated with recurrent wheezing in a one-year follow-up study. Am J Respir Crit
Care Med 2000; 161: 1518-1523.
134. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JM, Pekelharing-
Berghuis M, van Diemen-Steenvoorde RA, Kimpen JL. Local interferon-gamma levels
during respiratory syncytial virus lower respiratory tract infections are associated with
disease severity. J Infect Dis 2001; 184: 355-358.
135. Kotecha S. Cytokines in chronic lung disease of prematurity. Eur J Pediatr 1996; 155:
Suppl. 2, S14-S17.
36
Chapter 1
136. Groneck P, Speer CP. Inflammatory mediators and bronchopulmonary dysplasia. Arch
Dis Child 1995; 73: F1-F3.
137. Yoon BH, Romero R, Jun JK, Park KH, Park JD, Ghezzi F, Kim BI. Amniotic fluid
cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1-beta, and
interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am
J Obstet Gynecol 1997; 177: 825-830.
138. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK,
Waltenberger J, Voelkel NF. Inhibition of VEGF-receptors causes lung cell apoptosis
and emphysema. J Clin Invest 2000; 106: 1311-1319.
139. Tirouvanziam R, de Bentzmann S, Hubeau C, Hinnrasky J, Jacquot J, Peault B,
Puchelle E. Inflammation and infection in naïve human cystic fibrosis airway grafts.
Am J Respir Cell Mol Biol 2000; 23: 121-127.
140. Muhlebach MS, Stewart PW, Leigh MW, Noah TL. Quantification of inflammatory
response to bacteria in young cystic fibrosis and control patients. Am J Respir Crit
Care Med 1999; 160: 186-191. 
141. Armstrong DS, Hook SM, Jamsen KM, Nixon GM, Carzino R, Carlin JB, Robertson CF,
Grimwood K. Lower airway inflammation in infants with cystic fibrosis detected by
newborn screening. Pediatr Pulmonol 2005; 40: 500-510.
142. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M. Normal
bronchial epithelial cells constitutively produce the anti-inflammatory cytokine
interleukin-10, which is down-regulated in cystic fibrosis. Am J Respir Cell Mol Biol
1995; 13: 257-261.
143. Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J,
Guggino WB, Atabani SF, Belkaid Y, Xu Y, Whitsett JA, Accurso FJ, Wills-Karp M,
Petasis NA. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis
airway. Nat Immunol 2004; 5: 388-392.
144. Davies JC, Stern M, Dewar A, Caplen NJ, Munkonge FM, Pitt T, Sorgi F, Huang L,
Bush A, Geddes DM, Alton EW. CFTR gene transfer reduces the binding of
Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell
Mol Biol 1997; 16: 657-663.
145. Scheid P, Kempster L, Griesenbach U, Davies JC, Dewar A, Weber PP, Colledge WH,
Evans MJ, Geddes DM, Alton EW. Inflammation in cystic fibrosis airways: relationship
to increased bacterial adherence. Eur Respir J 2001; 17: 27-35.
146. Saadane A, Soltys J, Berger M. Role of IL-10 deficiency in excessive nuclear factor-
kappa? activation and lung inflammation in cystic fibrosis transmembrane
conductance regulator knockout mice. J Allergy Clin Immunol 2005; 115: 405-411.
147. van Heeckeren AM, Schluchter MD, Drumm ML, Davis PB. Role of CFTR genotype in
the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J
Physiol Lung Cell Mol Physiol 2004; 287: L944-L952.
148. Eigen H, Rosenstein B, Fitxsimmons S, Schidlow D. A multi-center study of alternate
day prednisolone therapy in patients with cystic fibrosis. J Pediatr 1995; 126: 515-
523.
149. de Jongste JC, Baraldi E, Lombardi E. Clinically relevant early functional and diagnostic
markers of lung disease in children. In: Frey U, Gerritsen J, eds. Respiratory diseases
in infants and children. Eur Respir Mon 2006; 37: 120-141.
37
General Introduction
150. Cabana MD, Rand CS, Becher OJ, Rubin HR. Reasons for paediatrician nonadherence
to asthma guidelines. Arch Pediatr Adolesc Med 2001; 155: 1057-1062.
151. Hilliard TN, Witten H, Male IA, Langton Hewer S, Peddon PC. Management of acute
childhood asthma: a prospective multicentre study. Eur Respir J 2000; 15: 1102-1105.
152. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF Jr, Sorkness CA. Classifying
asthma severity in children: mismatch between symptoms, medication use, and lung
function. Am J Respir Crit Care Med 2004; 170: 426-432.
153. Cane RS, McKenzie SA. Parents’ interpretations of children’s respiratory symptoms
on video. Arch Dis Child 2001; 84: 31-34.
154. Fiese BH, Wamboldt FS, Anbar RD. Family asthma management routines: connections
to medical adherence and quality of life. J Pediatr 2005; 146: 171-176.
155. Merikallio VJ, Mustalahti K, Remes RT, Valovirta EJ, Kaila M. Comparison of quality
of life between asthmatic and healthy school children. Pediatr Allergy Immunol
2005; 16: 332-340.
156. Williams J, Williams K. Asthma-specific quality of life questionnaires in children: Are
they useful and feasible in routine clinical practice? Pediatr Pulmonol 2003; 35: 114-
118.
157. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring
quality of life in children with asthma. Qual Life Res 1996; 5: 35-46.
158. Janse AJ, Sinnema G, Uiterwaal CSPM, Kimpen JLL, Gemke RJBJ. Quality of life in
chronic illness: perception of parents and paediatricians. Arch Dis Child 2005; 90:
486-491.
159. Fonseca JA, Delgado L, Costa-Pereira A, Tavares C, Moreira A, Morete A, de Oliveira
F, Rodrigues J, Vaz M. Evaluation of the Asthma Life Quality test for the screening
and severity assessment of asthma. Allergy 2004; 59: 1198-1204.
160. Kaugars AS, Klinnert MD, Bender BG. Family influences on pediatric asthma. J Pediatr
Psychol 2004; 29: 475-491.
161. Quanjer Ph, Stocks J, Polgar G, Wise M, Karlberg J, Borsboom G. Compilation of
reference values for lung function measurements in children. Eur Respir J 1989; 2:
Suppl. 4, 184S-261S.
162. Merkus PJFM, de Jongste JC, Stocks J. Respiratory function measurements in infants
and children. In: Gosselink R, Stam H, eds. Lung Function Testing. Eur Respir Mon
2005; 31: 166-194.
163. Spahn JD, Cherniack R, Paull K, Gelfand EW. Is forced expiratory volume in one
second the best measure of severity in childhood asthma? Am J Respir Crit Care Med
2004; 169: 784-786.
164. American Thoracic Society. Standardisation of spirometry: 1994 update. Am J Respir
Crit Care Med 1995; 152: 1107-1136.
165. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical
control and histopathologic outcome of asthma when using airway
hyperresponsiveness as an additional guide to long-term treatment. The AMPUL
study group. Am J Respir Crit Care Med 1999; 159: 1043-1051.
166. Zacharasiewicz A, Wilson N, Lex C, et al. Clinical use of noninvasive measurements
of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med
2005; 171: 1077-1082.
38
Chapter 1
167. De Meer G, Marks GB, Postma DS. Direct or indirect stimuli for branchial challenge
testing: what is the relevance for asthma epidemiology? Clin Exp Allergy 2004; 34: 9-16.
168. Joos GF, O’Connor BJ, on behalf of the ERS Task Force. Indirect airway challenges.
Eur Respir J 2003; 21: 1050-1068.
169. American Thoracic Society. Guidelines for metacholine and exercise challenge testing
– 1999. Am J Respir Crit Care Med 2000; 161: 309-329.
170. Pattemore PK, Asher MI, Harrison AC, Mitchell EA, Rea HH, Stewart AW. The
interrelationship among bronchial hyperresponsiveness, the diagnosis of asthma,
and asthma symptoms. Am Rev Respir Dis 1990; 142: 549-554.
171. Salome CM, Peat JK, Britton WJ, Woolcok AJ. Bronchial hyperresponsiveness in two
populations of Australian children. I. Relation to respiratory symptoms and diagnosed
asthma. Clin Allergy 1987; 17: 271-281.
172. Cockcroft DW. How best to measure airway hyperresponsiveness. Am J Respir Crit
Care Med 2001; 163: 1514-1515.
173. Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, Szefler SJ. Safety
and application of induced sputum analysis in childhood asthma. J Allergy Clin
Immunol 2004; 114: 575-582.
174. Wood RE. Diagnostic and therapeutic procedures in pediatric pulmonary patients. In:
Taussig LM, Landau LI, eds. Pediatric Respiratory Medicine. Philadelphia, USA, Mosby
Inc, 1999; pp. 244-262.
175. Gibson PG, Grootendorst DC, Henry RL, Pin I, Rytila PH, Wark P, Wilson N, Djukanovic
R. Sputum induction in children. Eur Respir J 2002; 20: 44s-46s.
176. Paggiaro PL, on behalf of working group 1. Sputum induction. Eur Respir J 2002; 20:
Suppl. 37, 3s-8s.
177. Spanevello A, Beghé B, Bianchi A, Migliori GB, Ambrosetti M, Neri M, Ind PW.
Comparison of two methods of processing induced sputum: selected versus entire
sputum. Am J Respir Crit Care Med 1998; 157: 665-668.
178. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum
induction and processing. Eur Respir J 2002; 20: Suppl. 37, 1s-2s.
179. Efthimiadis A, Spanevello A, on behalf of working group 3. Methods of sputum
processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir
J 2002; 20: Suppl. 37, 19s-23s.
180. Kelly MM, on behalf of working group 4. Analysis of fluid-phase mediators. Eur
Respir J 2002; 20: Suppl. 37, 24s-39s.
181. Lex C, Payne DNR, Zacharasiewicz A, Li AM, Wilson NM, Hansel TT, Bush A. Sputum
induction in children with difficult asthma: safety, feasibility, and inflammatory cell
pattern. Pediatr Pulmonol 2005; 39: 318-324.
182. Jones PD, Hankin R, Simpson J, Gibson PG, Henry RL. The tolerability, safety, and
success of sputum induction and combined hypertonic saline challenge in children.
Am J Respir Crit Care Med 2001; 164: 1146-1149.
183. De Boeck K, Alifier M, Vandeputte S. Sputum induction in young cystic fibrosis
patients. Eur Respir J 2000; 16: 91-94.
184. Suri R, Marshall LJ, Wallis C, Metcalfe C, Shute JK, Bush A. Safety and use of sputum
induction in children with cystic fibrosis. Pediatr Pulmonol 2003; 35: 309-313.
39
General Introduction
185. Reinhardt N, Chen CIU, Loppow D, Schink T, Kleinau I, Jörres RA, Wahn U, Magnussen
H, Paul KP. Cellular profiles of induced sputum in children with stable cystic fibrosis:
comparison with BAL. Eur Respir J 2003; 22: 497-502.
186. Pizzichini E, on behalf of working group 2. Safety of sputum induction. Eur Respir J
2002; 20: Suppl. 37, 9s-18s.
187. Li AM, Tsang TW, Chan DF, Lam HS, So HK, Sung RY, Fok TF. Sputum induction in
children with asthma: a tertiary-center experience. Pediatr Pulmonol 2006; 41: 720-725.
188. Wilson NM, Bridge P, Spanevello A, Silverman M. Induced sputum in children:
feasibility, repeatability, and relation of findings to asthma severity. Thorax 2000; 55:
768-774.
189. Li AM, Lex C, Zacharasiewicz A, Wong E, Erin E, Hansel T, Wilson NM, Bush A. Cough
frequency in children with mild asthma: correlation with lung function, exhaled nitric
oxide, and sputum eosinophil count. Thorax 2003; 58: 974-978.
190. Gibson PG, Simpson JL, Hankin R, Powell H, Henry RL. Relationship between induced
sputum eosinophils and the clinical pattern of childhood asthma. Thorax 2003; 58:
116-121.
191. Papadopouli E, Tzanakis N, Tsoumakidou M, Kyriakoy D, Plataki M, Mantzouranis EC,
Siafakes NM. Comparison of induced sputum inflammometry profiles between
childhood and adult-onset asthma. Respir Med 2006; 100: 1442-1450. 
192. Sloane AJ, Lindner RA, Prasad SS, Sebastian LT, Pedersen SK, Robinson M, Bye PT,
Nielson DW, Harry JL. Proteomic analysis of sputum from adults and children with
cystic fibrosis and from control subjects. Am J Respir Crit Care Med 2005; 172: 1416-
1426.
193. Lex C, Jenkins G, Wilson NM, Zacharasiewicz A, Erin E, Hansel TT, Bush A, Payne DN.
Does sputum eosinophilia predict the response to systemic corticosteroids in children
with difficult asthma? Pulmonol 2007; 42: 298-303.
194. Sagel SD, Kapsner R, Osberg I, Sontag MK, Accurso FJ. Airway inflammation in
children with cystic fibrosis and healthy children assessed by sputum induction. Am
J Respir Crit Care Med 2001; 164: 1425-1431.
195. Sagel SD, Sontag MK, Wagener JS, Kapsner RK, Osberg I, Accurso FJ. Induced
sputum inflammatory measures correlate with lung function in children with cystic
fibrosis. J Pediatr 2002; 141: 811-817.
196. Ho SA, Ball R, Morrison LJ, Brownlee KG, Conway SP. Clinical value of obtaining
sputum and cough swab samples following inhaled hypertonic saline in children with
cystic fibrosis. Pediatr Pulmonol 2004; 38: 82-87.
197. Ordonez CL, Kartashov AI, Ellen M. Variability of markers of inflammation and infection
in induced sputum in children with cystic fibrosis. J Pediatr 2004; 145: 689-692.
198. Vignola AM, Bousquet J, Chanez P, Gagliardo R, Merendino AM, Chiappara G,
Bonsignore G. Assessment of airway inflammation in asthma. Am J Respir Crit Care
Med 1998; 157: S184-S187.
199. Payne D, McKenzie SA, Stacey S, Misra D, Haxby E, Bush A. Safety and ethics of
bronchoscopy and endobronchial biopsy in difficult asthma. Arch Dis Child 2001; 84:
423-426.
200. Bush A. Bronchoscopy in paediatric intensive care. Paediatr Respir Rev 2003; 4: 67-
73.
40
Chapter 1
201. Balfour-Lynn IM, Spencer H. Bronchoscopy – how and when? Paediatr Respir Rev
2002; 3: 255-264.
202. Nussbaum E. Pediatric fiberoptic bronchoscopy: clinical experience with 2836
bronchoscopies. Pediatr Crit Care Med 2002; 3: 171-176.
203. Saglani S, Payne DN, Nicholson AG, Scallan M, Haxby E, Burh A. Safety and quality
of endobronchial biopsy in children under five years old. Thorax 2003; 58: 1053-
1057.
204. Salva PS, Theroux C, Schwartz D. Safety of endobronchial biopsy in 170 children with
chronic respiratory symptoms. Thorax 2003; 58: 1058-1060.
205. Payne DN, Wilson NM, James A, Hablas H, Agrafioti C, Bush A. Evidence for different
subgroups of difficult asthma in children. Thorax 2001; 56: 345-350.
206. Faul JL, Demers EA, Burke CM, Poulter LW. The reproducibility of repeat measures of
airway inflammation in stable atopic asthma. Am J Respir Crit Care Med 1999; 160:
1457-1461.
207. Pijnenburg M. Towards better treatment of childhood asthma: inflammometry with
exhaled nitric oxide. PhD-Thesis Erasmus University Rotterdam, 2006
208. Haahtela T, Laitinen A, Laitinen LA. Using biopsies in the monitoring of inflammation
in asthmatic patients. Allergy 1993; 48: 65-69.
209. Ennis M, Turner G, Schock BC, Stevenson EC, Brown V, Fitch PS, Heaney LG, Taylor
R, Shields MD. Inflammatory mediators in bronchoalveolar lavage samples from
children with and without asthma. Clin Exp Allergy 1999; 29: 362-366.
210. Stempel DA, Fuhlbrigge AL. Defining the responder in asthma therapy. J Allergy Clin
Immunol 2005; 115: 466-469.
211. Braunstahl GJ. The unified immune system: respiratory tract: nasobronchial
interaction mechanisms in allergic airway disease. J Allergy Clin Immunol 2005; 115:
142-148.
212. Jöbsis Q. Exhaled hydrogen peroxide and nitric oxide. PhD-Thesis Erasmus University
Rotterdam, 2000.
213. Lavoisier A. Traité élémentaire de chimie, présenté dans un ordre nouveau et d’après
les découvertes modernes, 2 volumes. Paris, Chez Cuchet, ed. 1789.
214. Scheideler L, Manke HG, Schwulera U, Inacker O, Hämmerle H. Detection of
nonvolatile macromolecules in breath. A possible diagnostic tool? Am Rev Respir Dis
1993: 148: 778-784.
215. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological
activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
216. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S. Endogenous nitric
oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem
Biophys Res Commun 1991; 181: 852-857.
217. The Nobel Foundation.
http://nobelprize.org/nobel_prizes/medicine/laureates/1998/index.html.
Date last accessed: May 28 2007.
218. Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric
oxide measurements in healthy and asthmatic adults and children. Eur Respir J 2003;
21: 433-438.
41
General Introduction
219. American Thoracic Society. ATS/ERS recommendations for standardized procedures
for the online and offline measurement of exhaled lower respiratory nitric oxide and
nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912-930.
220. Baraldi E, de Jongste JC. Measurement of exhaled nitric oxide in children, 2001. Eur
Respir J 2002; 20: 223-237.
221. Buchvald F, Baraldi E, Carraro S, Gaston B, de Jongste J, Pijnenburg MW, Silkoff PE,
Bisgaard H. Measurements of exhaled nitric oxide in healthy subjects age 4 to 17
years. J Allergy Clin Immunol 2005; 115: 1130-1136.
222. Kharitonov SA. Exhaled markers of inflammatory lung diseases: ready for routine
monitoring? Swiss Med Wkly 2004; 134: 175-192.
223. Pijnenburg MW, Bakker EM, Hop WC, de Jongste JC. Titrating steroids on exhaled
nitric oxide in children with asthma. Am J Respir Crit Care Med 2005; 172: 831-836.
224. Pijnenburg MW, Hofhuls W, Hop WC, de Jongste JC. Exhaled nitric oxide predicts
asthma relapse in children with clinical asthma remission. Thorax 2005; 60: 215-218.
225. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, Peter
Herbison G, Robin Taylor D. Exhaled nitric oxide: a predictor of steroid response. Am
J Respir Crit Care Med 2005; 172: 453-459.
226. Smith AD, Cowan JO, Brasset KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide
measurements to guide treatment in chronic asthma. N Eng J Med 2005; 352: 2163-
2173.
227. Mattes J, Storm van’s Gravesande K, Reining U, Alving K, Ihorst G, Henschen M,
Kuehr J. NO in exhaled air is correlated with markers of eosinophilic airway
inflammation in corticosteroid-dependent childhood asthma. Eur Respir J 1999; 13:
1391-1395.
228. Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Sperandio S, Boner AL.
Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic
children. Eur Respir J 1999; 13: 1386-1390.
229. Thomas PS, Gibson PG, Wang H, Shah S, Henry RL. The relationship of exhaled nitric
oxide to airway inflammation and responsiveness in children. J Asthma 2005; 42:
291-295.
230. del Giudice MM, Brunese FP, Piacentini GL, Pedulla M, Capristo C, Decimo F, Capristo
AF. Fractional exhaled nitric oxide (FeNO), lung function and bronchial
hyperresponsiveness in naïve atopic asthmatic children. J Asthma 2004; 41: 759-765.
231. Piacentini GL, Bodini A, Costella S, Suzuki Y, Zerman L, Peterson CG, Boner AL.
Exhaled nitric oxide, serum ECP and airway responsiveness in mild asthmatic children.
Eur Respir J 2000; 15: 839-843.
232. Van den Toorn LM, Prins JB, Overbeek SE, Hoogsteden HC, de Jongste JC. Adolescents
in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and
bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162: 953-957.
233. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between
exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult
asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001;
164: 1376-1381.
42
Chapter 1
234. Buchvald F, Bisgaard H. FeNO measured at fixed exhalation flow rate during controlled
tidal breathing in children from the age of 2 yr. Am J Respir Crit Care Med 2001;
163: 699-704.
235. Baraldi E, Dario C, Ongaro R, Scollo M, Azzolin NM, Panza N, Paganini N, Zacchello
F. Exhaled nitric oxide concentrations during treatment of wheezing exacerbation in
infants and young children. Am J Respir Crit Care Med 1999; 159: 1284-1288.
236. Avital A, Uwyyed K, Berkman N, Godfrey S, Bar-Yishay E, Springer C. Exhaled nitric
oxide and asthma in young children. Pediatr Pulmonol 2001; 32: 308-313.
237. Hall GL, Reinmann B, Wildhaber JH, Frey U. Tidal exhaled nitric oxide in healthy,
unsedated newborn infants with prenatal tobacco exposure. J Appl Physiol 2002; 92:
59-66.
238. Gabriele C, Asgarali R, Moll HA, Hop W, Hofman A, de Jongste JC. Measurement of
fractional exhaled nitric oxide in 6-month-old infants: the generation R study. Eur
Respir J 2005; 2: A312.
239. Franklin PJ, Turner SW, Mutch RC, Stick SM. Measuring exhaled nitric oxide in infants
during tidal breathing: methodological issues. Pediatr Pulmonol 2004; 37: 24-30.
240. Wildhaber JH, Hall GL, Stick SM. Measurements of exhaled nitric oxide with the
single-breath technique and positive expiratory pressure in infants. Am J Respir Crit
Care Med 1999; 159: 74-78.
241. Daniel PF, Klug B, Valerius NH. Measurement of exhaled nitric oxide in young children
during tidal breathing through a facemask. Pediatr Allergy Immunol 2005; 16: 248-
253.
242. Martinez TM, Weist AD, Williams T, Clem C, Silkoff P, Tepper RS. Assessment of
exhaled nitric oxide kinetics in healthy infants. J Appl Physiol 2003; 94: 2384-2390.
243. Malmberg LP, Pelkonen AS, Haahtela T, Turpeinen M. Exhaled nitric oxide rather than
lung function distinguishes preschool children with probable asthma. Thorax 2003;
58: 494-499.
244. Napier E, Turner SW. Methodological issues related to exhaled nitric oxide
measurement in children aged four to six years. Pediatr Pulmonol 2005; 40: 97-104.
245. Latzin P, Kuehni CE, Baldwin DN, Roiha HL, Casaulta C, Frey U. Elevated exhaled nitric
oxide in newborns of atopic mothers precedes respiratory symptoms. Am J Respir
Crit Care Med 2006; 174: 1292-1298.
246. Henriksen AH, Sue-Chu M, Lingaas Holmen T, Langhammer A, Bjermer L. Exhaled
and nasal NO levels in allergic rhinitis: relation to sensitization, pollen season and
bronchial hyperresponsiveness. Eur Respir J 1999; 13: 301-306.
247. de Gouw HW, Grunberg K, Schot R, Kroes AC, Dick EC, Sterk PJ. Relationship
between exhaled nitric oxide and airway hyperresponsiveness following experimental
rhinovirus infection in asthmatic subjects. Eur Respir J 1998; 11: 126-132.
248. Murphy AW, Platts-Mills TA, Lobo M, Hayden F. Respiratory nitric oxide levels in
experimental human influenza. Chest 1998; 114: 452-456.
249. Kharitonov SA, Yates D, Barnes PJ. Increased nitric oxide in exhaled air of normal
human subjects with upper respiratory tract infections. Eur Respir J 1995; 8: 295-297.
250. Sanders SP, Proud D, Permutt S, Siekierski ES, Yachechko R, Liu MC. Role of nasal
nitric oxide in the resolution of experimental rhinovirus infection. J Allergy Clin
Immunol 2004; 113: 697-702.
43
General Introduction
251. Cremona G, Higenbottam TW, Mayoral V, Alexander G, Demoncheaux E, Borland C,
Roe P, Jones GJ. Elevated exhaled nitric oxide in patients with hepatopulmonary
syndrome. Eur Respir J 1995; 8: 1883-1885.
252. Rolla G, Brussino L, Bertero MT, Colagrande P, Converso M, Bucca C, Polizzi S,
Caligaris-Cappio F. Increased nitric oxide in exhaled air of patients with systemic
lupus erythematosus. J Rheumatol 1997; 24: 1066-1071.
253. Rolla G, Brussino L, Colagrande P, Scappaticci E, Morello M, Bergerone S, Ottobrelli A,
Cerutti E, Polizzi S, Bucca C. Exhaled nitric oxide and impaired oxygenation in cirrhotic
patients before and after liver transplantation. Ann Intern Med 1998; 129: 375-378.
254. Brightling CE, Symon FA, Birring SS, Bradding P, Wardlaw AJ, Pavord ID. Comparison
of airway immunopathology of eosinophilic bronchitis and asthma. Thorax 2003; 58:
528-532.
255. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of
exhaled nitric oxide levels following lung transplantation. Thorax 1998; 53: 454-458.
256. Gabbay E, Walters EH, Orsida B, Whitford H, Ward C, Kotsimbos TC, Snell GI,
Williams TJ. Post-lung transplant bronchiolitis obliterans syndrome (BOS) is
characterized by increased exhaled nitric oxide levels and epithelial inducible nitric
oxide synthase. Am J Respir Crit Care Med 2000; 162: 2182-2187.
257. Verleden GM, Dupont LJ, Van Raemdonck DE, Vanhaecke J. Accuracy of exhaled
nitric oxide measurements for the diagnosis of bronchiolitis obliterans syndrome
after lung transplantation. Transplantation 2004; 78: 730-733.
258. Brugiere O, Thabut G, Mal H, Marceau A, Dauriat G, Marrash-Chahla R, Castier Y,
Leseche G, Colombat M, Fournier M. Exhaled NO may predict the decline in lung
function in bronchiolitis obliterans syndrome. Eur Respir J 2005; 25: 813-819.
259. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric
oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;
157: 998-1002.
260. Rutgers SR, Meijer RJ, Kerstjens HA, van der Mark TW, Koeter GH, Postma DS. Nitric
oxide measured with single-breath and tidal-breathing methods in asthma and
COPD. Eur Respir J 1998; 12: 816-819.
261. Clini E, Bianchi L, Vitacca M, Porta R, Foglio K, Ambrosino N. Exhaled nitric oxide and
exercise in stable COPD patients. Chest 2000 ; 117 : 702-707.
262. Delen FM, Sippel JM, Osborne ML, Law S, Thukani N, Holden WE. Increased exhaled
nitric oxide in chronic bronchitis : comparison with asthma and COPD. Chest 2000;
117: 695-701.
263. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, Ciaccia A, Fabbri
LM. Partial reversibility of airflow limitation and increased exhaled NO and sputum
eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2000; 162: 1773-1777.
264. Kharitonov SA, Wells AU, Oçonnor BJ, Cole PJ, Hansell DM, Logan-Sinclair RB, Barnes
PJ. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med
1995; 151: 1889-1893.
265. Tsang KW, Leung R, Fung PC, Chan SL, Tipoe GL, Ooi GC, Lam WK. Exhaled and
sputum nitric oxide in bronchiectasis: correlation with clinical parameters. Chest
2002; 121: 88-94.
44
Chapter 1
266. Ho LP, Innes JA, Greening AP. Exhaled nitric oxide is not elevated in the inflammatory
airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J 1998; 12: 1290-
1294.
267. Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S, Bucca C,
Morello M, Bergerone S, Bardini D, Zaccagna A, Puiatti P, Fava C, Cortese G. Exhaled
nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary
hypertension. J Rheumatol 2000; 27: 1693-1698.
268. Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ. Decreased nitric oxide in
the exhaled air of patients with systemic sclerosis and pulmonary hypertension.
Thorax 1997; 52: 1051-1055.
269. Moodley YP, Lalloo UG. Exhaled nitric oxide is elevated in patients with progressive
systemic sclerosis without interstitial disease. Chest 2001; 119: 1449-1454.
270. Baraldi E, Bonetto G, Zacchello F, Filippone M. Low exhaled nitric oxide in school-age
children with bronchopulmonary dysplasia and airflow limitation. Am J Respir Crit
Care Med 2005; 171: 68-72.
271. Storme L, Riou Y, Leclerc F, Dubois A, Deschildre A, Pierre MH, Logier R, Robin H,
Lequien P. Exhaled nitric oxide (NO) and respiratory function measured with body
plethysmography in children. Arch Pediatr 1998; 5: 389-396.
272. Mieskonen ST, Malmberg LP, Kari MA, Pelkonen AS, Turpeinen MT, Hallman NM,
Sovijari AR. Exhaled nitric oxide at school age in prematurely born infants with
neonatal chronic lung disease. Pediatr Pulmonol 2002; 33: 347-355.
273. Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM, Barnes PJ. Exhaled nitric
oxide is increased in active fibrosing alveolitis. Chest 1999; 115: 1352-1356.
274. Moodley YP, Chetty R, Lalloo UG. Nitric oxide levels in exhaled air and inducible nitric
oxide synthase immunolocalization in pulmonary sarcoidosis. Eur Respir J 1999; 14:
822-827.
275. Ziora D, Kaluska K, Kozielski J. An increase in exhaled nitric oxide is not associated
with activity in pulmonary sarcoidosis. Eur Respir J 2004; 24: 609-614.
276. Dotch J, Demirakca S, Terbrack HG, Huls G, Rascher W, Kuhl PG. Airway nitric oxide in
asthmatic children and patients with cystic fibrosis. Eur Respir J 1996; 9: 2537-2540.
277. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased concentration of exhaled
nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 1997; 24: 173-177.
278. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic
fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102: 1200-
1207.
279. Downey D, Elborn JS. Nitric oxide, iNOS, and inflammation in cystic fibrosis. J Pathol
2000; 190: 115-116.
280. Grasemann H, Ioannidis I, Tomkiewicz RP, de Groot H, Rubin BK, Ratjen F. Nitric oxide
metabolites in cystic fibrosis lung disease. Arch Dis Child 1998; 78: 49-53.
281. Ojoo JC, Mulrennan SA, Kastelik JA, Morice AH, Redington AE. Exhaled breath
condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis.
Thorax 2005; 60: 22-26.
282. Ho LP, Innes JA, Greening AP. Nitrite levels in breath condensate of patients with
cystic fibrosis is elevated in contrast to exhaled nitric oxide. Thorax 1998; 53: 680-
684.
45
General Introduction
283. Narang I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in
children: diagnostic use and pathophysiological significance. Thorax 2002; 57: 586-589.
284. Karadag B, James AJ, Gultekin E, Wilson NM, Bush A. Nasal and lower airway level
of nitric oxide in children with primary ciliary dyskinesia. Eur Respir J 1999; 13: 1402-
1405.
285. Horvath I, Loukides S, Wodehouse T, Csiszer E, Cole PJ, Kharitonov SA, Barnes PJ.
Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels
in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003;
58: 68-72.
286. Brett SJ, Evans TW. Measurement of endogenous nitric oxide in the lungs of patients
with the acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:
993-997.
287. Loveless MO, Phillips CR, Giraud GD, Holden WE. Decreased exhaled nitric oxide in
subjects with HIV infection. Thorax 1997; 52: 185-186.
288. Riley MS, Porszasz J, Miranda J, Engelen MP, Brundage B, Wasserman K. Exhaled
nitric oxide during exercise in primary pulmonary hypertension and pulmonary
fibrosis. Chest 1997; 111: 44-50.
289. Moeller A, Horak FJ, Lane C, Knight D, Kicic A, Brennan S, et al. Inducible NO
synthase expression is low in airway epithelium from young children with cystic
fibrosis. Thorax 2006; 61: 514-520.
290. Corbelli R, Bringolf-Isler B, Amacher A, Sasse B, Spycher M, Hammer J. Nasal nitric
oxide measurements to screen children for primary ciliary dyskinesia. Chest 2004;
126: 1013-1014.
291. Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. Lancet 2002; 360: 1313-1322.
292. Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL. Inflammation,
infection, and pulmonary function in infants and young children with cystic fibrosis.
Am J Respir Crit Care Med 2002; 165: 904-910.
293. Özdemir A, Brown MA, Morgan WJ. Markers and mediators of inflammation in
neonatal lung disease. Pediatr Pulmonol 1997; 23: 292-306.
294. Eber E, Zach MS. Long term sequellae of bronchopulmonary dysplasia (chronic lung
diseas of infancy). Thorax 2001; 56: 317-323.
295. De Rose V. Mechanisms and markers of airway inflammation in cystic fibrosis. Eur
Respir J 2002; 19: 333-340.
296. Scheinmann P, Pedersen S, Warner JO, de Blic J. Methods for assesment of airway
inflammation: paediatrics. Eur Respir J 1998; 26: 53s-58s.
297. Kim JS, Hackley GH, Okamoto K, Rubin BK. Sputum processing for evaluation of
inflammatory mediators. Pediatr Pulmonol 2001; 32: 152-158.
298. Kips JC, Fahy JV, Hargreave FE, Ind PW, in’t Veen JC. Methods for sputum induction
and analysis of induced sputum: a method for assessing airway inflammation in
asthma. Eur Respir J 1998; 11: 9s-12s.
299. Nightingale JA, Rogers DF, Barnes PJ. Effect of repeated sputum induction on cell
counts in normal volunteers. Thorax 1998; 53: 87-90.
300. Holz O, Richter K, Jorres RA, Speckin P, Mucke M, Magnussen H. Changes in sputum
composition between two inductions performed on consecutive days. Thorax 1998;
53: 83-86.
46
Chapter 1
301. Jöbsis Q, Raatgreep HC, Schellekens SL, Hop WC, Hermans PW, de Jongste JC.
Hydrogen peroxide in exhaled air of healthy children: reference values. Eur Respir J
1998; 12: 483-485.
302. Baraldi E, Ghiro L, Piovan V, Carraro S, Zacchello F, Zanconato S. Safety and success
of exhaled breath condensate collection in asthma. Arch Dis Child 2003; 88: 358-
360.
303. Hunt J. Exhaled breath condensate: an evolving tool for noninvasive evaluating of
lung disease. J Allergy Clin Immuol 2002; 110: 28-34.
304. Horak FJr, Stoer H, Holler B. Measurement of nitrite in the breathing-condensate of
healthy infants and infants with cystic fibrosis. Am J Respir Crit Care Med 2002; 165:
A485.
305. Moeller A, Franklin PJ, Hall GL, Stick SM. Limitations of breath condensates in
infants. Am J Respir Crit Care Med 2003; 167: A987.
306. Griese M, Latzin P, Beck J. A noninvasive method to collect nasally exhaled air
condensate in humans of all ages. Eur J Clin Invest 2001; 31: 915-920.
307. Jöbsis Q, Raatgreep HC, Hermans PW, de Jongste JC. Hydrogen peroxide in exhaled
air is increased in stable asthmatic children. Eur Respir J 1997; 10: 519-521.
308. Dohlman AW, Black HR, Royall JA. Expired breath hydrogen peroxide is a marker of
acute airway inflammation in pediatric patients with asthma. Am Rev Respir Dis
1993; 148: 955-960.
309. Latzin P, Griese M. Exhaled hydrogen peroxide, nitrite and nitric oxide in healthy
children: decrease of hydrogen peroxide by atmospheric nitric oxide. Eur J Med Res
2002; 30: 353-358.
310. Jöbsis Q, Raatgreep HC, Schellekens SL, Kroesbergen A, Hop WC, de Jongste JC.
Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis
during antibiotic treatment. Eur Respir J 2000; 16: 95-100.
311. Baraldi E, Ghiro L, Piovan V, Carraro S, Ciabattoni G, Barnes PJ, Montuschi P. Increased
exhaled 8-isoprostane in childhood asthma. Chest 2003; 124: 25-31.
312. Baraldi E, Carraro S, Alinovi R, Pesci A, Ghiro L, Bodini A, Piacentini G, Zacchello F,
Zanconato S. Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate
of children with asthma exacerbations. Thorax 2003; 58: 505-509.
313. Csoma Zs, Kharitonov SA, Balint B, Bush A, Wilson NM, Barnes PJ. Increased
leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit
Care Med 2002; 166: 1345-1349.
314. Formanek W, Inci D, Lauener RP, Wildhaber JH, Frey U, Hall GL. Elevated nitrite in breath
condensates of children with respiratory disease. Eur Respir J 2002; 19: 487-491.
315. Cunningham S, McColm JR, Pei Ho L, Greening AP, Marshall TG. Measurement of
inflammatory markers in the breath condensate of children with cystic fibrosis. Eur
Respir J 2000; 15: 955-957.
316. Csoma Zs, Bush A, Wilson NM, Donnelly L, Balint B, Barnes PJ, Kharitonov SA. Nitric
oxide metabolites are not reduced in exhaled breath condensate of patients with
primary ciliary dyskinesia. Chest 2003; 124: 633-638.
317. Shahid SK, Kharitonov SA, Wilson NM, Bush A, Barnes PJ. Increased interleukin-4
and decreased interferon-g in exhaled breath condensate of children with asthma.
Am J Respir Crit Care Med 2002; 165: 1290-1293.
47
General Introduction
318. Corradi M, Folesani G, Andreoli R, Manini P, Bodini A, Piacentini G, Carraro S,
Zanconato S, Baraldi E. Aldehyde and glutathione in exhaled breath condensate of
children with asthma exacerbation. Am J Respir Crit Care Med 2003; 167: 395-399.
48
Chapter 1
49
General Introduction

CHAPTER 2
EXHALED BREATH CONDENSATE IN CHILDREN:
PEARLS AND PITFALLS.
Rosias PPR, Dompeling E, Hendriks JH, Heijnens JW, Donckerwolcke RAMG, Jöbsis Q.
Pediatric Allergy and Immunology 2004; 15: 4-19.
Abstract 
Exhaled breath condensate (EBC) is a rapidly growing field of research in respiratory
medicine. Airway inflammation is a central feature of chronic lung diseases, like
asthma, cystic fibrosis, bronchopulmonary dysplasia and primary ciliary dyskinesia.
EBC may be a useful technique for non-invasive assessment of markers of airway
inflammation. The non-invasive character of EBC ‘inflammometry’ and the general
lack of appropriate other techniques makes it particularly interesting for paediatrics.
We provide a detailed update on the methods currently used for EBC collection
and measurement of mediators. We emphasise on paediatric data. The apparent
simplicity of the EBC method must not be over-stated, as numerous methodological
pitfalls have yet to overcome. Comparison and interpretation of data on this rapidly
growing field of research is mainly hampered by the lack of standardisation and the
lack of specific high-sensitivity immunochemical or colorimetric assays. The initiative
of the European Respiratory Society to institute a task force on this topic is a first step
towards a uniform technique of EBC. Meanwhile, when using this technique or when
interpreting research data, one should be fully aware of the possible methodological
pitfalls.
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Introduction
Coughing, wheezing and dyspnoea are common presenting respiratory symptoms in
children. They constitute a major diagnostic challenge, not only due to the coexistence
of different types of inflammatory lung diseases in infancy and childhood, like asthma,
cystic fibrosis, bronchopulmonary dysplasias and primary ciliary dyskinesia, but also
due to the lack of appropriate diagnostic techniques in young children 1-4.
Markers of airway inflammation may help to: distinguish between different
inflammatory phenotypes, assess the severity of airway inflammation, monitor
customized treatment, and develop new therapeutic strategies, resulting in more
accurate use of anti-inflammatory medication. Furthermore, it may improve compliance
and disease control, and may even lead to new pathophysiological insights 5. Especially
in young children, there is a strong need for a reliable non-invasive assessment of
airway inflammation or ‘inflammometry’.
The collection of exhaled breath condensate (EBC) has been proposed as a simple,
quick, safe, comfortable and non-invasive technique suitable for assessment of airway
inflammation by obtaining samples from the lower respiratory tract of humans with
inflammatory lung disease at any age, without disturbing the ongoing inflammation 6-13.
EBC ‘inflammometry’ is particularly interesting for paediatrics. The purpose of this
review is to facilitate comparison and interpretation of data on this rapidly growing
field of research, by assessing its pearls and pitfalls. Therefore, we provide a detailed
update on the methods currently used for EBC collection and measurement of
mediators. If available, we emphasise on paediatric data, from full papers rather than
abstracts (which are known not to have undergone peer review and, therefore, are
marked with an asterisk).
Principles of EBC
Exhaled breath is saturated with water vapour, which will condensate by breathing
through a cooling or freezing system. Although the condensate consists mostly of
water vapour, it also contains aerosol particles or respiratory fluid droplets. These
droplets are released from the lung epithelial lining fluid, and they contain traces of
non-volatile solutes, which can be recovered in EBC samples 6,13-16,17*-18*.
The mechanism of formation of aerosol particles has not yet been fully elucidated.
Aerosolization of extracellular lining fluid can occur as a result of turbulence in the
airways, or during the popping-open of closed respiratory bronchioles and alveoli in
the absence of bulk flow 3. The number of aerosol particles formed in the respiratory
tract depends on the current velocity of air and the surface tension of extracellular
lining fluid: a higher velocity and a lower surface tension favour the production of
aerosols 3,8. The balance between low velocity and high surface tension at alveolar
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level determines the generation of aerosols. In addition, turbulent flow and higher
number of edges in branching points may facilitate aerosol formation 3,8. The bronchial
circulation is essential in humidification of inspired air, which in turn may be a
determinant of the rate at which EBC is formed 19. In mechanical ventilation, increased
pressure amplitude leads to an increase in EBC volume (per total respired volume), due
to increased alveolar closure and reopening. This pressure amplitude-induced shear
stress results in generation of aerosolized droplets 20*.
During tidal breathing, concentrations of aerosol particles range between <0.1
and 4 particles/cm3, depending upon the subject and its activity. Subjects at rest exhale
lower concentrations of particles, whereas exercise causes an increase in the number
of exhaled particles. Their mean diameter is <0.3 µm, and few particles (<2%) have
diameters >1 µm 6,21-22.
Various inflammatory diseases and each of their different stages may influence
aerosol formation in a particular way. In asthma, laser spectroscopy of EBC showed
different particle distribution at different stages of disease: preponderant small
particles (diameter ranging from 51 to 200 nm) in severe forms of asthma, and more
large particles (diameter >600 nm) in mild and moderate asthma 23*.
The exact location where aerosol particles originate in the respiratory tract and
their proportional contribution to EBC composition is not fully understood 24*-26*. To
our knowledge, no paediatric data on this subject have been published.
Collection of EBC
1. Condenser systems
Currently, different research groups use different condenser systems, all based on the
same principle of cooling exhaled air 27-31,32*-33*. Most widely used designs include
immersion of a Teflon-lined tubing in an ice-filled bucket, and a specially designed
double-wall borosilicate glass condenser system (Fig. 1). Commercially available
condensers are EcoScreen (Erich Jaeger GmbH, Hoechberg, Germany) and RTube
breath condensate collector (Respiratory Research Inc, Charlottesville, USA). Although
cooling of exhaled air, conducted through a Teflon-lined tubing, can be readily
achieved using wet ice as well as dry ice or liquid nitrogen, complete obstruction of
the collection tube has been reported 8. The EcoScreen system conducts exhaled air
through a lamellar condenser with a sample collection vial inserted into a cooling cuff
(electric refrigerator) 12. Alternative methods are the use of countercurrent circulating
ice-water for cooling of exhaled air which is conducted through a double-wall
borosilicate glass condenser system, or the portable RTube breath condensate collector
which consists of a re-usable and pre-cooled aluminium sleeve, placed over the
outside of a disposable vertical condensation or collection (polypropylene) tube, and
connected to two one-way valves and a mouthpiece. The latter systems are not
associated with the problem of complete obstruction. 
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Minimal or no adaptation is necessary for use of these condenser systems either
in children, or in mechanically ventilated subjects, which are connected through the
expiratory limb of the ventilatory tubing 27.
The main obstacle for developing a standardised sampling device, may be the
variety of physical characteristics associated with each condenser system design. The
coating or adhesive properties of the inner surface of the condenser system and even
of the collection container and/or the aliquot vials have to be compared, because this
can influence the concentration of the inflammatory mediator in the collected
condensate. Ideal coating properties for one specific type of mediator(s) may not hold
for another. When analysis of bioactive lipids is planned, polypropylene should be
considered for collection to avoid the problem of adsorption that can occur with
borosilicate glass or polystyrene containers 8.
Nasal collection of EBC is reported in minimal co-operative patients like children
aged 4 weeks and older for the analysis of hydrogen peroxide 34. Nasal prongs are
serially connected to two polypropylene tubes, submerged in a cold trap, and in turn
connected to an electric air suction pump. This procedure allows the collecting of only
a fraction of about 20-30% of the exhaled breath water vapour 34. However,
contamination with nasal secretions may interfere with the actual concentration of
the mediator in the lower respiratory tract. 
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Figure. 1. Schematic representation of an exhaled breath condensate collection device
The subject breaths tidally and inhales room air (1) through a two-way non-rebreathing valve (2).
Exhaled air is guided by the tubing through a double-wall glass condenser (4), which is cooled by
a counter-current circulating ice-water pump (3). The two-way non-rebreathing valve (2) and
tubing also serve as a saliva trap.
2. EBC collecting procedure
Minimal co-operation from the subjects is required for the technique of EBC collection.
In children, the main issue for inclusion for EBC sampling is if they are able to use a
mouthpiece properly for 10-15 minutes. Adequate instruction of the procedure and
distraction of the child, for example by using video cartoons, is important. Collecting
EBC is not only a simple procedure, but also a safe one. No adverse effects were seen
in an EBC collection study in 93 healthy children aged 8-13 years 35. In a study of 91
children with asthma of varying severity, the EBC procedure proved to be safe, even
in children with an asthma exacerbation. The success rate was 100% starting from 4
years of age 36.
Currently, the most widely used procedure is to breath tidally and directly into the
tubing system. Often, a mouthpiece is used, connected to a two-way non-rebreathing
valve, which also prevents potential re-breathing of exhaled breath samples. Minute
ventilation (or total respired volume) and breathing pattern are the major determinants
of EBC volume over time 37-40,41*. It is suggested to describe these respiratory parameters
per EBC measurement, because their influence on mediator concentration is not yet
known. Exhalation flow may influence the concentration of biomarkers in EBC as it
does in exhaled nitric oxide measurements. Therefore, assessing the flow dependence
of different biomarkers is crucial for the standardization and reproducibility of
measurements. On the basis of the flow dependence, EBC sampling will be carried out
either at a constant flow rate for a fixed time, or at a constant total exhaled volume
for a variable time 5.
The use of nose clips in the prevention of contamination of the EBC with nasal air,
remains controversial 9,12. Application of nose clips could open the nasopharyngeal
velum, thereby contaminating the exhaled breath with nasal air. This could be relevant
when measuring mediators, such as eicosanoids, which are also formed in the nose
and paranasal sinuses 8,12. Alternatively, a facemask that separates nasal from oral
exhaled air can be used. In infants, who are preferential nasal breathers, collection of
EBC via a facemask is feasible 42*. However, significant nasal contribution to total
nitrite/nitrate was found, suggesting to limit EBC analysis in infants to compounds not
affected by nasal contribution, or to limit EBC collection to sedated infants with
induced oral breathing 42*.
The influence of paranasal sinuses is shown in a study on nitric oxide and humming,
which generates an oscillating airflow and enhances paranasal sinus ventilation 43.
Humming increases significantly (15-fold) nasal nitric oxide levels compared with quiet
exhalation 43. Prostanoid levels in healthy subjects are the same with or without using
a nose clip 44*. The volume of EBC is larger when subjects inhale through the nose,
but mediator levels of adenosine, hypoxanthine, inosine, ammonia and thromboxane-
B2 are the same as with oral breathing 45.
Salivary contamination influences the level of several markers that are detectable
in EBC. Therefore, prevention of salivary contamination is important. This can be
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achieved by using a gravity-saliva trap, rinsing of the mouth/mouth-washing with
sodium bicarbonate 4.5% prior to collection, periodic swallowing of the accumulated
saliva to maintain a dry mouth during collection, and prevention of coughing or forced
expiration 8,46*. Amylase and phosphorus measurements can be used to exclude
salivary contamination of the condensate 6,15,47*.
Fluctuations of environmental and breath temperature during the sampling period
may influence the preservation of some labile lipid mediators 9. Leukotriene-B4 and
8-isoprostane values, but not ammonia and nitrite, are independent of collection
temperature in healthy subjects 48*. Furthermore, environmental ozone concentration
at the time of collecting samples is significantly related to the hydrogen peroxide
concentration in EBC 49*. A study on the short-term exposure to ozone showed
induction of airway inflammatory mediators: an immediate increase of hydrogen
peroxide and 8-isoprostane levels in EBC, and a delayed increase (at 18 hours after
exposure) of leukotriene-B4 and thiobarbituric acid reactive substances 50.
It is unclear whether a circadian rhythm in mediator concentrations exists 51*-53*,54.
Afternoon collection of EBC may increase or maximize the volume of EBC 55*.
The duration of EBC collection is variable. In general, a collection time of 15-20
minutes will yield 1-3 ml of EBC in children aged 4 years and over (own unpublished
data). A rapid two-minute method of EBC collection for ammonia and pH
measurements yields 0.25-0.35 ml 3,56*.
In summary, an optimal procedure for one specific mediator may not hold for
another, emphasising that during EBC collection one should systematically run through
a checklist of possible influencing factors or co-determinants (Table 1).
3. Preservation of EBC
In general, condensate is collected in small containers ‘on ice’. This method allows
subsequent pipetting of separate aliquot vials. This is not possible when the condensate
is collected in frozen condition, as with the EcoSscreen. The temperature of the cooling
sleeve of the RTube breath condensate collector can be chosen by the investigator, and
depends on the temperature of the refrigerator where the sleeve was stored in 3.
Subsequently, each separate aliquot vial can in turn rapidly be frozen and stored
at -20ºC to -70ºC until analysis is performed. In general, an EBC sample volume of
0.05-0.5 ml is sufficient to perform one of the currently used assays. 
Sequences of changing phases (gas–fluid–frozen) may influence the concentration
of some unstable EBC constituents, and should be kept limited. The value of high
velocity freezing processes (for example submerging the aliquot vials in a solution of
isopentane) needs to be investigated, as well as the effect of techniques to prevent
rapid degradation of instable proteins or cytokines (by adding bovine serum albumin,
phosphate buffer solution, or proteinase inhibitors). However, bovine serum albumin
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may disturb the determination of some mediators, as nitrite and hydrogen peroxide.
Furthermore, storage time and temperature itself may also be biomarker-dependent.
Acceptable storage conditions have to be evaluated.
58
Chapter 2
Table 1. Checklist of procedure for exhaled breath condensate collection.
Condenser
System
Coating
Cooling temperature
Subject
Age
Sexe
Weigth
Length
Disease (smoking / upper airway infection)
Medication
Breathing pattern (tidal breathing / forced exhalation)
Respiratory parameters (frequency / minute ventilation / total exhaled volume)
Flow
Breath temperature
Lung function parameters
Noseclip / face mask
Prevention of salivary contamination (gravity trap / rinsing mouth / swallowing)
Environment
Temperature
Ozone
Humidity
Collection
Date / hour
Phase of sample (solid / liquid)
Duration
Adverse effects
Volume of exhaled breath condensate
Preservation
Aliquot vial volume
Sample numbers
Products added
Storage temperature
Storage time
Analysis
Data
Assay
Detection limit
Analysis of EBC 
EBC is a human body fluid that contains not only aerosol particles or respiratory fluid
droplets with traces of non-volatile solutes, but also large amounts of pure water
vapour. Therefore, changes in the concentration of inflammatory mediators in EBC
may vary by a factor 100 or more, depending on variations in the concentration
gradient between respiratory fluid droplets and water vapour. 
The concentration of mediators or non-volatile substances in the respiratory tract
lining fluid may be calculated by a method reported by Effros and co-workers, which is
based upon urea or electrolyte concentrations in the condensate 14,18*,57,58*-59*. These
measurements of condensate reference indicators may permit a semi-quantitative analysis
of non-volatile substances in respiratory lining fluid, but need further modification 60*.
Currently, samples of EBC are mostly analysed by commercially available and sensitive
assays, developed for use in other media with higher mediator concentrations than
condensate. Their lower limits of detection are usually situated near the reported
concentrations of markers in EBC. Condensate measurements can be made more
reliable by the development of new, high-sensitivity assays, adapted to the unique
nature of EBC 3,14,61-62. However, current immunochemical or colorimetric assays lack
reference methods and are affected by poor sensitivity, specificity and selectivity 63. These
assays need to be validated with more specific analytical methods, such as gas
chromatography/mass spectrometry or high-performance liquid chromatography 5,63.
These techniques are considered the reference techniques for the determination of
complex mixtures of organic compounds present at nanomol levels in aqueous matrices
62-63. Recently, modified analytical methods have also been described to quantitate low
concentrations of the nitrite/nitrate balance as well as free 3-nitrotyrosine in EBC 64*-65*.
Freeze-drying may be of additional value to facilitate subsequent biochemical
analysis of certain non-lipid mediators. 
The first study identifying surface-active properties of EBC was published in Russia
in 1980 66. In the 1990s, this technique was rediscovered 6. Since then, several
inflammatory mediators have been identified in EBC. However, results from studies
using a wide variety of inflammatory markers have only shown group differences
between specific patient-populations and healthy control subjects, but evidence for
the diagnostic use of these markers in individual patients is scarce 10. Furthermore,
correlations between mediators in EBC and other biological measurements of lung
inflammation, as well as the level of disease control have not yet been demonstrated
sufficiently. Recently, in an animal model, a similar pattern of nitrite and total protein
levels was found in EBC and bronchoalveolar lavage fluid 67*.
Although it is presently an area of active research and an increasing number of
abstracts * are being presented, few studies have been published on children 28,35-
36,63,68-75. We reviewed the available data on this age group until June 2003.
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1. Hydrogen peroxide
Oxidative stress describes an imbalance between oxidants (reactive oxygen species)
and anti-oxidants (superoxide dismutase, catalase, glutathione, uric acid, lactoferrin,
vitamin C, and vitamin E) in favour of oxidants, which contributes to the pathogenesis
of several inflammatory lung diseases 76. The development of such an imbalance in
lung inflammation may activate redox-sensitive transcription factors such as nuclear
factor-kappa B and activator protein-1, which regulate the genes for pro-inflammatory
mediators and protective antioxidant genes 77. Activation of inflammatory and
structural cells result in an increased production of reactive oxygen species. Superoxide
anions are generated by nicotinamide adenine dinucleotide phosphate oxidase and
then converted to hydrogen peroxide by superoxide dismutases. Hydrogen peroxide
is then degraded to water by catalases. Superoxide anions and hydrogen peroxide
may generate the highly reactive hydroxyl radicals, leading to peroxidative damage of
airway structures and formation of volatile thiobarbituric acid reactive substances.
Hydrogen peroxide is less reactive than other reactive oxygen species, and because it
is soluble, increased hydrogen peroxide in the airway equilibrates with air 9,12,78.
Exhaled hydrogen peroxide has potential as a marker of oxidative stress in the
lungs. Exhaled hydrogen peroxide is less stable than other markers, and its concentration
appears to be expiratory flow rate dependent 79. Furthermore, symptomatic upper
respiratory tract infection may act as a confounder in studies on hydrogen peroxide and
chronic lower airway inflammation 80. No significant circadian rhythm in hydrogen
peroxide levels was reported in healthy subjects 52*. However, concentrations of exhaled
hydrogen peroxide showed diurnal variation in both stable chronic obstructive
pulmonary disease patients and healthy controls 54,81. Hydrogen peroxide is measured
in EBC by the spectrophotometric method or the fluorometric method with horseradish
peroxidase 82. Recently, some new techniques have been described: a fast
chemiluminescent method for hydrogen peroxide measurement in EBC 83, on-line
measurement of hydrogen peroxide based on a biosensor with electrochemical
detection and a detection limit of 12.5 nmol 84*-86* and a sensitive (0.02 µmol)
fluorometrical method with a stable storage time of 40 days 61.
Paediatric EBC data on hydrogen peroxide are summarised in Table 2.
Reference data for exhaled hydrogen peroxide have been described in a group of
93 healthy children 35. There was no correlation between the levels of exhaled hydrogen
peroxide and age, sex, or lung function in healthy children 35. Hydrogen peroxide levels
in a study on 102 healthy children was influenced by atmospheric nitric oxide 73.
Exhaled hydrogen peroxide levels were elevated in asthmatic children compared
to healthy controls 28,69. Higher levels of hydrogen peroxide correlated with severity
of asthma 87*. Besides diagnostic purposes, hydrogen peroxide may be used to monitor
therapy. Little data are available on this topic. However, hydrogen peroxide levels were
increased in 16 children with an acute infectious pulmonary exacerbation of cystic
fibrosis, and significantly decreased in EBC during intravenous antibiotic treatment 70.
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In mechanically ventilated children with various non-specified underlying
conditions, hydrogen peroxide was detected in all EBC specimens, but did not correlate
with the severity of illness 88*.
2. Eicosanoids
Eicosanoids are potent mediators of inflammation, which are derived from arachidonic
acid. They include prostaglandins, thromboxane, isoprostanes, leukotrienes and lipoxins.
Prostaglandins and thromboxane are formed through increased expression of inducible
cyclo-oxygenase-2. Most prostaglandins and thromboxane have proinflammatory
properties. Prostaglandin-E2 and Prostaglandin-I2 are anti-inflammatory. 
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Table 2. Hydrogen peroxide in EBC of children, measured by fluorimetric assay (with horseradish peroxidase)
Median value   Median value Lower limit of
patient group healthy controls detection
Disease (micromol) (micromol) P value Reference (µmol)
Asthma 0.81 (†) 0.25 (†) 0.013 28 -
Asthma, stable 0.54 (†) - - 28 -
Asthma, acute 1.50 (†) - < 0.001 28 -
(vs. stable 
asthma)
Asthma 0.60 0.15 < 0.05 69 0.1
Asthma, no ICS 0.80 0.15 < 0.01 69 0.1
Asthma, with ICS 0.45 0.15 n.s. 69 0.1
Asthma, severe 149.5 (‡) 10.9 (‡) < 0.001 87* -
CF, acute infective 0.28 - - 70 0.01
CF, after AB iv 0.16 - 0.002 70 0.01
(vs. acute 
infective)
Ventilated 0.45 - - 88* 0.083
Healthy - 0.13 - 35 0.01
Healthy - 0.49 (§) - 34 -
Healthy - 0.51 - 73 0.05
EBC : exhaled breath condensate
† : µmol/l
‡ : uM/ml
§ : nasally collected EBC
CF : cystic fibrosis
AB iv : antibiotics intravenously
ICS : inhalation corticosteroids
n.s. : not significant
Leukotrienes are lipid mediators derived from arachidonic acid via the 5-lipoxygenase
pathway. Leukotrienes are potent constrictors and proinflammatory mediators that contribute
to the pathophysiology of asthma 9. The cysteinyl-leukotrienes (leukotriene-C4, leukotriene-
D4 and leukotriene-E4) are generated predominantly by mast cells and eosinophils. By
contrast, leukotriene-B4 has potent chemotactic activity towards neutrophils 9,12.
Isoprostanes are formed by free radical-catalysed lipid peroxidation of arachidonic
acid during oxidative stress 9,12,78. They are initially esterified in membrane
phospholipids, from which they are cleaved by a phospholipase-A2 9. F2-isoprostanes
are not only relatively stable and specific markers of lipid peroxidation, but also posses
potent biological activity 89. They can be mediators of the cellular effects of oxidant
stress and are a reflection of complex interactions between the reactive nitrogen
species and reactive oxygen species 8,9,89. The most prevalent isoprostane in humans
is 8-epi-PGF2-alpha also known as 8-isoprostane 9.
Lipoxin-A4 and lipoxin-B4 have potential anti-inflammatory action in asthma, and
lipoxin-A4 is detected in supernatant of induced sputum 90.
Eicosanoids are measured by enzyme immunoassays, using commercially available
detection kits. Recently, validation of measurement of 8-isoprostanes, prostaglandin-E2
and leukotriene-B4 in EBC by reverse-phase high-performance liquid chromatography
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Table 3. 8-isoprostanes in EBC of children
Median Median
value value Lower limit
patient healthy of
group controls detection
Disease (pg/ml) (pg/ml) P value Reference Assay (pg/ml) 
Asthma, acute 12.00 2.60 < 0.01 75 EIA -
Asthma, after OCS 8.40 2.60 < 0.001 75 EIA -
(< 0.05 
vs acute)
Asthma, no ICS 9.34 3.81 < 0.01 95* EIA 4
Asthma, with ICS 6.73 3.81 < 0.01 95* EIA 4
Asthma, no ICS 61.90 33.60 < 0.01 101* RIA -
Asthma, with ICS 64.30 33.60 < 0.01 101* RIA -
Asthma, with ICS 47.20 34.20 < 0.008 99* RIA -
EBC : exhaled breath condensate
EIA : enzyme immuno assay
ICS : inhalation corticosteroids
OCS : oral corticosteroids
RIA : radio immuno assay
or by gas chromatography/mass spectrometry has been reported 12,91,92*-93*. Exhaled 8-
isoprostane and prostaglandin-E2 are not flow dependent in healthy subjects 94*. The
EBC levels of prostaglandin-E2 and thromboxane-B2 in healthy subjects with or
without nose clip are comparable 44*.
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Table 4. Cysteinyl-leukotrienes in EBC of children
Median Median
value value Lower
Patient healthy limit of
group controls detection
Disease (pg/ml) (pg/ml) P value Reference Assay (pg/ml)
Asthma, mild intermittent 19.90 18.50 n.s. 74 EIA† 15
Asthma, mild persistent 27.90 18.50 < 0.01 74 EIA† 15
Asthma, moderate 31.50 18.50 < 0.05 74 EIA† 15
to severe
Asthma, mild 19.40 17.20 - 96* EIA† 17
Asthma, moderate 22.90 17.20 < 0.001 96* EIA† 17
Asthma, severe 27.70 17.20 - 96* EIA† 17
Asthma, allergic 14.26 - 102* EIA
Asthma, after 3 months 4.60 - < 0.01  102* EIA
HDM free (vs allergic
asthma)
Asthma, no ICS 12.30 4.90 0.01 97* EIA† 17
Asthma, with ICS 10.50 4.90 0.01 97* EIA† 17
Asthma, no ICS 30.50 15.90 < 0.05 100* EIA -
Asthma, with ICS 31.80 15.90 < 0.05 100* EIA -
Asthma, acute 12.70 4.30 < 0.01 75 EIA† 17
Asthma, after OCS 5.20 - < 0.01  75 EIA† 17
(vs. acute
asthma)
Asthma 14.70 - - 106* ELISA 4.5
CF 9.30 - - 106* ELISA 4.5
PCD 21.70 17.20 - 107* EIA† 17
EBC : exhaled breath condensate
n.s. : not significant
EIA† : enzyme immuno assay (Cayman Chemical, Ann Arbor, Michigan, USA)
HDM : house dust mite
ICS : inhalation corticosteroids
OCS : oral corticosteroids 
ELISA : enzyme linked immuno sorbent assay (DPC Biermann, Bad-Neuheim, Germany)
CF : cystic fibrosis
PCD : primary ciliary dyskinesia
Paediatric EBC data on eicosanoids are summarised in Tables 3-6.
In asthmatic children, elevated eicosanoids were found when compared with
healthy children 74,95*-101*. An inverse correlation between exhaled cysteinyl-
leukotrienes and leukotriene-B4 in children with mild persistent asthma was assessed,
which may reflect the contrary effect of steroids on eosinophil and neutrophil survival
74. No significant diurnal variation in cysteinyl-leukotriene levels was found in asthmatic
children 51*. Reduced cysteinyl-leukotrienes were reported after 3 months of house
dust mite avoidance in allergic asthmatic children 102*. After a course of oral steroid
therapy, a reduction was seen in cysteinyl-leukotrienes and 8-isoprostanes of children
with an asthma exacerbation 75. Leukotriene-B4 was significantly increased after
isocapnic hyperventilation with cold air in children with stable asthma, but not in the
control group 103*-104*. No correlation with spirometric measurements was found
74,96*-99*.
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Table 5. Leukotriene-B4 in EBC of children
Median Median
value value Lower limit
patient healthy of
group controls detection
Disease (pg/ml) (pg/ml) P value Reference Assay (pg/ml) 
Asthma, mild intermittent 52.7 47.9 n.s. 74 EIA† 4.4
Asthma, mild persistent 126.0 47.9 < 0.0001 74 EIA† 4.4
Asthma, moderate 131.9 47.9 < 0.0001 74 EIA† 4.4
to severe
Asthma, mild 69.8 62.7 - 96* EIA† 4
Asthma, moderate 137.7 62.7 < 0.001 96* EIA† 4
Asthma, severe 137.5 62.7 < 0.001 96* EIA† 4
Asthma, before IHV 25.8 - 103* - -
Asthma, after IHV 35.5 - < 0.05 103* - -
(vs before)
Asthma, no ICS 26.3 19.8 n.s. 100* EIA -
Asthma, with ICS 24.8 19.8 n.s. 100* EIA -
Asthma 58.0 37.8 n.s. 98* EIA†
PCD 54.7 54.5 - 107* EIA† 4
EBC : exhaled breath condensate
n.s. : not significant
EIA† : enzyme immuno assay (Cayman Chemical, Ann Arbor, Michigan, USA)
IHV : isocapnic hyperventilation
ICS : inhalation corticosteroids
PCD : primary ciliary dyskinesia
In children with severe atopic eczema but without asthma, increased cysteinyl-
leukotrienes were found in EBC 105*.
In children with cystic fibrosis and primary ciliary dyskinesia, cysteinyl-leukotrienes
were detected in EBC 106*-107*.
Decreased concentrations of prostaglandin-E2 were reported in children with primary
ciliary dyskinesia, compared with healthy controls 107*. No differences were seen in the
levels of leukotriene-B4 and cysteinyl-leukotrienes between these children 107*.
3. Nitrogen-reactive species
Nitrite/nitrate, S-nitrosothiols and 3-nitrotyrosine are nitrogen-reactive species. The
reaction between nitric oxide and superoxide anions in the airways results in the
formation of peroxynitrite, a reactive oxygen species. Peroxynitrite can be trapped by
thiol-containing biomolecules such as cysteine and glutathione, to form S-nitrosothiols
or can be oxidized to nitrate and nitrite 9,12,78. Peroxynitrite reacts with tyrosine
residues in proteins to form the stable end-product 3-nitrotyrosine, which is used as
a diagnostic tool to identify involvement of nitric oxide-derived oxidants in various
disease states 8,9,12. The balance between nitrite/nitrate, S-nitrosothiols, and
nitrotyrosine gives insight into nitric oxide synthesis and short- and long-term changes
in nitric oxide production 9,12.
The nitrite/nitrate balance is determined by colorimetric assay (based on the Griess
reaction), by fluorometric assay (based on the 2,3-diaminonaphtalene reaction), or by
an ionic chromatograph analyser 108-109,110*. Recently, a method based on gas
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Table 6. Prostaglandin-E2 in EBC of children
Median Median
value value Lower limit
patient healthy of
group controls detection
Disease (pg/ml) (pg/ml) P value Reference Assay (pg/ml) 
PCD 15.7 19.7 <0.05 107* EIA 15
Asthma, no ICS 28.8 22.6 n.s. 101* RIA -
Asthma, with ICS 24.0 22.6 n.s. 101* RIA -
Asthma, with ICS 51.5 46.8 n.s. 99* RIA -
EBC : exhaled breath condensate
PCD : primary ciliary dyskinesia
EIA : enzyme immuno assay (Cayman Chemical, Ann Arbor, Michigan, USA)
ICS : inhalation corticosteroids
n.s. : not significant
RIA : radio immuno assay
chromatography/mass spectrometry was developed that allows simultaneous
quantification of nitrite and nitrate in various biological fluids 111. Furthermore, a
modification of the Griess method is described for use with EBC, with a detection limit
of 0.640 µmol 64*. Several methods are used for the detection of S-nitrosothiols and
nitrotyrosine 112-115. To quantitate low concentrations of free 3-nitrotyrosine in EBC, a
mass-selective determination was developed and validated 65*.
Paediatric EBC data on nitrogen-reactive species are summarised in Tables 7 and 8.
In healthy children, nitrite values were not related to the levels of exhaled nitric
oxide 73.
Although, in 23 children with and without respiratory disease, expiratory flow
patterns did not significantly alter mean total nitrite/nitrate levels in EBC, large intra-
subject variation was found 116*.
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Table 7. Nitrite in EBC of children
Median Median
value value Lower limit
patient healthy of
group controls detection
Disease (µmol) (µmol) P value Reference Assay (µmol)
Asthma, no ICS 0.87 0.31 0.009 118* - -
Asthma, mild 2.02 0.41 < 0.05 71 C -
Asthma, moderate 3.51 0.41 < 0.05 71 C -
CF, mild 2.16 0.41 < 0.05 71 C -
CF, moderate 1.87 0.41 < 0.05 71 C -
CF, severe 2.13 0.41 < 0.05 71 C -
CF 3.30 1.00 0.018 68 C 0.074
CF 4.13 3.70 n.s. 33* C -
PCD 2.40 1.80 n.s. 120* F -
Cough 0.75 0.41 n.s. 71 C -
Healthy - 3.30 - 73 F 0.1
EBC ; exhaled breath condensate
ICS : inhalation corticosteroids
C : colorimetric assay (Griess reaction)
CF : cystic fibrosis
n.s. : not significant
PCD : primary ciliary dyskinesia
F : fluorimetric assay (2,3 di-amino-naphtalene)
In children with cystic fibrosis, elevated levels of nitrite were found in EBC compared
to controls 68,71. There was no significant correlation between condensate nitrite
values and age, lung function indices, chest radiograph score, or the use of inhaled
steroids 68. Nitrite levels were not correlated with the severity of cystic fibrosis 68. In
infants with cystic fibrosis, nitrite was measured using a copper baby-condensate-
sampler 33*. However, no statistical difference in nitrite was found between infants
with cystic fibrosis and healthy infants 33*. Nitrotyrosine levels did not differentiate
between children with cystic fibrosis and healthy subjects, and there was no correlation
with lung function 117*.
In asthmatic children, significantly elevated levels of nitrite were found in EBC
compared to controls 71,118*. Nitrite levels were not correlated with age, family history
of asthma, anti-inflammatory treatment, number of allergic sensitisations, or the
severity of asthma 71.
After treatment with inhaled corticosteroids, a significant reduction in nitrite was
only observed in asthmatic patients with a clinical improvement 118*. Nitrotyrosine
levels were increased in asthmatic children compared to normal children, but no
correlation was observed with exhaled nitric oxide 119*.
In primary ciliary dyskinesia, levels of nitrite and nitrite/nitrate were not increased 120*.
4. Other markers of oxidative stress
A key feature in the pathophysiology of inflammatory lung diseases is the development
of an imbalance between oxidants (reactive oxygen species) and anti-oxidants
(glutathione), known as oxidative stress 76.
Glutathione is formed by the selenium-dependent enzyme glutathione peroxidase
and it is a vital intra- and extra-cellular protective antioxidant against oxidative/ nitrosative
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Table 8. 3-nitrotyrosine in EBC of children
Median Median
value value Lower limit
patient healthy of
group controls detection
Disease (pg/ml) (pg/ml) P value Reference Assay (pg/ml) 
Asthma, moderate 13.5 5.3 <0.05 119* EIA -
CF 1.60 1.69 n.s. 117* EIA -
EBC : exhaled breath condensate
EIA : enzyme immuno assay (Cayman Chemical, Ann Arbor, Michigan, USA)
CF : cystic fibrosis
n.s. : not significant
stresses, which play a key role in the control of proinflammatory processes in the lung
76,77. Glutathione is important in immunomodulation, remodelling of the extracellular
matrix, apoptosis and mitochondrial respiration 77. Glutathione can be measured in EBC
by modified high-performance liquid chromatography with fluorescence detection 63.
Reactive oxygen species generated close to cell membranes deplete intracellular
glutathione and oxidize membrane phospholipids (membrane lipid peroxidation), which
may continue in a chain reaction 77. Endogenously generated aldehydic lipid peroxidation
products are malondialdehyde, α,ß-unsaturated aldehydes and saturated aldehydes
(hexanal, heptanal, nonanal). Aldehydes are involved in many of the pathophysiologic
effects associated with oxidative stress in cells and tissues 77,121. Malondialdehyde is
generated mainly by arachidonic acid and docosahexenoic acid. α,ß-unsaturated
aldehydes are formed by lipid peroxidation of ω-6 (arachidonic acid and linoleic acid) and
ω-3 (oleic acid) polyunsaturated fatty acids. Saturated aldehydes are breakdown products
of oxidised linoleic acid and arachidonic acid, palmitoleic acid and oleic acid 63.
Malondialdehyde can be quantified as (volatile) thiobarbituric acid reactive substances,
but the colorimetric assay lacks specificity 63. Recently, malondialdehyde was measured
by high-performance liquid chromatography separation and fluorescence detection (with
a detection limit of 4.1 nmol), or after derivatization by liquid chromatography-tandem
mass spectrometry 62-63,122. In subjects with asthma and chronic obstructive pulmonary
disease, the concentration of aldehydes in condensate was not affected by expiratory
flow rates, sampling time, total exhaled air volume, and total condensate volume 63,122.
Paediatric EBC data on glutathione and malondialdehyde are summarised in Table 9.
In children with an asthma exacerbation, malondialdehyde levels were higher and
glutathione levels were lower compared to healthy controls 63. After a course of oral
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Table 9. Malondialdehyde and glutathione in EBC of children
Median value Median value
patient group healthy controls
Mediator Disease (nanomol) (nanomol) P value Reference
Malondialdehyde Asthma, 30.2 19.4 0.002 63
acute
Asthma, 18.5 0.001 63
after OCS (vs.acute)
Glutathione Asthma, 5.96 14.1 <0.0001 63
acute
Asthma, 8.44 0.04 63
after OCS (vs.acute)
EBC : exhaled breath condensate
OCS : oral corticosteroids
prednisone, malondialdehyde levels decreased, whereas glutathione levels increased 63.
No differences were observed among these marker levels obtained at different flow
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Table 10. Cytokines in EBC of children
Median Median
value value Lower limit
patient healthy of
group controls detection
Cytokine Disease (pg/ml) (pg/ml) P value Reference Assay (pg/ml) 
IL-4 Atopy 1.94 - - 125* ELISA† 0.13
Asthma, 7.68 1.34 - 124* EIA -
atopic
Allergic 5.36 1.34 - 124* EIA -
rhinitis
Allergic 1.78 1.34 n.s. 123* EIA -
rhinitis
Asthma, 1.54 1.34 n.s. 123* EIA -
atopic
Asthma, 5.67 - n.s. 123* EIA -
acute (vs. atopic
asthma)
Asthma, 53.7 35.7 < 0.05 72 ELISA‡ 20
no ICS
Asthma, 37.5 < 0.05 72 ELISA‡ 20
with ICS (vs. no ICS)
IFN-g Asthma, 3.7 5.1 < 0.01 72 EIA§ 0.5
no ICS
Asthma, 4.1 n.s. 72 EIA§ 0.5
with ICS (vs. no ICS)
IL-8 CF 47 10 n.s. 68 ELISA¶ 0.5
EBC : exhaled breath condensate
IL : interleukin
ELISA : enzyme linked immuno-sorbent assay
† : R&D systems, Minneapolis, USA
EIA : enzyme immuno assay
n.s. : not significant
ICS : inhalation corticosteroids
‡ : Cayman Chemical, Ann Arbor, Michigan, USA
IFN-g : interferon gamma 
§ : Pierce Endogen, Rockfort, Illinois, USA
CF : cystic fibrosis
¶ : home made
rates 63. No correlation was found between biomarker levels and spirometric values 63.
α,ß-unsaturated aldehydes were detectable only in a few EBC samples, but chemically
stable saturated aldehydes were detectable in all EBC samples 63.
Furthermore, the observed bi-directional changes in malondialdehyde and
glutathione levels in EBC of asthmatic children show that EBC analysis does not simply
represents alterations of turbulent airflow and airway obstruction 63.
5. Cytokines
Cytokines are intercellular low molecular weight (<80 kDa) immune regulatory peptides
involved in controlling the local and/or systemic consequences of injury, inflammation,
haematopoiesis, and tissue repair. Their effects start by binding to specific high-affinity
cell surface receptors that cause alteration of gene expression in the target cells. An
increasing number of cytokines are being described. They are categorised as T-cell
derived lymphokines, proinflammatory cytokines, anti-inflammatory (inhibitory)
cytokines and growth factors. Analysis of cytokines is performed by enzyme
immunoassay, using (modified) commercially available detection kits. 
Paediatric EBC data on cytokines are summarised in Table 10.
In cystic fibrosis, proinflammatory interleukin-8 was present in only 30% of the
children with clinically stable disease 68. Although the values were higher than in
healthy controls, there was no statistically significant difference 68.
In asthmatic children, significantly increased mean interleukin-4 levels and decreased
mean interferon-gamma levels were found compared with normal children 72. The
levels of exhaled interleukin-4 were lower under steroid treatment 72.
In atopic children with stable asthma or allergic rhinitis, the concentrations of
interleukin-4 were statistically not different from those in non-atopic controls 123*-124*.
After allergen exposure or asthma exacerbation, higher levels of interleukin-4 were
found 123*,125*.
6. Immunoglobulin E
Immunoglobulin E was not demonstrated by nephelometric technique in EBC of
children with allergic asthma 32*. However, by enzyme immunoassay, immunoglobulin-
E was detected in all samples of atopic children and controls with considerable
overlap, values ranging from 20 to 230 IU/ml 123*-126*. After allergen exposure, an
increase of immunoglobulin-E in EBC was found 126*.
7. Eosinophilic Cationic Protein
In EBC of children with asthma and healthy controls, eosinophilic cationic protein was
detected in similar concentration 127*.
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8. Acidity of EBC 
The degree of airway acidification or acidopnea may serve as a simple and inexpensive
method to monitor respiratory inflammation. However, the measurement of the pH
of EBC remains controversial because of methodological issues and the possible
influence of salivary contamination 128-135,136*-139*. Furthermore, the complex
determinants of the pH of EBC need to be clarified. A direct comparison between the
pH of EBC and in situ measurement of bronchial mucosal fluid pH in mechanically
ventilated adults, showed significantly higher in situ pH measurements 140*. These
results suggest different anatomo-pathophysiology, or may reflect that vaporization
by itself may favour the lower pH of EBC 140*.
In asthmatic children, no significant correlation between EBC acidity, lung function,
exhaled carbon monoxide and exhaled nitric oxide was found 141*.
In children with cystic fibrosis, the pH of EBC was decreased during infective
exacerbations, but there was no significant difference between stable children with
cystic fibrosis and healthy controls 142*. The reduced pH of EBC in children with cystic
fibrosis was associated with a lower level of EBC ammonium 143*.
9. Bacteria and inflammatory cells
Reports on negative detection results are scanty, but their interpretation may guide
further research developments. 
No bacteria or cells were detectable in EBC of 14 cystic fibrosis patients, aged 7-
28 years 144*. Cells could not be demonstrated in freshly obtained EBC of 11 atopic
children, aged 6-15 years, as assessed by fluorescence activated cell sorter (own data).
Pearls and pitfalls of EBC
Assessment of inflammatory markers in EBC is a challenging new technique for the
diagnosis and management of various lung diseases. The non-invasive character, the
direct information on airway inflammation, the relatively easy collection procedure,
and the general lack of appropriate techniques of pulmonary function testing in
young children makes it particularly interesting and potentially useful.
The management of different types of chronic respiratory inflammation in
childhood may improve by further developing EBC into an easy, reliable and ‘daily
practice’ clinical tool which may provide us with characteristic profiles of different
biomarkers for different stages of inflammatory lung disease. Hence, it may enlarge
our understanding of the disease process and may provide the potential for more
appropriate customised therapy 10.
Nevertheless, the apparent simplicity of EBC must not be over-stated, as numerous
methodological pitfalls are identified and several problems still have to be solved.
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Comparison and interpretation of data on this rapidly growing field of research is
mainly hampered by the lack of standardization and the lack of specific high-sensitivity
immunochemical or colorimetric assays (Tables 1-10). The application of proteomics,
with high resolution two-dimensional gel electrophoresis and micro-analysis of protein
spots, may allow the recognition of particular protein patterns in different disease and
may result in the recognition of new diagnostic proteins or therapeutic targets 4,145*.
Similarly, the use of fluorescence detection and mass spectrometry-related techniques,
and of high-performance liquid chromatography, may offer advantages not only in terms
of sensitivity, but also in terms of discriminative power and quantitative reliability 63. The
initiative of the European Respiratory Society to institute a task force on this topic is a first
step towards a uniform technique of EBC. 
Future efforts should be directed towards: (i) optimizing the EBC condenser system
and the EBC storage procedures; (ii) standardization of the measurement procedures
of inflammatory markers in EBC; (iii) improving the sensitivity of the assays of
inflammatory markers in EBC; (iv) validation or correlation of markers against more
direct measurements of airway inflammation (biopsies) in groups with various
inflammatory disorders and in healthy subjects; (v) reproducibility, normal variation
(intra- and inter-day) and reference ranges (age dependent) of the inflammatory
marker; (vi) evaluation of the sensitivity and specificity of the various markers or
profiles of markers in differentiating inflammatory airway disorders; (vii) predictive
value of the various exhaled inflammatory markers for early diagnosis and
exacerbations of disease; and (viii) assessing the usefulness of EBC for the guiding of
anti-inflammatory treatment, resulting in better outcome of disease. 
In this way, it will become clear whether EBC is the challenging new technique,
able to improve diagnosis and management of various chronic respiratory disorders in
childhood.
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CHAPTER 3
CHILDHOOD ASTHMA:
EXHALED MARKERS OF AIRWAY INFLAMMATION,
ASTHMA CONTROL SCORE AND LUNG FUNCTION TESTS.
Rosias PPR, Dompeling E, Dentener MA, Pennings HJ, Hendriks JHE, 
Van Iersel MPA, Jöbsis Q. 
Pediatric Pulmonology 2004; 38: 107-114.
Abstract 
Exhaled markers of airway inflammation become increasingly important in the
management of childhood asthma. The aims of the present study are: (i) to compare
exhaled markers of inflammation (nitric oxide, carbon monoxide, acidity of breath
condensate), with conventional asthma measures (lung function tests, asthma control
score) in childhood asthma; and (ii) to investigate the detectability of albumin, C-
reactive protein, interleukin-6, interleukin-8, tumor necrosis factor-alpha, soluble
intercellular adhesion molecule-1 and soluble tumor necrosis factor-receptor-75 in
exhaled breath condensate (EBC) of asthmatic children. 
Thirty-two children with mild to moderate persistent asthma, and healthy controls
aged 6-12 years were studied. We measured exhaled nitric oxide and carbon
monoxide, and subsequently EBC was collected. Inflammatory mediators in EBC were
measured using enzyme-linked immunosorbent assay. Respiratory symptoms and
asthma control were assessed using the asthma control questionnaire of Juniper et al.
Exhaled nitric oxide showed a significant correlation with exhaled carbon monoxide (r
= 0.59, p<0.05) and forced expiratory volume in 1 second (FEV1) (r = -0.59, p<0.05),
but not with asthma control questionnaire score (r = 0.48, p=0.06). 
Exhaled carbon monoxide was correlated with pre-bronchodilator FEV1 (r = –0.45,
p<0.05), but not with asthma control score (r = 0.18, p=0.35). Acidity of EBC was
significantly lower in asthmatic children than in healthy controls (p<0.05), but did not
correlate with any of the conventional asthma measures. We were not able to
demonstrate the presence of C-reactive protein, interleukin-6, interleukin-8, tumor
necrosis factor-alpha, soluble intercellular adhesion molecule-1 and soluble tumor
necrosis factor-receptor-75 in EBC. Albumin was found in two EBC samples of
asthmatic children. 
We conclude that exhaled nitric oxide had a better correlation with lung function
parameters and asthma control than exhaled carbon monoxide and acidity of EBC, in
mild to moderate persistent childhood asthma. However, exhaled nitric oxide, carbon
monoxide, and deaerated acidity of EBC did not differ between asthmatic children
and controls, possibly because of a too homogeneous and well-controlled study
population. To further evaluate the clinical utility of exhaled markers in monitoring
childhood asthma, more studies are required on a wider range of asthma severity, and,
preferably, with repeated measurements of markers and of asthma control.
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Introduction
Asthma is a chronic lung disorder characterised by airway inflammation, variable but
reversible airway obstruction, and episodic wheezing, coughing or dyspnoea 1,2. Non-
invasive assessment of inflammatory markers in exhaled air and exhaled breath
condensate (EBC) of asthmatic children becomes increasingly important 3,4. Airway
inflammation leads to increased expression of inducible nitric oxide synthase type 2,
and consequently, to an increase of exhaled nitric oxide. Indeed, exhaled nitric oxide
of asthmatic patients is elevated, and shows a dose-dependent decrease during
treatment with inhaled corticosteroids 5,6. A close correlation was found between
exhaled nitric oxide and the percentage of eosinophils in bronchoalveolar lavage fluid
in asthmatic children 7. Furthermore, exhaled nitric oxide may be useful to assess
clinical heterogeneity in children with moderate and difficult asthma 8-10. Increased
levels of exhaled carbon monoxide, by upregulation of the enzyme heme-oxygenase-
1 through oxidative stress and inflammatory cytokines, were described in asthmatic
patients 11,12. Recently, the acidity (pH) of EBC was suggested as a new marker of
inflammation in adult asthmatic patients: the pH of de-aerated EBC was approximately
two log orders lower in patients with acute asthma, than in healthy control subjects
13. However, only a few studies compared these different exhaled markers of
inflammation with such conventional asthma measures as lung function tests,
reversibility of airway obstruction, respiratory symptoms, and asthma control. It is
unknown which exhaled marker of airway inflammation is best related with
conventional asthma measures. 
Furthermore, data on inflammatory markers in EBC of asthmatic patients are
increasing 3. However, various other inflammatory parameters have not yet been
evaluated in EBC. Many cytokines play a critical role in orchestrating, perpetuating and
amplifying the inflammatory response in asthma 14. Tumor necrosis factor-alpha and
interleukin-6 are involved in many inflammatory diseases. Interleukin-6 is released in
asthma, has growth-regulatory effects on many cells and is involved in T-cell activation,
growth and differentiation. It is a terminal differentiation factor for B cells, and an
important cofactor in interleukin-4 dependent immunoglobulin-E synthesis. Interleukin-
6 may also have anti-inflammatory effects 15. Interleukin-8 appears to possess
chemotactic activity for primed eosinophils, however it’s major action is neutrophil
chemoattraction and activation. Interleukin-8 may be a marker of severe asthma 15.
Interleukin-8 levels in bronchoalveolar lavage fluid of asthmatic children were not only
strongly correlated with neutrophil counts, but also increased with more asthma
symptoms 16. Tumor necrosis factor-alpha may have an important amplifying effect in
asthmatic inflammation. The effects of tumor necrosis factor-alpha are very similar to
those of interleukin-1beta, which is an important growth factor for T-helper type 2 cells
in response to antigen-primed antigen-presenting cells 15. Tumor necrosis factor-alpha
interacts with two cell surface receptors, tumor necrosis factor-receptor-55 and tumor
necrosis factor-receptor-75. Soluble receptors may act as inhibitors of the effects of
tumor necrosis factor-alpha. Tumor necrosis factor-receptor-75 is the principal receptor
released by human alveolar macrophages and monocytes in the presence of interferon-
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gamma 15. Adhesion molecule interactions regulate the migration of inflammatory cells
from the circulation into the lungs. The intercellular adhesion molecule-1 was
demonstrated to mediate leukocyte rolling on inflamed pulmonary endothelium, and
was shown to mediate capillary sequestration in inflamed lungs 17. Soluble intercellular
adhesion molecule-1 levels were significantly increased in bronchoalveolar lavage fluid
from asthmatic children compared with control children, and these soluble intercellular
adhesion molecule-1 levels correlated with disease activity 18.
The aims of the present study in asthmatic and healthy children were: (i) to
compare exhaled markers of airway inflammation (exhaled nitric oxide, exhaled
carbon monoxide, and acidity of EBC) with conventional asthma measures (lung
function tests and asthma control score); and (ii) to investigate the detectability of
albumin, C-reactive protein, interleukin-6, interleukin-8, tumor necrosis factor-alpha,
soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor-receptor-
75 in EBC of asthmatic children.
Subjects and Methods
Subjects
In total, 32 nonsmoking children aged 6-16 years were selected for this study (23
asthmatic children and 9 healthy controls). The asthmatic children were recruited from
our outpatient clinic. 
Inclusion criteria were: (i) doctor-diagnosed asthma for at least 1 year, with a
history of at least two of the following: recurrent wheeze, chest tightness, shortness
of breath, and/or cough; and (ii) mild or moderate persistent asthma requiring, for at
least 6 months, daily treatment with inhaled corticosteroids 19.
Exclusion criteria were: (i) clinical evidence of a respiratory infection in the 4 weeks
prior to the study; and (ii) comorbidities such as severe mental retardation, congenital
anomalies of the respiratory tract, or congenital cardiac defects. Allergy, defined as at
least one positive radio-allergo-sorbent test (greater than or equal to class 2), was not
an obligatory criterium for the diagnosis of asthma. The 9 healthy controls had no
history of allergic rhinitis, asthma or eczema. All parents gave written informed
consent. The study was approved by the Medical Ethics Committee of the University
of Maastricht.
Lung function tests
Bronchodilator medication was stopped prior to lung function testing: short-acting
bronchodilators at least 8 hours before the test, and long-acting bronchodilators at
least 36 hours before. Dynamic spirometry was performed by means of a
pneumotachograph (Masterlab Jaeger, Würzberg, Germany), with measurement of
the forced expiratory volume in 1 second (FEV1) and the forced vital capacity, according
to the standards of the European Respiratory Society 20. The highest values of three
forced expiratory manoeuvres were used for data analysis. The bronchodilating
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response was assessed 15 minutes after administration of 400 µg salbutamol (Airomir®)
through a spacer (Volumatic®). The bronchodilating response was expressed as the
relative increase of FEV1 compared to the predicted value of the FEV1.
Nitric oxide in exhaled air
Exhaled nitric oxide was measured by means of the NIOX®(Aerocrine, Solna, Sweden)
according to the criteria of the American Thoracic Society 21. After inhalation of nitric
oxide-free air to total lung capacity, the child exhaled slowly, keeping a constant flow
rate at 50 ml/sec, guided by a balloon meter. In this way, a nitric oxide plateau was
created for at least 3 seconds. Automatic control of exhaled flow rate by a dynamic
flow restrictor was carried out by the apparatus, in order to achieve a constant flow
rate of 50 ml/sec. The fractional exhaled nitric oxide concentration was determined
by averaging the nitric oxide levels during the nitric oxide-plateau for 5-8 seconds of
exhalation. The mean fractional exhaled nitric oxide concentration of three consecutive
measurements was used for analysis. 
Carbon monoxide in exhaled air
Exhaled carbon monoxide was measured by a modified electrochemical analyser
(EC50-MICRO smokerlyzer CO monitor, Bedfont Scientific Ltd, UK), sensitive to carbon
monoxide from 0-1000 parts per million by volume with a resolution of 1 part per
million. Prior to the start of this study, the analyser was calibrated with a mixture of
50 part per million carbon monoxide in air. Subjects were asked to inhale maximally
and hold their breath for 20 seconds before exhaling rapidly into a disposable
mouthpiece 22. This procedure was repeated three times, with 1 minute of normal
breathing between each manoeuvre. The mean value was used for analysis 22.
Exhaled breath condensate
EBC was collected on ice, while the children were wearing a noseclip and breathed
quietly through a mouthpiece, connected to a two-way nonrebreathing valve and a
cooled (0°C) double-jacketed 30 cm-long borosilicate glass tube 23. In order to prevent
salivary contamination of EBC samples, the two-way valve and tubing were used as a
saliva gravity trap. Acidification of the condensate was measured immediately after
collection, using a portable pH-meter (Radiometer, type PHM201, Lyon, France) 13. A
stable pH was achieved by deaeration of the condensate with nitrogen at a flow rate
of 250-500 ml/min for 10 minutes. The remaining condensate was frozen rapidly by
submerging the microtubes in isopentane at –24°C, and was subsequently stored at
–75°C to –80°C. Inflammatory mediators were measured in EBC using sandwich
enzyme-linked immunosorbent assay, as reported previously 24-29. The time interval
between the collection of EBC and the measurement of mediators was not longer
than 2 months.
In short, for detection of soluble tumor necrosis factor-receptor-55 and soluble
tumor necrosis factor-receptor-75, monoclonal antibody MR1-1 and monoclonal
antibody MR2-2 were used for coating. Specific biotin labelled polyclonal rabbit anti-
human soluble tumor necrosis factor-receptor immunoglobulin-G were used as
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detector reagents 24. Monoclonal antibody 5E1 was used as coating for the interleukin-
6 enzyme-linked immunosorbent assay, and biotinylated polyclonal rabbit anti-human
interleukin-6 immunoglobulin-G was used for detection 25. Interleukin-8 was coated
by the interleukin-8 monoclonal antibody HM.5, and detected by biotinylated
polyclonal rabbit anti-human interleukin-8 immunoglobulin-G 26. Tumor necrosis
factor-alpha measurement was performed by coating with anti-human tumor necrosis
factor-alpha monoclonal antibody 61E71, and detection was done with rabbit anti-
human tumor necrosis factor-alpha 27. Enzyme-linked immunosorbent assay for
soluble intercellular adhesion molecule-1 consisted of monoclonal antibody HM2 as
coatings reagent, and biotinylated HM1 for detection 28. For detection of human
albumin, plates were coated with monoclonal antibody HM17. Albumin was detected
with a horseradish peroxidase-labeled polyclonal rabbit anti-human albumin
immunoglobulin G (Cappel; Organon Teknika Corporation, West Chester, PA) 29. The
C-reactive protein concentration was measured by using a polyclonal enzyme-linked
immunosorbent assay, for which antibodies and standard were obtained from Dako
A/S (Glostrup, Denmark). Sensitivity of the assays was 40 pg/ml for both soluble tumor
necrosis factor-receptors; 20 pg/ml for interleukin-6, interleukin-8, and tumor necrosis
factor-alpha; 3 ng/ml for soluble intercellular adhesion molecule-1; 8 ng/ml for
albumin; and 50 pg/ml for C-reactive protein. 
Immunoassay plates (NUNC Immuno Plate Maxisorp, Roskilde Denmark) were used
for enzyme-linked immunosorbent assays. Biotinylated samples were detected using
streptavidin-peroxidase conjugate, obtained from Zymed Laboratories Inc. (San Fransisco,
CA). The substrate used was 3,3',5,5'-tetramethylbenzidine (KPL, Gaithersburg, MD).
Absorbence was measured spectro-photo-metrically at 450 nm using a micro-enzyme-
linked immunosorbent assay autoreader.
Asthma control and symptoms
Respiratory symptoms and the degree of asthma control were measured in a
standardised way by the Asthma Control Questionnaire of Juniper et al 30. The validity
of the Dutch translation has been checked, and appeared to be excellent. 
Power analysis and statistics
A number of 22 subjects is necessary to assess clinically relevant correlations between
exhaled markers of airway inflammation and conventional measures of asthma severity
with a correlation coefficient of 0.60, a power of 90%, and an alpha of 0.05.
Differences between normally distributed parameters were tested with the unpaired
Student’s t-test, and non-normally distributed parameters with the Mann-Whitney
test. Relationships between exhaled markers of airway inflammation, lung function
tests and asthma control questionnaire score, were determined by Spearman
correlation coefficients. P < 0.05 was considered statistically significant. 
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Results
Characteristics of the study population
No difference in age, height, weight and postbronchodilator FEV1 were found between
asthmatic children and healthy controls (Table 1). As expected, asthmatic subjects had
a significantly higher asthma control questionnaire score, and a lower prebronchodilator
FEV1 than healthy controls (Table 1). The mean EBC collection time was 30 minutes in
the asthmatic and healthy control groups. The mean volume of collected condensate
was 2.6 ml (SD, 0.5) in the asthmatic children, 2.9 ml (SD, 0.3) in the control group,
and 2.7 ml (SD, 0.5) in the total study population.
Exhaled nitric oxide, exhaled carbon monoxide, and acidity of EBC 
Between asthmatic children and healthy controls, no significant differences in exhaled
nitric oxide and exhaled carbon monoxide were found (Table 2). Only the not deaerated
pH of EBC in the asthmatic group (median, 6.49) was significantly lower than in the
healthy control group (median, 6.64) (unpaired Student’s t-test, p<0.05).
Albumin, C-reactive protein, and cytokines in EBC
In all EBC samples, C-reactive protein was less than 50 pg/ml; interleukin-6 , interleukin-
8, and tumor necrosis factor-alpha were less than 20 pg/ml; soluble intercellular
adhesion molecule-1 was less than 3 ng/ml, and soluble tumor necrosis factor-
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Table 1. Characteristics of study population 1
Healthy controls Asthmatic children
Number 9 23
atopic / non-atopic - 16 / 7
mild / moderate - 13 / 10
ICS dose (µg) - 400 (456)
Age (years) 9.4 (1.0) 10.6 (2.8)
Weight (kg) 33.6 (10.2) 35.4 (12.3)
Height (m) 1.41 (0.15) 1.42 (0.14)
Pre-FEV1 (% pred) 104.6 (6.9) * 96.4 (16.2)
Post-FEV1 (% pred) 107.6 (6.6) 103.2 (16.7)
Reversibility (% pred) 3.0 (3.8) 6.8 (8.4)
ACQ score 0 ** 9.7 (8.2)
ICS beclomethasone dipropionate or equivalent 
Pre-FEV1 prebronchodilator forced expiratory volume in 1 second, in % predicted
Post-FEV1 postbronchodilator forced expiratory volume in 1 second, in % predicted
ACQ score asthma control questionnaire score
1median and (standard deviation)
* p=0.053, unpaired Student’s t-test
** p<0.0001, unpaired Student’s t-test
receptor-75 was less than 40 pg/ml. Albumine was detected in two samples of
asthmatic children, with a concentration of 116 and 243 ng/ml, respectively. The
highest value was found in a child with unstable disease. Albumin was not detected
in EBC samples of the healthy control group. 
Relationship between exhaled nitric oxide, exhaled carbon monoxide,
acidity of EBC, lung function tests, and asthma control questionnaire score
In the total study population, exhaled nitric oxide showed significant correlations with
exhaled carbon monoxide, and pre- and postbronchodilator FEV1, and showed a
nonsignificant correlation with asthma control score (Table 3). Figure 1 shows the
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Table 2. Noninvasive markers of airway inflammation (exhaled nitric oxide, exhaled carbon monoxide, and
pH of exhaled breath condensate) in asthmatic children and healthy controls1
Healthy controls Asthmatic children
eNO (ppb) 15.6 (8.1) 23.1 (5.0)
eCO (ppm) 2.1 (0.7) 2.3 (0.3)
pH-dea 8.11 (0.07) 8.14 (0.06)
pH-nondea 6.64 (0.05) * 6.49 (0.05)
eNO exhaled nitric oxide, in parts per billion
eCO exhaled carbon monoxide, in parts per million
pH-dea deaerated pH of exhaled breath condensate
pH-nondea nondearated pH of exhaled breath condensate
1median and (standard error of the mean)
* p<0.05, unpaired Student’s t-test
Figure 1. Scatterplots of (a) exhaled nitric oxide and prebronchodilator FEV1 (r = -0.59, p<0.05), and 
(b) exhaled nitric oxide and asthma control questionnaire score (r = 0.48, p = 0.06).
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Table 3. Spearman correlation coefficients between conventional asthma measures (FEV1 and asthma
control questionnaire score), and noninvasive markers of airway inflammation (exhaled nitric oxide,
exhaled carbon monoxide, and pH of exhaled breath condensate) in total study population (n=32)
eNO eCO pH-nondea pH-dea pre-FEV1 post-FEV1 ACQ
eNO - 0.59* -0.23 0.20 -0.59* -0.67** 0.48†
eCO 0.59* - -0.41* -0.13 -0.45* -0.33 0.18
pH-nondea -0.23 -0.41* - 0.68** 0.10 0.07 -0.25
pH-dea 0.20 -0.13 0.68** - -0.25 -0.25 0.08
pre-FEV1 -0.59* -0.45* 0.10 -0.25 - 0.86** -0.26
post-FEV1 -0.67** -0.33 0.07 -0.25 0.86** - -0.16
ACQ 0.48*** 0.18 -0.25 0.08 -0.26 -0.16 -
eNO exhaled nitric oxide
eCO exhaled carbon monoxide
pH-nondea nondearated pH of exhaled breath condensate
pH-dea deaerated pH of exhaled breath condensate
pre-FEV1 prebronchodilator forced expiratory volume in 1 second
post-FEV1 postbronchodilator forced expiratory volume in 1 second
ACQ score asthma control questionnaire score
* p< 0.05
** p<0.01
*** p=0.06
Figure 2. Nondeaerated pH of exhaled breath condensate with time (hours) in 2 subjects of the study
population.
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correlations found between exhaled nitric oxide and prebronchodilator FEV1 (r = -0.59,
p<0.05), and exhaled nitric oxide and asthma control score (r = 0.48, p=0.06). Exhaled
carbon monoxide was significantly correlated with prebronchodilator FEV1 and
nondeaerated pH of EBC. Although the nondeaerated pH of EBC was significantly
lower in asthmatics than in controls, it only correlated with exhaled carbon monoxide,
and not with FEV1, asthma control score, and exhaled nitric oxide. When correlations
were analysed in asthmatics separately, comparable results were found. Deaeration of
EBC did not influence the correlations of pH with the other variables. There was a
substantial increase of pH levels of nondeaerated EBC samples over time (Figure 2).
This effect in pH was almost 0.5 units in the first hour after EBC collection.
Discussion
Noninvasive assessment of inflammatory markers in exhaled air and EBC is a growing
research field 3,4. This is the first study in a paediatric population comparing exhaled
inflammatory markers (exhaled nitric oxide, exhaled carbon monoxide, and acidity of
EBC) with lung function tests and asthma control score. Exhaled nitric oxide showed
higher correlations with conventional measures of asthma, than did exhaled carbon
monoxide, and pH of EBC: exhaled nitric oxide did correlate with pre- and post-
bronchodilator FEV1, and with asthma control score. Exhaled nitric oxide levels were
significantly related to exhaled carbon monoxide levels, but exhaled carbon monoxide
was less related to lung function parameters and symptoms than exhaled nitric oxide.
Although the pH of EBC was lower in asthmatics than in healthy control children, the
acidity was not related to any other parameter. It was not possible to demonstrate C-
reactive protein, interleukin-6, interleukin-8, tumor necrosis factor-alpha, soluble
intercellular adhesion molecule-1, and soluble tumor necrosis factor-receptor-75 in EBC.
Significant correlations between exhaled nitric oxide and lung function parameters
were described in asthma previously, both cross-sectionally 5,31 and longitudinally 5,32.
However, several other studies found no relationship between exhaled nitric oxide and
lung function tests 33,34. In our study, a significant correlation existed between exhaled
nitric oxide and lung function tests. However, the percentage of variance in exhaled
nitric oxide by changes in lung function (= r2) was less than 45%, indicating that
exhaled nitric oxide and lung function tests probably reflect different aspects of the
airway pathophysiology 35,36.
With respect to exhaled carbon monoxide and lung function parameters, we
found a significant but moderate correlation between exhaled carbon monoxide and
prebronchodilator FEV1. Conflicting results are reported in the adult literature 
37,38. In
childhood asthma, however, no significant correlation was found between exhaled
carbon monoxide and FEV1
12,22,39. The different correlations of exhaled nitric oxide
and carbon monoxide with conventional asthma measures may be due to the
differences in standardization and methodology. Extensive recommendations on
standardization of measurements are formulated for exhaled nitric oxide, but not for
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exhaled carbon monoxide 21,40. Comparable to exhaled nitric oxide, it may be that
exhaled carbon monoxide is flow-dependent, and that ambient air carbon monoxide
levels may disturb exhaled carbon monoxide measurements. Ambient air carbon
monoxide levels were not recorded in our study.
Our data suggest that exhaled nitric oxide has a better correlation with lung
function parameters and asthma control in childhood asthma, than exhaled carbon
monoxide. This view is supported by other recent findings 39. Before oral prednisone
therapy, both exhaled nitric oxide and carbon monoxide were elevated in 30 children
with an asthma exacerbation, compared with healthy controls 39. After steroid
treatment, exhaled nitric oxide, but not exhaled carbon monoxide, significantly
improved 39.
We did not find a significant difference for exhaled nitric oxide or carbon monoxide,
between asthmatic children and healthy controls. Several explanations are possible. (i)
Maintenance treatment with inhaled corticosteroids is known to rapidly decrease
exhaled nitric oxide levels, and may also decrease exhaled carbon monoxide 6,41,42. All
asthmatic children in our study were on long term inhalation corticosteroids. Inclusion
of a group of steroid-free asthmatic children, would have facilitated interpretation of
the influence of inhaled corticosteroids on exhaled markers. (ii) Most children had mild
to moderate persistent asthma with fairly well-controlled disease, which may lower
exhaled nitric oxide and also exhaled carbon monoxide levels 22,34.
Our data showed lower pH of EBC in asthmatic children than in healthy controls,
which corresponds to the results of others in adults 13,43. However, this potential
marker of inflammation was not correlated with lung function tests and asthma
control at all. We demonstrated a substantial increase of pH level with time for
nondeaerated samples of EBC, averaging about 0.5 units in the first hour after
collection. Deaeration of EBC samples did not improve correlation of pH of EBC with
conventional asthma measures. The influence of deaeration on the pH of EBC needs
further clarification.
Albumin was detected in two EBC samples of asthmatic children, of which one
had unstable disease. Furthermore, albumin was not detected in EBC of the healthy
controls. In asthmatic subjects, albumin was demonstrated in induced sputum 44.
Albumin may reach the epithelial lining fluid by microvascular leakage in the airway
epithelium 44. Therefore, the detection of albumin in EBC may be related to airway
inflammation in asthma.
We were not able to demonstrate the presence of C-reactive protein, interleukin-6,
interleukin-8, tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, and
soluble tumor necrosis factor-receptor-75 in EBC samples of our children. Possibly the
detection limit of the assays used was not low enough to measure the concentration
of these substances in EBC. Alternatively, the concentrations of these inflammatory
mediators in EBC may have been adequately down-regulated by the long-term
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treatment with inhaled corticosteroids used by our asthmatic children. On the other
hand, these mediators may not be present in EBC of asthmatic children, because these
cytokines are not derived from T-helper type 2 cells, in contrast to interleukin-4 and
interleukin-5, which are more specific to allergic airway inflammation. Until now,
interleukin-8 has only been demonstrated in EBC of children with cystic fibrosis, but
not in asthma 45. The lower detection limit of the interleukin-8 assay used by
Cunningham and co-workers was 0.5 pg/ml, which is more sensitive than the limit of
20 pg/ml used in our study 45. So far, soluble intercellular adhesion molecule-1, soluble
tumor necrosis factor-receptor-75, tumor necrosis factor-alpha, and C-reactive protein
have not been found in EBC of asthmatic patients. We recommend the use of assays
with the lowest possible detection limit for measurement of inflammatory markers in
EBC. Methodological standardizations of EBC collection systems, procedures,
preservation methods, and analysis are needed, as recently reported 46.
A limitation of our study may be the relatively small number of subjects. However,
the power analysis showed that 22 subjects were sufficient to assess a clinically
relevant correlation of 0.60 between exhaled inflammatory markers and conventional
measures of asthma severity, with a power of 90%, and an alpha of 0.05. Therefore,
the number of subjects was sufficient to answer the aims of this study.
Asthmatic heterogeneity implicates a variable degree of chronic airway inflammation,
airway hyperresponsiveness, reversible airway obstruction, and potential but irreversible
structural remodeling of the airways 47. Moreover, asthmatic airway inflammation is not
necessarily correlated with airway calibre 8,34,36, and many inflammatory and structural
changes may begin early in life 47,48. Hence, a discordant pattern of generally low
correlations between measures of airway inflammation, clinical parameters of disease
severity, and physiological variables such as spirometric measurement of airflow
obstruction, as shown in our study, may not be surprising at an early stage 35,49-51.
Childhood asthma management should include noninvasive integrated monitoring of all
of these aspects: disease severity, disease control, airflow obstruction, airway
hyperresponsiveness, airway inflammation, and airway remodeling.
In the present study, exhaled nitric oxide showed better correlations with conventional
asthma measures. However, this does not imply that exhaled nitric oxide is the ‘ideal’
parameter of asthmatic inflammation. Pragmatically, the question remains whether
exhaled nitric oxide is sensitive and specific enough to discriminate (some or all) asthmatic
children from children with other chronic lung diseases, to guide adjustment of a
maintenance dose of inhaled corticosteroids, to predict asthmatic exacerbations, and to
improve and individualize the care for asthmatic children. Furthermore, the analysis of
EBC is still hampered by the lack of methodological standardization. Numerous
methodological pitfalls await further investigation, before clinical studies will help to
evaluate the diagnostic and monitoring capacity in children with various chronic
inflammatory lung diseases. Basically, at present it is not possible to make a judgement
of whether EBC markers have value or not.
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In conclusion, exhaled nitric oxide had a better correlation with lung function parameters
and asthma control than did exhaled carbon monoxide and pH of EBC in mild to
moderate persistent childhood asthma. However, exhaled nitric oxide, exhaled carbon
monoxide, and deaerated pH of EBC did not differ between asthmatic children and
healthy controls. Albumin was detected in two condensate samples of asthmatic
children, but C-reactive protein, interleukin-6, interleukin-8, tumor necrosis factor-
alpha, soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor-
receptor-75 were not found in EBC of asthmatic and healthy children. Methodological
standardisation of EBC is mandatory. To further evaluate the clinical utility of exhaled
markers in monitoring childhood asthma, more studies are required on a wider range
of asthma severity, and preferably, with repeated measurements of markers and of
asthma control.
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CHAPTER 4.1
EXHALED BREATH CONDENSATE:
A SPACE ODYSSEY,
WHERE NO ONE HAS GONE BEFORE ...
Rosias P, Robroeks C, Hendriks J, Dompeling E, Jöbsis Q. 
European Respiratory Journal 2004; 24: 189-190.
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Exhaled breath condensate: 
a space odyssey, where no one has gone before …
Letter to the Editor of the European Respiratory Journal:
We read with great interest the editorial of Rahman 1 on the reproducibility of oxidative
stress biomarkers in breath condensate. As a consequence, we would like to share
some of our thoughts, as ultimately, we all may want to walk on planet Mars. However,
this does not mean that we are already able to lift off, as many methodological
problems first need to be properly addressed. 
Similarly, exhaled breath condensate (EBC) is an interesting noninvasive technique
to explore inflammatory lung diseases, where no one has gone before … Many
methodological issues are still waiting to be solved, as recently reviewed 2. Indeed, the
development of EBC is currently hampered by many conflicting reports on biomarker
reproducibility. As clearly stated, one of the main obstacles consists of current analytical
problems, due to limitations of sensitivity and specificity of the assays used to date 3.
However, the statement that “now with the use of EcoScreen, collection of EBC
is being standardised in many leading laboratories” may be misleading, as it suggests
that “this would no longer be a confounding factor contributing to the variations in
biomarkers in EBC” 1. We want to clearly point out that the EBC collection method
still remains a possible confounding factor and an important source of biomarker
variability, because standardisation involves applying more than one identical collection
technique. To our knowledge, there is no scientific evidence that the EcoScreen
condenser would be the most valid technique to collect EBC for the measurement of
inflammatory mediators in condensate. In fact, the key issue is not the reproducibility
of a certain biomarker, but the reproducibility of a certain biomarker for a certain
condenser system 2. We compared the influence of different inner condenser coatings
on the detection of human albumin and 8-isoprostane in EBC 4. Our data show a
much greater efficiency of condenser systems with a borosilicate glass or silicone
coating, compared with the EcoScreen, or condensers with aluminium, polyproylene
and teflon coating. This implicates that the EcoScreen may not be the most valid
apparatus, at least not for some biomarkers.
Although the need for clear-cut methodological recommendations is incontestable,
one has to recognise that we are not yet able to give such recommendations. Further
research on the reproducibility of biomarkers with different condenser systems is
urgently needed.
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CHAPTER 4.2
BREATH CONDENSER COATINGS AFFECT
MEASUREMENT OF BIOMARKERS
IN EXHALED BREATH CONDENSATE
Rosias PP, Robroeks CM, Niemarkt HJ, Kester AD, Vernooy JH, Suykerbuyk J, Teunissen
J, Heynens J, Hendriks HJ, Jöbsis Q, Dompeling E. 
European Respiratory Journal 2006; 28: 1036-1041.
Abstract
Exhaled breath condensate collection is not yet standardised and biomarker measurements
are often close to lower detection limits. In the current study, it was hypothesised that
adhesive properties of different condenser coatings interfere with measurements of
eicosanoids and proteins in breath condensate. 
In vitro, condensate was derived from a collection model using two test solutions
(8-isoprostane and albumin) and five condenser coatings (silicone, glass, aluminium,
polypropylene, and Teflon). In vivo, condensate was collected using these five coatings
and the EcoScreen® condenser to measure 8-isoprostane, and three coatings (silicone,
glass, EcoScreen®) to measure albumin. 
In vitro, silicone and glass coatings had significantly higher albumin recovery
compared with the other coatings. A similar trend was observed for 8-isoprostane
recovery. In vivo, median (interquartile range) 8-isoprostane concentrations were
significantly higher using silicone (9.2 (18.8) pg/mL) or glass (3.0 (4.5) pg/mL) coating,
compared with aluminium (0.5 (2.4) pg/mL), polypropylene (0.5 (0.5) pg/mL), Teflon
(0.5 (0.0) pg/mL), and EcoScreen® (0.5 (2.0) pg/mL). Albumin in vivo was mainly
detectable using glass coating. 
In conclusion, a condenser with silicone or glass coating is more efficient for
measurement of 8-isoprostane or albumin in exhaled breath condensate, than
EcoScreen®, aluminium, polypropylene or Teflon. Guidelines for exhaled breath
condensate standardisation should include the most valid condenser coating to
measure a specific biomarker. 
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Introduction
The collection of exhaled breath condensate (EBC) has been rediscovered as a simple
and noninvasive technique to measure mediators of airway inflammation. EBC consists
not only of water vapor, but also contains aerosolised respiratory fluid droplets
released from the respiratory epithelial lining fluid. These fluid droplets contain traces
of nonvolatile solutes, which can be recovered in EBC samples 1. EBC is collected by
guiding and cooling exhaled air of a tidally breathing subject in a condenser system.
EBC does not affect the airways; in contrast to bronchial biopsy, bronchoalveolar
lavage and induced sputum. It can be obtained with minimal risk and minimal
inconvenience for both adults and children 2. Although the American Thoracic Society
and European Respiratory Society Task Force on EBC recently published general
methodological recommendations on the collection of EBC, there are still some
methodological pitfalls and unresolved questions 3-4. The most commonly used
condensers are the Ecoscreen® (Erich Jaeger, GmbH, Hochberg, Germany), RTube®
(Respiratory Research Inc., Charlottesville, VA, USA), and home-made glass or Teflon
devices.
Two important groups of inflammatory biomarkers in EBC of adults and children
are eicosanoids and cytokines 3-10. Eicosanoids, such as 8-isoprostane, are formed by
lipid peroxidation of arachidonic acid during oxidative stress 11. 8-Isoprostane
(molecular weight 354 Dalton) can be measured in EBC of adults and children,
although reproducibility remains controversial 12-13. Cytokines are low molecular
weight (<80.000 Dalton) proteins involved in mediating inflammation and tissue
repair. Reports on the detection of cytokines in EBC are incidental, with the exception
of a report on interleukin-6 by Carpagnano and co-workers 14. Albumin, a protein
with a similar molecular weight (66.000 Dalton), was demonstrated in induced sputum
and EBC in asthmatic subjects 15-16.
The reported mean biomarker values in EBC are usually situated in the lower range
of detection 3,6. It may be that the biomarker concentration in the epithelial lining fluid
is intrinsically low, or that only minor amounts are released from the lining fluid into
exhaled air. An alternative explanation may be that adhesive properties of different
inner condenser coatings interfere with the detection of various inflammatory markers
in EBC 13,17.
The aim of this study was to investigate the influence of different inner condenser
coating surfaces (silicone, borosilicate glass, aluminium, polypropylene, Teflon, and
EcoScreen® with a Teflon-like coating) on the measurement of 8-isoprostane and
albumin in EBC using both an in vitro and in vivo approach.
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Methods 
In vitro studies 
In close collaboration with the department of Instrument Development Engineering &
Evaluation of the University of Maastricht (Maastricht, the Netherlands), an in vitro EBC
collection model was developed consisting of a rechargeable condenser system
connected in series with an ultrasonic nebuliser (Ultra-NebTM2000, DeVilbiss) and a
ventilator (Servo-900C, Siemens) (figure 1A). The rechargeable condenser system
consisted of a fixed 30-cm metal outer cylinder (diameter 4cm) (Felix Philips Maatmetaal
BV, Maastricht, the Netherlands) connected to a counter current circulating ice-water
pump at 0°C, and an exchangeable inner cylinder (diameter 2cm), as shown in figure
1B. The exchangeable inner cylinder was available in five different coatings: silicone,
borosilicate glass, aluminium, polypropylene and Teflon. The borosilicate glass tubes
were manufactured by Louwers Glass and Ceramic Technologies (Hapert, the
Netherlands). Identical glass tubes were coated internally with silicone by Imbreglon BV
(Beuningen, the Netherlands). The aluminium tubes were manufactured by Felix Philips
Maatmetaal BV. Identical aluminium tubes were coated internally with Tempcoat 1011F
(Teflon) by Imbreglon BV. The polypropylene tubes were produced by Applikon BV
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1A. In vitro exhaled breath condensate collection
model consisting of a rechargeable condenser
system, connected in series with an ultrasonic
nebuliser and a ventilator. The nebuliser could be
filled with a test solution of a known concentration
of 8-isoprostane or human albumin. The nebulised
test solution is propelled by the ventilator through
the condenser system.
1B. Schematic representation of the rechargeable
condenser tube system, which consisted of a fixed
30cm metal outer cylinder (diameter 4cm), connected
to a counter-current circulating ice-water pump, and
an exchangeable inner cylinder (diameter 2cm). The
exchangeable inner cylinder was available in five
different coatings: silicone, borosilicate glass,
aluminium, polypropylene, and Teflon. The outer
surface of this inner cylinder was in direct contact
with the counter-current circulating ice-water, while
its inner surface was in direct contact with the
exhaled breath or the volatile substances derived
from the nebuliser and propelled by the ventilator.
A B
Figure 1A-1B. The rechargeable exhaled breath condenser system
(Schiedam, the Netherlands). The outer surface of the inner cylinder was in direct
contact with the counter current circulating ice-water, while its inner surface was in
direct contact with the exhaled breath or the volatile substances derived from the
nebuliser and propelled by the ventilator. The nebuliser was filled with a biomarker test
solution (42 pg/mL 8-isoprostane or 0.1 mg/mL albumin in a 22 mL saline 0.9%
solution), which was nebulised and propelled by a ventilator through the condenser
system, simulating tidal breathing for 15 minutes (ventilator settings: inspiration time
33%, respiratory frequency 20/minute, tidal volume 200 mL). The construction of the
collection device only allowed contact between the propelled air/exhaled breath and
one specific type of inner coating that was chosen at that moment (figure 1B). The
condensate was collected at the open end of the condenser device directly into vials.
For each coating, 15 experiments were performed (see the power analysis in the
Statistics section). After each experiment, the coated tubes were rinsed repeatedly with
bi-distilled water and subsequently dried at room air for at least 24 hours. Multiple
coated tubes of each type were available to allow a smooth continuation of the
experiments, without any delay due to the drying of the coated tube that was used in
the preceding test. The biomarker condensate recovery percentage was defined as the
ratio of biomarker concentration in condensate, to biomarker concentration in the test
solution.
In vivo 8-isoprostane study
As 8-isoprostane has been detected in EBC of healthy subjects, the influence of
condenser coatings on 8-isoprostane measurements in vivo was studied in 28 healthy
volunteers (see the power analysis in the Statistics section). Standardised questionnaires
from the International Study of Asthma and Allergies in Childhood (ISAAC) were
completed to exclude the presence of respiratory infections, asthma or allergic disease
18. Each subject was asked to breathe tidally, while wearing a nose-clip, into a
mouthpiece connected to a two-way non-rebreathing valve that was in turn connected
by tubing to the condenser. The two-way valve and tubing also served as a saliva trap.
In this way, each subject exhaled during 15 minutes along each of the five coatings
in random order, as well as along the EcoScreen®, a commercial condenser system
with a modified Teflon coating. 
In vivo albumin study
In contrast to 8-isoprostane, the in vivo albumin study was planned in asthmatic
children, as the chance on positive albumin detections is larger in a disease population
16. EBC was collected in 40 asthmatic children. Inclusion criteria were doctor-diagnosed
mild or moderate persistent asthma requiring daily inhaled corticosteroids for at least
6 months 19. Exclusion criteria were clinical evidence of respiratory infection 4 weeks
prior to study, and co-morbidity (mental retardation, respiratory tract anomalies, or
cardiac defects). In contrast to the in vivo 8-isoprostane study, the asthmatic children
in the albumin study were only asked to exhale tidally along one type of coating
(silicone or glass or EcoScreen®), to allow parallel group comparison. Children were
randomly allocated to one out of three coating groups.
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Sample processing
Immediately after collection, the condensate samples were snap-frozen at -78°C using
dry ice and subsequently stored at -80ºC until analysis. A reaction mixture of the
immunoassay was not added to the condensate samples before storage. In order to
maintain optimal condensate sample preservation, for subsequent 8-isoprostane and
albumin measurement, samples were analysed within 6 to 8 weeks of storage at -80ºC.
Samples were only defrosted once, at the time of analysis. All isoprostane and albumin
concentrations were determined in duplicate by specific enzyme immunoassay (Cayman
Chemical®, Ann Arbor, MI, USA) and sandwich enzyme-linked immunosorbent assay,
respectively 16. The lower limit of detection was 2.45 and 32 pg/mL, respectively. 
Statistics
The condensate recovery percentage of a specific coating was the primary outcome
measure of the in vitro experiments. Mean values and standard deviations of recovery
percentages were calculated. A comparison between the five different coatings and
between the two biomarkers in vitro was made by means of univariate analysis of
variance (ANOVA). Power analysis demonstrated a required number of 15 experiments
in each group, in order to detect a relevant difference between coatings of 25% with
a power of 90%, an alpha of 0.05 and a standard deviation of 20% (the standard
deviation in the first set of 10 experiments was 20%). 
In the in vivo studies, the number of positive detections, median and mean values,
standard deviations (based on the first 15 subjects) and interquartile ranges were
calculated. Power calculation showed that 23 patients are needed to detect a 10%
difference in biomarker concentration with a power of 90%, an alpha of 0.05, and a
standard deviation of 14% (paired t-test). Due to a number of negative detections,
the Wilcoxon paired signed-rank test was used to compare data within subjects. A
sample with negative detection is not considered as a missing value, because it
actually informs us that the measurement of a marker was below the detection limit.
Therefore, the negative detection is given an arbitrary value of 0.5.
Ethics
All subjects gave written informed consent. The study was approved by the Medical
Ethics Committee of the University Hospital of Maastricht.
Results
in vitro study of albumin and 8-isoprostane
Albumin was detected in 93% of condensate samples (figure 2). Overall, the mean
albumin recovery in condensate was only 52% using this experimental model. The
albumin recovery percentages varied from 22.9% using a Teflon coating, to 69.4 and
94.7% using a glass and silicone coating, respectively. The albumin recovery percentage
was significantly higher using the silicone and glass coating compared with the other
coatings (p=0.03, ANOVA). No other statistically significant differences were present.
114
Chapter 4.2
Isoprostane was detected in 77 out of 78 condensate samples (figure 3). The
isoprostane recovery percentages varied from 93.1% using an aluminium coating to
102.7 and 105.6% using a glass and silicone coating, respectively, which did not reach
statistical significance (ANOVA, F-test, p=0.09). Overall, the mean 8-isoprostane
recovery in condensate was close to 100%, which was significantly higher than the
overall albumin recovery percentage of 52% (ANOVA, p=0.0001).
In vivo study of 8-isoprostane
Subject characteristics are shown in table 1. Isoprostane was detected in 41% of
condensate samples (figure 4). For each coating, the number of positive / negative
isoprostane detections in EBC was 23 / 5 (silicone), 15 / 13 (glass), 11 / 17 (aluminium),
7 / 21 (polypropylene), 5 / 23 (Teflon) and 8 / 20 (EcoScreen®). The median 8-isoprostane
concentrations in EBC in 28 healthy subjects ranged from 0.5 pg/mL for aluminium
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Figure 2. In vitro albumin condensate recovery percentages using five different condenser coatings.
Figure 3. In vitro 8-isoprostane condensate recovery percentages using five different condenser coatings.
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Albumin was detected in 65 out of 70 condensate
samples (one negative sample using glass (G), four
negative samples using Teflon (T)). Silicone (S) and
glass coatings had significantly higher albumin
condensate recovery percentages compared with the
other coatings (p=0.03).
Data are presented as mean ± SEM.
A: aluminium
P: polypropylene
Isoprostane was detected in all (n=78) but one
condensate sample (one negative sample using
polypropylene (P)). Silicone (S) and glass (G)
coatings had higher 8-isoprostane condensate
recovery percentages, although statistically not
different compared with the other coatings
(p=0.09).
Data are presented as mean ± SEM.
A: aluminium
T: Teflon
(interquartile range 0.5-2.9), polypropylene (0.5-1.0), Teflon (0.5-0.5) and the
EcoScreen® (0.5-2.5), to 3.0 pg/mL (0.5-5.0) pg/mL and 9.2 (5.1-23.9) pg/mL for the
glass and silicone coating, respectively. Condensate 8-isoprostane concentrations were
significantly higher using silicone coating compared with each of the other coatings
(p<0.001, Wilcoxon signed-rank test). Similarly, glass coating was better than
polypropylene, Teflon and the EcoScreen® (p<0.02, Wilcoxon test). The 8-isoprostane
concentrations obtained with aluminium, polypropylene, Teflon and the EcoScreen®
did not differ from each other (p=0.763, Friedman test). As median values and
interquartile ranges in smokers and nonsmokers were comparable, smoking was not a
confounder in this study.
In vivo study of albumin
Subject characteristics are shown in table 1. Albumin was detected in 8 out of 40
condensate samples (0.04-0.24 µg/mL). Positive detections were almost exclusively
found with a glass coating: 7 out of 13 samples using a glass coating, 1 out of 14
samples using the EcoScreen®, and none out of 13 samples using a silicone coating
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Table 1. Subject characteristics.
Healthy subjects Asthmatic subjects
8-isoprostane study albumin study
Subjects 28 40
Male 10 27
Smoking 5 0
Atopic 0 36
Age yrs 26 (20-57) 11 (5-17)
Data are presented as n or median (range)
Figure 4. In vivo 8-isoprostane condensate concentrations in 28 healthy volunteers using six different
condenser coatings.
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Isoprostane was detected in 69 out of 168
condensate samples. Isoprostane condensate
concentrations were significantly higher using a
silicone (S) coating (p<0.001) or a glass (G) coating
(p<0.02) compared with the other coatings.
Data are presented as median ± interquartile range.
A: aluminium
P: polypropylene
T: Teflon
E: EcoScreen condenser
(p<0.008, Chi-square test). Disease stability, lung function and atopic status were not
confounding factors, as these characteristics were equally distributed across the three
coating groups (data not shown).
Discussion
Both in vitro and in vivo, the present study demonstrates a significant influence of the
different inner condenser coatings on the measurement of eicosanoid and protein
biomarkers in EBC. In particular, silicone and glass coatings were superior to aluminium,
polypropylene and Teflon with respect to the recovery of both 8-isoprostane and
albumin in EBC in vitro and in vivo.
A careful MEDLINE online database search for all available studies on 8-isoprostane
in EBC, demonstrates data in line with the results of our study. When considering an
identical assay (enzyme- or radio-immunoassay), higher 8-isoprostane concentrations
were reported using a glass coating compared with the EcoScreen®. In vivo using the
EcoScreen®, present 8-isoprostane concentrations (median (range) 3.5 (2.5-4.8)
pg/mL) were comparable to the values reported by Van Hoydonck et al (4.6 (3.9-7.7)
pg/mL). Specific data on detectability of isoprostane in EBC are scarce. The current
study reports 41% of detectability in volunteers, which is in agreement with the
findings (36%) of Van Hoydonck et al in smokers 20.
In vitro, the overall mean albumin condensate recovery percentage was 52%,
compared with 100% isoprostane recovery. This suggests a more difficult condensate
recovery of protein biomarkers, which is supported by the present limited number of
positive albumin detections in vivo. Also, the relatively few positive studies on cytokines
or proteins in EBC versus several positive reports on 8-isoprostane and leukotrienes in
EBC may suggest that the recovery of proteins in EBC is less easily than of eicosanoids.
Recently, Tufvesson and Bjermer also showed that the detection of eicosanoids and
cytokines in EBC in asthmatic subjects may be facilitated by coating of all collection
surfaces with Tween 20 and bovine serum albumin, respectively, combined with
vacuum-centrifugation of condensate samples 21. Moreover, 30-fold differences in
condensate levels of interleukin-4 in asthmatic children were found using different
condenser systems and enzyme immunoassays 22-24. The latter finding indicates that
variability of biomarker levels in condensate may also be attributed to intrinsic
analytical problems of currently used immunoassays, as illustrated recently for
thromboxane-A2 metabolite measurements in EBC 24.
In vitro, the mean 8-isoprostane condensate recovery percentages did not differ
significantly between the condenser coatings (p=0.09). An explanation may be the
higher overall mean condensate recovery of isoprostane, in contrast to albumin, which
may illustrate a different behavior of these biomarkers during the expiratory phase of
the EBC collection. In turn, this may be a reflection of difficulties experienced by
molecules with a higher molecular weight, in their transition from respiratory fluid
117
Condenser coatings affect EBC
droplets and exhaled air, to condensate. Conversely, overload in the 8-isoprostane in
vitro tests seems unlikely when considering that the absolute amount in the test tubes
must have been very close to concentrations found in vivo. Hence, it may be that the
nebuliser set-up is producing 8-isoprostane aerosols that are more effectively
condensed as compared to the real EBC in vivo. Therefore, further studies on the
optimal condenser coating should always include in vivo experiments.
The EcoScreen® is a commonly used and commercially available condenser system
with distinctive physical characteristics. In contrast to the current authors’ collection
system and the RTube®, which collect EBC in the liquid phase, the EcoScreen® collects
EBC mainly as ice, which may be associated with more drastic freeze-thaw cycles that
can affect the molecules collected 23,25. The EcoScreen® is a condenser system based
on a modified inner Teflon coating. The 8-isoprostane EBC concentrations were similar
for the EcoScreen® and the Teflon coating, suggesting no significant influence from
the specific physical characteristics of the EcoScreen® condenser device in vivo.
A different design of the in vivo 8-isoprostane and albumin study was chosen,
although ideally both study parts should have had a similar design. However,
considerations in support of differing designs were decisive: (i) subjects with asthma
are more likely to have positive albumin detection in EBC than healthy controls 16; and
(ii) a 90 minutes EBC collection period, like in the in vivo 8-isoprostane study, was
neither realistic nor feasible in the asthmatic children of the in vivo albumin study.
Therefore, a between-subject (parallel groups), rather than an intra-subject,
comparison of condenser coatings was chosen for the in vivo albumin study.
Standardisation of the EBC collection method implicates more than applying one
identical collection technique. It implicates the development of a condenser system
with the highest and least varying recovery percentages. Optimalisation of condensate
recovery percentages may lead to an improvement of biomarker reproducibility.
Therefore, the current authors recommend the use of a condenser system with an
inner glass or silicone coating for the measurement of 8-isoprostane and albumin in
EBC. The reproducibility of measurements by using different condenser coatings
should be evaluated in vivo.
An explanation for this superiority of glass and silicone coatings may be that water
acts as a bipolar vehicle. The pH of exhaled breath ranges from 6.50 to 7.80, whereas
the isoelectrical point of human albumin is situated at pH 4.80 3,26. In other words, at
higher pH values (such as reported in EBC) albumin acts as a negatively charged
molecule. Therefore, the negatively charged albumin in exhaled breath may be
repulsed by glass that is also negatively charged. This may promote the recovery of
albumin in EBC. In contrast, the same albumin molecule may be attracted by aluminum
metal ions that are positively charged. This may hamper the recovery of albumin in
EBC in this case. Furthermore, 8-isoprostane acts in an extremely hydrophobic manner
and will stick to neutral surfaces (such as Teflon) in the presence of aqueous solutions,
to lipids and to detergents.
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Not only adhesive and electrical properties of the condensation equipment may affect
whether a compound is collected in EBC, but also issues such as the length of the
condensation tube, thermal conduction of the coating, and solute solubility, volatility,
and its dissociation constant (pKa = -log Ka).
Finally, these findings in 8-isoprostane and albumin do not necessarily hold for all
other biomarkers. Every biomarker has its own chemical and physical characteristics.
Currently, one may speculate that most eicosanoids act in a similar way. Likewise,
small proteins such as cytokines may act differently from eicosanoids, but similarly
when compared one cytokine to another.
The present authors conclude that a condenser system with a silicone or glass
coating is more efficient for the measurement of 8-isoprostane or albumin in EBC,
compared with the EcoScreen®, or condensers with aluminium, polypropylene or
Teflon coating. The increased efficiency of the borosilicate glass and silicone coatings
may be due to less adhesive properties resulting in more biomarker recovery in the
condensate. To establish methodological standardisation of the collection of EBC, the
most valid and inert condenser coating has to be applied for the measurement of a
specific inflammatory biomarker.
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CHAPTER 5
BIOMARKER REPRODUCIBILITY
IN EXHALED BREATH CONDENSATE COLLECTED
WITH DIFFERENT CONDENSERS
Rosias PP, Robroeks CM, Kester AD, den Hartog GJ, Wodzig WK, Rijkers GT,
Zimmermann LJ, van Schayck CP, Jöbsis Q, Dompeling E. 
European Respiratory Journal; in press.
Abstract
Optimal collection and analysis of exhaled breath condensate (EBC) are prerequisites for
standardisation and reproducibility of assessments. We aimed to assess reproducibility
of EBC volume, hydrogen peroxide, 8-isoprostane, and cytokine measurements using
different condensers, including a newly developed glass condenser.
At four points in time, 30 healthy subjects performed sequential EBC collections
randomly using four condensers: glass, silicone, EcoScreen®, and an optimised glass
condenser. In small EBC samples, hydrogen peroxide was measured by spectrophotometer,
8-isoprostane by enzyme immunoassay, and cytokines by multiplexed xMAP® technology.
The optimised glass condenser yielded significantly more EBC volume (median
2025µL, interquartile range 1056), reproducibility of EBC volume was comparable
with EcoScreen® (coefficient of variation: 19-20%), but was significantly better
compared to silicone and glass (coefficient of variation: 29-37%). The new condenser
was associated with significantly more detections of hydrogen peroxide, 8-isoprostane,
interleukin-2, interleukin-4, interleukin-5, interleukin-13, and tumor necrosis factor-
alpha. Isoprostane concentrations were significantly higher using the new condenser,
whereas hydrogen peroxide and cytokine concentrations were not. Reproducibility of
biomarkers was equally variable for all condenser types. 
In conclusion, significantly more EBC volume and biomarker detections were
found using the optimised glass condenser, including higher 8-isoprostane levels.
However, biomarker reproducibility in EBC in healthy adults was not influenced by the
type of condenser.
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Introduction
The collection of exhaled breath condensate (EBC) is a non-invasive, safe technique
to obtain direct samples from the lower respiratory tract, without disturbing an
ongoing inflammation 1-3. Analysis of EBC reveals the presence of inflammatory
markers such as eicosanoids, hydrogen peroxide, and cytokines 1-3. Although the
American Thoracic Society and European Respiratory Society Task Force on EBC
published general methodological recommendations on the collection and analysis of
EBC, there are still some unresolved methodological pitfalls, as illustrated by the use
of various nonstandardised collection systems 1-3.
Optimal condensate collection, and optimal biomarker detection and measurement
in EBC are reciprocal prerequisites for any standardisation. However, current condensation
systems are suboptimal, with relatively short-measured, open ended designs and loss of
noncondensed exhaled breath, as reflected by variable EBC volumes and biomarker
reproducibility 1. Logically, modification by using guided breath flows, enlarged
condensation surface, and optimised condensate recovery may improve condensation.
Moreover, current designs have different inner coatings, featuring different adhesive
interactions with exhaled markers 4. Recently, loss of biomarker within the sampling
system was demonstrated, in vitro and in vivo, for 8-isoprostane and albumin, at the
expense of nonglass condenser systems, and in favour of glass and silicone condensers
4. To assess clinical relevance, a study on the reproducibility of these biomarker
measurements in vivo, using different condenser coatings including glass, is needed 4.
Furthermore, conventional biomarker assays are not always suitable for use in even large
sample volumes of condensate, a bio fluid highly ‘diluted’ by water vapour 5, whereas
new analytical techniques are rapidly emerging and may offer new perspectives 6-7.
Recently, multiplexed cytometric bead array was used in children to simultaneously
measure different cytokines in only 50µL condensate samples, however, the detection
level did not reach 50% 6. Liquid bead-based multiplexing xMAP® technology (Luminex
Corporation, Austin, USA), based on flow cytometry and (faster) liquid microspheres
reaction kinetics, is less laborious, highly sensitive and specific, allows simultaneous
measurements in small sample sizes, and improves interarray reproducibility 7. Therefore,
we hypothesised that optimised condensate collection with minimal adhesive properties,
improves the reproducibility of different measurements in EBC. 
The aim of the present study is to assess the effect of four different condensers
(glass, silicone, EcoScreen®, and a new, optimised glass condenser) on the reproducibility
of breath condensate volume, and the detection, concentration and reproducibility of
inflammatory biomarkers, including hydrogen peroxide, 8-isoprostane, interleukin-2,
interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-13,
and tumor necrosis factor-alpha, in EBC in healthy nonasthmatic adults.
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Methods
Study subjects
We recruited 30 eligible healthy nonasthmatic adult volunteers (table 1) among
medical students and staff at the University Hospital Maastricht, based on the following
criteria: each volunteer was able to breath tidally into a mouthpiece for at least 15
minutes; exclusion criteria were: history of asthma, upper or lower airway infection,
and use of antibiotics, corticosteroids, cromoglycate, nedocromil, theophylline or
leukotrien-antagonist. Nonasthmatic healthy adults were chosen to eliminate possible
confounding factors attributable to heterogeneous disease expression and/or
variability of disease control.
Study design
To assess within-day, between-day and between-week reproducibility, each volunteer
was asked to perform four tests: on the first day in the morning (test 1) and afternoon
(test 2), the day after at the same time as test 1 (test 3), and one week later at the
same time (test 4). In turn, each test consisted of four sequential EBC collections,
using ad random different types of condenser.
Exhaled breath condensate collection
EBC was collected using one of the following condensers: the commercial Teflon-like
EcoScreen®, a condenser with exchangeable inner cylinder of silicone or glass, as
described previously 4, and a new, optimised glass condenser that was developed in
close collaboration with the Department of Instrument Development Engineering &
Evaluation of the Maastricht University (patent number EP 07102586), as extensively
described in figure 1. Briefly, the inclined condensation surface is enlarged (using a
length of 90cm), condensate recovery is optimised (using a downwards moveable
plunger), and breath flows are turbinately directed towards the condenser wall (by the
plunger’s multiple breath channels).
To perform one EBC collection, each subject was asked to exhale tidally, while
using a nose clip, through a mouthpiece and two-way nonrebreathing valve connected
with the condenser, during a fixed period of 15 minutes.
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Table 1. Subject characteristics of healthy nonasthmatic adult volunteers (n=30).
male : female ratio 19 : 11
age (in years)* 23 (14)
weight (in kg)* 75 (25)
height (in cm)* 180 (14)
non smoking 28
history of eczema and/or hay-fever 6
* median and (interquartile range)
Condensate sample processing
Immediately after collection, condensate samples were snap-frozen at -78°C using dry
ice and stored at -80°C. Analysis was performed within three months from sampling
time. 
Hydrogen peroxide was measured in 50µL EBC, in duplicate by spectrophotometer
(Perkin Elmer® UV-VIS Lambda 10 Spectrometer, Shelton/Norwalk, Connecticut, USA)
with a lower detection limit of 0.05µM, as described previously 8.
Isoprostane was measured in 100µL EBC, by specific enzyme immunoassay (Cayman
Chemical®, Ann Arbor, Michigan, USA), that was modified to reach a lower limit of
detection of 1.0pg/mL. The standard curve of this assay ranged from 250pg/mL to
1.95pg/mL. We were able to report 8-isoprostane values as low as 1.0pg/mL, as a
logit/log transformation was used. Isoprostane recovery experiments were performed,
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Figure 1A, 1B, and 1C. The new optimised glass condenser system.
A
1. inclined glass condenser with a tube length of 90 cm (to enlarge the
condensation surface), and downwards moveable plunger (to optimise
condensate recovery from the inner condenser wall), with tangential and
axial breath flow channels (to turbinately direct the tidally exhaled breath
flows towards the cooled inner condenser wall)
2. swan-neck tubing (serving as gravitational saliva trap) and two-way
nonrebreathing valve, connected to a mouthpiece
3. entrance of inspired room air
4. cooling unit consisting of a counter-current circulating ice-water pump
5. removable, cooled glass sample vial (to collect exhaled breath
condensate)
B
Photograph of the glass condenser
tube with plunger in situ.
C
Photographic detail of the glass
condenser tube with downwards
moveable plunger in situ. The plunger
has three tangential and axial breath
flow channels (to turbinately direct the
tidally exhaled breath flows towards
the cooled inner condenser wall).
and coefficients of variation of the absorption signals were assessed. When spiking
for the lower 8-isoprostane values of 3.9pg/mL and 7.8pg/mL, an isoprostane recovery
of 92% (coefficient of variation of concentration 16%), and 95% (coefficient of
variation of concentration 15%) were found, respectively. A coefficient of variation (of
absorption signals) below 15% was considered highly acceptable. Hence, the
corresponding coefficient of variation of concentrations may be higher. Therefore, the
coefficients of variation found in the 8-isoprostane recovery experiments using these
low values, were considered good. Standard curves, patient samples and quality
control samples of 2.5pg/mL and 10pg/mL isoprostane were assayed in triplicate.
Intra-assay variation of standard curves, patient samples and quality control samples
should be less than 15%, otherwise all samples measured in that assay were excluded
and reanalysed. Finally, in all accepted samples, 8-isoprostane concentrations were
determined from mean absorption signal intensities.
Cytokines were measured in 50µL EBC, using the liquid bead-based multiplexing
xMAP® technology (Luminex Corporation, Austin, USA). Multiplex immunoassay was
performed as described previously 7,9-10. The corresponding lower limits of cytokine
and chemokine detection were: interleukin-2 (1.0pg/mL), interleukin-4 (1.2pg/mL),
interleukin-5 (1.2pg/mL),  interleukin-6 (0.4pg/mL), interleukin-8 (1.1pg/mL),
interleukin-10 (1.2pg/mL), interleukin-13 (1.0pg/mL), and tumor necrosis factor-alpha
(1.3pg/mL). Measurement and data analysis were performed using the Bioplex 100
system and Bioplex Manager software version 3.0 (Bio-Rad Laboratories, Hercules,
CA). All multiplex immunoassays were performed in 96 well format 1.2µm filter
bottom plates (Millipore, Amsterdam, The Netherlands) and a 12 point standard curve
in duplicate was included on every plate. In order to minimise interassay variation,
positive and negative control samples were included. As far as possible, EBC samples
from one donor series of experiments were run on one plate. Three EBC samples were
spiked with 100 or 10pg/mL cytokines (interleukin-2, interleukin-4, interleukin-5,
interleukin-6, interleukin-8, interleukin-10, interleukin-13, and tumor necrosis factor-
alpha), and measured them in quadruplicate. The mean coefficient of variation of
these cytokine measurements was 12.2%. The recovery of 100pg/mL spiked cytokine
was 103% (range from 71 to 129%). At 10pg/mL, the mean recovery was somewhat
lower at 89% (range from 64% in interleukin-13, to 111% in interleukin-4). It was
concluded that there was a slight matrix effect of EBC, but this did not result in an
overestimation of cytokine measurements.
Statistics
Statistical calculations were performed using SPSS 11.5 (SPSS Inc, Chicago, USA). Not
normally distributed data were expressed as median and interquartile range. Normally
distributed data were expressed as mean and standard error. To estimate variance
within a single method of measurement (coating), coefficient of variation (= (standard
deviation/mean) x100%) were used. The coefficient of variation was calculated as the
mean of individual coefficients of variation, calculated over the two or four relevant
measurements. Within-subjects, coefficients of variation were used as data distribution
was normal. When the distribution of individual coefficients of variation was not
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normal, the nonparametric Friedman test was used to see if these coefficients of
variation were different between coatings. To test for differences among normally
distributed repeated measures, analysis of variance (ANOVA) was used. The Chi-
square test was used to evaluate statistically the differences between proportions for
four groups in a data set. Condensate samples with biomarker concentration below
the lower detection limit, in strictu sensu negative detections, were not considered as
missing values, because they actually informed us that marker concentrations were
below the lower detection limit. Therefore, these negative detections were given an
arbitrary value between zero and the lower detection limit: 0.025µM for hydrogen
peroxide, 0.1pg/mL for 8-isoprostane, and 0.1pg/mL for cytokines. Samples were
defined missing if the EBC volume, yielded after 15 minutes collection time, was zero,
or insufficient to analyse. 
Power calculation
Ideally, power calculations should be based on the expected changes in biomarker
concentrations and on their variability. However, these changes in biomarker
concentrations and their variability were unknown. In fact, the objective of this study
was to answer this question. Therefore, we took the uncertainty of the estimated
variability as a basis for power calculations. For each of the estimated variances
(within-day, between-day and between-week) we have data from 30 volunteers.
Using standard results for the variance of a chi-square random variable, we infer that,
with 30 subjects, the relative confidence limits (relative to the observed value of the
variance) will be 0.634 and 1.807. For the standard deviation this implies relative limits
of 0.80 and 1.34 11.
Ethics
All parents gave written informed consent. The study was approved by the Medical
Ethics Committee of the University Hospital of Maastricht.
Results
EBC volume
In 5 out of 480 manoeuvres, we were not able to collect condensate due to erroneously
connected tubing. EBC collection by the optimised glass condenser yielded significantly
more median condensate volume, compared to the other condensers (p=0.001,
Friedman) (table 2). Within-day, between-day, between-week and overall reproducibility
of EBC volume (expressed as coefficient of variation) were comparable in the new
condenser and EcoScreen® (p=0.715, Chi-square), but was significantly better
compared to silicone and glass (p<0.028, Chi-square). 
Hydrogen peroxide measurements in EBC
Overall, 29% of hydrogen peroxide measurements were missing (table 3). Significantly
more positive hydrogen peroxide detections were found using the optimised glass
condenser, compared to silicone and glass (p<0.050, Chi-square). Median hydrogen
peroxide concentrations and reproducibility (expressed as coefficient of variation) did
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Table 2. Volume of exhaled breath condensate, and reproducibility (expressed as coefficients of variation)
in four different condenser systems.
EBC Silicone Glass New EcoScreen p-value
missings 4/120 0/120 1/120 0/120 -
volume * 525 (319) 712 (297) 2025 (1056) 1237 (759) 0.001 †
CVin-day * 20 (27) 21 (19) 11 (15) 9 (21) 0.002 †
CVbe-day * 28 (36) 30 (26) 11 (26) 13 (23) 0.027 †
CVbe-week * 35 (36) 26 (28) 15 (22) 15 (21) 0.003 †
CVoverall * 37 (22) 29 (16) 20 (17) 19 (27) 0.001 †
EBC exhaled breath condensate
New optimised glass condenser
missings number of failed EBC collections, after 15 minutes, to total number of tests
volume volume of EBC, in µL
CV coefficient of variation, in percentage
in-day within day
be-day between day
be-week between week
* expressed as median (interquartile range)
† Friedman test
Table 3. Hydrogen peroxide measurements in exhaled breath condensate: detection, concentration, and
reproducibility (expressed as coefficients of variation) in four different condenser systems.
H2O2 Silicone Glass New EcoScreen p-value
missings 59/120 49/120 10/120 23/120 -
detections 52/9 62/9 77/33 75/22 0.003 †
conc * 2.6 (2.7) 2.1 (2.3) 1.8 (1.6) 2.2 (2.5) 0.286 ‡
CVin-day * 17 (25) 12 (28) 46 (71) 13 (21) 0.271 ‡
CVbe-day * 22 (33) 30 (42) 30 (118) 16 (52) 0.821 ‡
CVbe-week * 18 (46) 26 (42) 32 (44) 12 (32) 0.256 ‡
CVoverall * 23 (25) 29 (21) 24 (52) 22 (13) 0.080 ‡
H2O2 hydrogen peroxide
New optimised glass condenser
missings number of missing measurements to total number of tests
detections number of positive to negative detections
conc concentration of H2O2 in EBC, in µM
CV coefficient of variation, in percentage
in-day within day
be-day between day
be-week between week
* expressed as median (interquartile range)
† Chi-square test
‡ Friedman test
not significantly differ between the four condensers (p=0.286 and p>0.080,
respectively, Friedman). 
8-Isoprostane measurements in EBC
Overall, 13% of 8-isoprostane measurements were missing (table 4). Significantly
more positive 8-isoprostane detections were found using the optimised glass
condenser, compared to silicone and glass (p<0.023, Chi-square). The median
concentration of 8-isoprostane was significantly higher using the new condenser
compared with the other three condensers (p=0.001, Friedman). Statistically, 8-
isoprostane reproducibility (expressed as coefficient of variation) did not significantly
differ between the four condensers (p>0.151, Friedman).  
Cytokine measurements in EBC
Overall, 20% of cytokine measurements were missing (table 5.a). Overall, the levels
of cytokine detection using xMAP’s technology were: interleukin-2 (68%), interleukin-
4 (97%), interleukin-5 (73%), interleukin-6 (46%), interleukin-8 (46%), interleukin-
10 (61%), interleukin-13 (70%) and tumor necrosis factor-alpha (64%). The optimised
glass condenser had significantly more positive detections of interleukin-2, interleukin-
4, interleukin-5, interleukin-13 and tumor necrosis factor-alpha, compared to silicone
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Table 4. Isoprostane measurements in exhaled breath condensate: detection, concentration, and
reproducibility (expressed as coefficients of variation) in four different condenser systems.
8-IP Silicone Glass New EcoScreen p-value
missings 27/120 16/120 9/120 10/120 -
detections 89/4 98/6 110/1 109/1 0.001 †
conc * 2.0 (2.2) 2.9 (2.3) 3.6 (2.7) 2.5 (1.8) 0.001 ‡
CVin-day * 6 (29) 20 (55) 23 (35) 24 (29) 0.297 ‡
CVbe-day * 31 (65) 26 (57) 23 (32) 15 (32) 0.559 ‡
CVbe-week * 22 (42) 22 (57) 15 (31) 25 (28) 0.954 ‡
CVoverall * 31 (57) 48 (55) 29 (22) 26 (26) 0.151 ‡
8-IP 8-isoprostane
New optimised glass condenser
missings number of missing measurements to total number of tests
detections number of positive to negative detections
conc concentration of 8-IP in EBC, in pg/ml
CV coefficient of variation, in percentage
in-day within day
be-day between day
be-week between week
* expressed as median (interquartile range)
† Chi-square test
‡ Friedman test
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Table 5.a. Number of positive to negative detections of cytokines in exhaled breath condensate, collected
with four different condenser systems.
detections Silicone Glass New EcoScreen p-value *
missings 49/120 37/120 1/120 10/120 -
IL-2 50/21 60/23 82/37 68/42 0.001
IL-4 69/2 81/2 113/6 108/2 0.001
IL-5 58/13 65/18 87/32 70/40 0.001
IL-6 41/30 45/38 48/71 43/67 0.811
IL-8 44/27 45/38 44/75 44/66 0.999
IL-10 54/17 57/26 63/56 61/49 0.654
IL-13 53/18 58/25 88/31 71/39 0.001
TNF-alpha 52/19 57/26 72/47 65/45 0.050
detections number of positive to negative detections
New optimised glass condenser
missings number of missing measurements to total number of tests
IL interleukin
TNF tumor necrosis factor
* Chi-square test
Table 5.b. Concentration of cytokine measurements in exhaled breath condensate, collected with four
different condenser systems.
conc Silicone Glass New EcoScreen p-value
missings 49/120 37/120 1/120 10/120 -
IL-2 * 1.9 (5.0) 1.6 (4.4) 1.2 (3.5) 1.6 (4.0) 0.494
IL-4 † 5.8 (0.3) 5.1 (0.3) 4.7 (0.3) 5.4 (0.3) 0.129
IL-5 * 4.4 (13.8) 3.0 (12.1) 3.2 (11.4) 3.1 (12.1) 0.544
IL-6 * 0.9 (4.3) 0.9 (4.5) 0.7 (3.8) 0.6 (4.4) 0.113
IL-8 * 2.0 (4.6) 2.1 (4.0) 2.7 (4.8) 2.1 (3.9) 0.341
IL-10 † 1.5 (0.3) 1.6 (0.9) 1.4 (0.8) 1.3 (0.7) 0.872
IL-13 † 6.6 (1.1) 6.6 (1.1) 6.3 (0.7) 5.9 (0.8) 0.946
TNF-alpha † 2.1 (0.4) 2.0 (0.4) 1.8 (0.3) 1.7 (0.3) 0.876
conc concentration in EBC, in pg/ml
New optimised glass condenser
missings number of missing measurements to total number of tests
IL interleukin
TNF tumor necrosis factor
* expressed as median (interquartile range), Friedman test
† expressed as mean (standard error), analysis of variance
and glass (p<0.050, Chi-square), and more interleukin-5 and interleukin-13 detections,
compared to EcoScreen® (p<0.021, Chi-square). Cytokine concentrations were not
significantly different between the four condenser types (p>0.113, Friedman or
ANOVA, respectively) (table 5.b). Reproducibility (expressed as coefficient of variation)
of cytokine measurements did not significantly differ, neither overall (table 5.c), nor
within-day, between-day and between-week (data not shown). Best range of overall
coefficients of variation was found for the measurement of interleukin-6 (11-14%),
interleukin-8 (2-15%), interleukin-10 (11-30%) and tumor necrosis factor-alpha (8-
22%). When coefficients of variation were evaluated using the positive values only
(without negative and/or arbitrary values), also no differences between condensers
were found (data not shown).
Discussion
We demonstrated that EBC volume, and the detection of biomarkers were significantly
influenced by the condenser system, in favour of the new glass condenser, whereas
biomarker reproducibility was not influenced by the type of condenser. The proposed
optimised glass condenser yielded significantly more condensate volume compared to
the silicone, glass and EcoScreen® condensers. Reproducibility of EBC volume was
comparable for the new condenser and EcoScreen®, and was significantly better
compared to the other two condenser types. 
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Table 5.c. Overall reproducibility (expressed as coefficients of variation) of cytokine measurements in
exhaled breath condensate, collected with four different condenser systems.
CV overall Silicone Glass New EcoScreen p-value
missings 49/120 37/120 1/120 10/120 -
IL-2 † 80 (12) 75 (11) 84 (10) 70 (11) 0.802
IL-4 † 33 (7) 32 (6) 36 (5) 26 (4) 0.494
IL-5 † 74 (13) 71 (12) 73 (11) 81 (13) 0.941
IL-6 * 12 (77) 12 (68) 14 (78) 11 (69) 0.690
IL-8 * 15 (28) 12 (21) 2 (18) 9 (25) 0.766
IL-10 * 30 (48) 17 (48) 16 (39) 11 (53) 0.719
IL-13 † 51 (11) 68 (12) 73 (10) 63 (10) 0.574
TNF-alpha * 17 (45) 22 (64) 19 (62) 8 (68) 0.878
CV coefficient of variation, in percentage
New optimised glass condenser
missings number of missing measurements to total number of tests
IL interleukin
TNF tumor necrosis factor
* expressed as median (interquartile range), Friedman test
† expressed as mean (standard error), analysis of variance
In EBC collected with this new condenser, significantly more positive hydrogen
peroxide, 8-isoprostane, interleukin-2, interleukin-4, interleukin-5, interleukin-13 and
tumor necrosis factor-alpha detections were found, supporting improved sampling of
EBC. Moreover, 8-isoprostane concentrations were significantly increased in EBC
yielded by the new condenser, compared to the other three condensers, which is in
accordance with former findings 4. On the other hand, reproducibility of hydrogen
peroxide, 8-isoprostane, and cytokine measurements in EBC did not significantly differ
between the four condensers, suggesting no significant influence of the type of
condenser coating on reproducibility. In literature and to date, no formal study
addressing this issue has been published, although reproducibility using other analytical
techniques has been reported 12-14, and/or could not be calculated due to small
number of subjects 15-17.
Variations in biomarker measurements in EBC may be attributed to variations in
the dilution and/or quality of condensate that is influenced by different collection
techniques and procedures, sample processing and storage conditions, and/or
sensitivity of the analytical techniques used 17. The levels of the highly volatile hydrogen
peroxide in EBC may be susceptible to different cooling temperatures during collection
18, circadian rhythm 19, flow dependency 20, different methods of measurement with
widely varying values (even in healthy subjects) close to lower detection limits 3,17,21-
22, and high chemical reactivity with salivary and exhaled compounds by which (some)
hydrogen peroxide is consumed over time during collection and storage 3,17,22.
Isoprostanes are relatively stable end-products of in vivo arachidonate peroxidation,
and are measured in EBC by immunoassay, that may be influenced by cross reactivity
with closely related substances 17. Other confounding factors may be age, diets rich
in antioxidants, and smoking habits 17.
The use of coefficients of variation is not always the ideal way of expressing
variability: when mean values are low, coefficients of variation can be abnormally
high. Therefore, we also expressed our results as standard deviations and intraclass
correlation coefficients. When using both of these alternative expression methods,
results were comparable: no difference in biomarker variability between condensers
was found (data not shown). Furthermore, biomarker levels were assessed in
condensate originating from healthy adults, and thus, may have been more
pronounced in a steroid naïve population with documented chronic respiratory
inflammation, and comparable levels of disease control. Hence, one may expect
increased mean concentrations, and lowered coefficients of variation in diseased
subjects. On the other hand, with these very low concentrations of cytokines and 8-
isoprostane, we cannot rule out an influence of analytical variability.
Cytokines were simultaneously measured by xMAP’s technology in small 50µL EBC
samples. The overall level of detection was 46-97%, that was much better compared
to cytometric bead array in small samples in children (<50%), and in large 1000-
2000µL lyophilisated samples in adults (3-100%) 6,23-26. When compared with
conventional (solid-phase) immunoassays, multiplexed immunoassays detect bioactive
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and inactive molecules, have a growing analytical range, are rapid (hours instead of
days), have good precision (coefficient of variation: 10-15%), are not interfered by
drugs, and have simple protocols 7.
Currently, different nonstandardised techniques to collect EBC are in use 1-3. All
systems are based on the cooling of exhaled breath, whereas their design may vary from
immersed plastic tubing, over glass distilling columns, to commercial systems, such as
the lamellar Teflon-like EcoScreen® condenser (Erich Jaeger GmbH, Hoechberg,
Germany), the hand-held disposable polypropylene RTube™ (Respiratory Inc.,
Charlottesville, Virginia, USA), and the thermostatically-controlled polyethylene Turbo-
Deccs (ItalChill, Parma, Italy) 1-3,27. These designs implicate relatively short-measured and
open-ended systems that tolerate the needless loss of noncondensed exhaled breath,
whether initially, or after a prolonged collection time. Moreover, also biomarkers may be
lost within these collection systems, as recently demonstrated for 8-isoprostane and
albumin measurements, in vitro and in vivo, in nonglass condensers (including
EcoScreen®) 4. This superiority of glass coatings may be mainly related to the behaviour
of water as bipolar vehicle 4. Three other studies report the influence of sampling
systems on biomarkers in EBC 28-30. Tufvesson et al proposed to coat EcoScreen®
collection surfaces with bovine serum albumin and Tween-20, to measure cytokines and
eicosanoids, respectively 28. However, they also reported possible false-positive
(eicosanoid) results, and the need of sample concentration, by vacuum-centrifugation,
prior to analysis 28. Soyer et al found significantly higher cysteinyl leukotrienes and
eotaxin using EcoScreen®, compared to RTube™, due to susceptibility of precooled
RTube™ sleeves to (increased) ambient temperatures during collection, and due to
different materials that could affect sample recovery 29. Prieto et al compared RTube™
and EcoScreen®, and reported that EBC pH values are dependent on the collection
device used 30. Furthermore, the EcoScreen® has been associated with deposition of
frozen condensate on its lamellar walls. For all the above mentioned reasons, we
developed an optimised glass condenser system. The new glass condenser had an
improved condensation process and condensate recovery, using an inclined and enlarged
condensation surface, with a condensate sweeping plunger, having tangentially and
axially guiding breath flow channels.
In the present study, these improvements resulted in significantly increased EBC
volumes, and increased biomarker detections with the new glass condenser, compared
to silicone, glass and EcoScreen®. This suggests both an improved condensation
process, and an increased opportunity to perform a broad spectrum of analyses.
Moreover, the optimised glass and EcoScreen® condenser were both significantly
associated with less variation in the generated EBC volume, compared to the other
condensers. Hereby, reducing a possible confounding influence of the variable quantity
of EBC collected over a given time, and even within individuals. 
Optimisation of EBC collection, using the modified new glass condenser with
statistically equivalent coefficients of variation compared to the commercial
EcoScreen®, and optimisation of EBC analysis, using rapid, multiplexed measurement
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of cytokines in small EBC sample sizes, may all together open a window of
opportunities, even in strained collection procedures, such as in young or dyspnoeic
subjects (with less sustained efforts to cope with sampling procedures), by allowing
the search for, and identification of, particular profiles of different exhaled markers,
involved in the regulation of chronic respiratory inflammation, for diagnostic and
monitoring purposes.
In conclusion, the optimised glass condenser yielded significantly more EBC
volume, with good reproducibility. Furthermore, significantly more positive detections
of hydrogen peroxide, 8-isoprostane, interleukin-2, interleukin-4, interleukin-5,
interleukin-13 and tumor necrosis factor-alpha were found in EBC collected with the
new condenser, hereby offering an increased capacity to analyse for complex
biomarker profiles. Moreover, concentrations of 8-isoprostane were significantly
increased using the optimised glass condenser, compared to the other three
condensers. However, reproducibility of biomarker measurements in EBC was not
influenced by the type of condenser.
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CHAPTER 6
FREE RADICALS IN EXHALED BREATH CONDENSATE IN
CYSTIC FIBROSIS AND HEALTHY SUBJECTS
Rosias PPR, den Hartog GJM, Robroeks CMHHT, Bast A, Donckerwolcke RAMG,
Heynens JWCM, Suykerbuyk J, Hendriks HJE, Jöbsis Q, Dompeling E.
Free Radical Research 2006; 40: 901-909.
Abstract 
Many markers of airway inflammation and oxidative stress can be measured
noninvasively in exhaled breath condensate. However, no attempt has been made to
directly detect free radicals using electron paramagnetic resonance spectroscopy. 
Condensate was collected in 14 children with cystic fibrosis and seven healthy
subjects. Free radicals were trapped by 5,5-dimethyl-1-pyrroline-N-oxide. Electron
paramagnetic resonance spectra were recorded using a Bruker EMX® spectrometer.
Secondly, to study the source of oxygen centered radical formation, catalase or
hydrogen peroxide was added to the condensate. 
Radicals were detected in 18 out of 21 condensate samples. Analysis of spectra
indicated that both oxygen and carbon centered radicals were trapped. Within-subject
reproducibility was good in all but one subject. Quantitatively, there was a trend
towards higher maximal peak heights of both oxygen and carbon centered radicals in
the children with cystic fibrosis. Catalase completely suppressed the signals in
condensate. Addition of hydrogen peroxide resulted in increased radical signal
intensity. 
Detection of free radicals in exhaled breath condensate of children with cystic
fibrosis and healthy subjects is feasible using EPR spectroscopy. 
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Introduction
The collection of exhaled breath condensate (EBC) is a simple and noninvasive
technique to measure mediators of airway inflammation. EBC consists not only of
water vapor, but also contains aerosolized respiratory fluid droplets released from the
respiratory epithelial lining fluid. These fluid droplets contain traces of nonvolatile
solutes, which can be recovered in EBC samples 1. EBC is collected by guiding and
cooling exhaled air of a tidally breathing subject through a condenser system. The
collection of EBC does not disturb the airways, in contrast to bronchial biopsy,
bronchoalveolar lavage and induced sputum, and thus, can be obtained with minimal
risk and inconvenience in both adults and children 2. Many inflammatory mediators,
such as 8-isoprostane, have been demonstrated in EBC of adults and children with
chronic inflammatory lung diseases 3-12.
Oxidative stress appears to play an important role in several inflammatory lung
diseases, including asthma and cystic fibrosis. Oxidative stress is defined as an imbalance
between oxidants (reactive oxygen species, and reactive nitrogen species) and
antioxidants (superoxide dismutase, catalase, glutathione, uric acid, lactoferrin, vitamin
C, vitamin E) in favor of oxidants 13. By virtue of their unpaired electrons, many reactive
oxygen species are unstable compounds, capable of initiating widespread oxidative
events. Increased production of reactive oxygen species has been directly linked to
protein, DNA and lipid oxidation, which may cause direct lung injury or induce a variety
of cellular responses, through the generation of secondary metabolic reactive species 14.
The measurement of F2-isoprostanes is currently the most reliable approach to assess
oxidative stress status in vivo 11. In EBC, 8-isoprostane can be measured in both adults
and children, although reproducibility remains controversial 11-12,15-16. On the other
hand, spin trapping is the only direct method for the detection of free radicals 14,17.
Reactive oxygen and nitrogen species can be detected by electron paramagnetic
resonance spectroscopy using various spin traps, e.g. 5,5-dimethyl-1-pyrroline N-oxide
(DMPO) 14,18,19.
However, as the increased production of radicals appears to play an important role
in inflammatory lung diseases, as far as we know, no attempt has been made to detect
free radicals in EBC. The aim of this study was the detection of free radicals in EBC of
children with cystic fibrosis using electron paramagnetic resonance spectroscopy. 
Materials and methods
Study subjects
EBC was collected in 14 children with cystic fibrosis, routinely attending the cystic
fibrosis centre of the Maastricht University Hospital, and seven healthy controls
(including one adult). Cystic fibrosis was defined as a positive quantitative sweat test
in conjunction with chronic airway obstruction and/or recurrent infections of the
airways and/or exocrine pancreatic insufficiency and maldigestion. Children with cystic
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fibrosis were clinically stable at the time of the assessment. Healthy subjects were
asked to complete a standardized questionnaire of the International Study of Asthma
and Allergies in Childhood (ISAAC) in order to exclude the presence of asthma or
allergic disease 20. The subject characteristics are shown in Table I. The study was
approved by the medical ethical committee of the University of Maastricht.
Collection of exhaled breath condensate
Each subject was asked to exhale tidally, while wearing a nose clip, through a mouthpiece
connected to a two-way non-rebreathing valve and a cooled (0°C) double-jacketed 50-
cm borosilicate glass tube as shown in figure 1 and described previously 3,10. In order to
prevent salivary contamination of EBC samples, the two-way valve and tubing were used
as a saliva gravity trap. Condensate was collected at the open end of the glass condenser,
as shown in figure 1, directly into vials containing spin trap (DMPO) (Table II). Thus, no
resistance was created during exhalation. Each vial was wrapped in aluminum paper to
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Table I. Subject characteristics.
Cystic fibrosis Healthy subjects
Number of subjects 14 7
Age (years) 14 (6 – 17)* 13 (9 - 25)*
Male / female ratio 9 / 5 4 / 3
Weight (kg) 38 (18 – 60)* 44 (37 - 85)*
Height (cm) 153 (114 – 176)* 164 (144 - 179)*
FEV1 (%predicted) 66 (31 – 108)* -
Use of corticosteroids 4 0
Use of antibiotics 4 0
*median and (range)
FEV1 forced expiratory volume in 1 second
Figure 1. Schematic representation of the exhaled breath condensate collection device.
The subject breaths tidally and inhales
room air (1) through a two-way non-
rebreathing valve (2). Exhaled air is
guided by the tubing through a
double-wall glass condenser (4),
which is cooled by a counter-current
circulating ice-water pump (3). The
two-way non-rebreathing valve (2)
and tubing also serve as a saliva trap.
protect DMPO against daylight. The condensate collection continued until the minimal
required volume of EBC was obtained necessary to perform one test (Table II). Samples
were analyzed immediately. Four different test conditions were applied, as shown in
Table II. Test 1-4 were performed to study DMPO-condensate samples under different
volumes and concentrations of EBC and DMPO (Table II).
Electron paramagnetic resonance spectroscopy
Electron paramagnetic resonance spectra of the DMPO trapped radicals were recorded
at room temperature using a Bruker EMX® electron paramagnetic resonance
spectrometer (Bruker Biospin GmbH, Karlsruhe, Germany). The experimental conditions
were as follows: Klystron frequency 9.85 GHz, microwave power 30 mW, field
147
Free radicals in EBC
Table II. Specific test conditions.
CF Healthy EBC DMPO
Test 1 2 1 1 mL 1 mL (50 mM)
Test 2 4 - 0.5 mL 0.5 mL (100 mM)
Test 3 5 6 0.5 mL 0.25 mL (100 mM)
Test 4 3 - 0.3 mL 0.25 mL (100 mM)
CF number of cystic fibrosis patients
Healthy number of healthy subjects
EBC volume of collected exhaled breath condensate
DMPO volume and (concentration) of spin trap (5,5-dimethyl-1-pyrroline N-oxide)
Figure 2. The DMPO-background signal and the condensate-specific radical adduct signal.
The upper part of figure 2
shows the signal of 5,5-
dimethyl-1-pyrroline N-oxide
(DMPO) in water, or the
DMPO-background signal.
The lower part of figure 2
shows the condensate-
specific radical adduct signal
after subtraction of the
DMPO-background signal.
X-axis: magnetic field strength
(Gauss)
Y-axis: intensity of the electron
paramagnetic resonance
signal 
modulation amplitude 2G at 100 kHz frequency, time constant 40.96 msec and 1.0 x
106 gain, and a sweep width of 60G. Each sample was scanned 50 times. The signal
of DMPO in H2O was subtracted from the DMPO-condensate signal to obtain
condensate-specific spectra (Figure 2). 
Within-subject reproducibility of the electron paramagnetic resonance signals was
assessed in five subjects by measuring electron paramagnetic resonance spectra in
EBC collected with a one-hour interval. The results were expressed as coefficients of
variation (CV = [SD/mean] x100%).
In order to quantify the method, we assigned to each electron paramagnetic resonance
signal an arbitrary unit derived from it’s maximal peak height, as illustrated in figure 3.
Additionally, test A and B were designed to study the source of oxygen centered
radical formation. In test A, catalase (50 µL of a 5000 U/mL catalase solution) was
added to the DMPO vials of test three. Catalase converts hydrogen peroxide in water
and oxygen. Therefore, catalase was expected to reduce free radical signals derived
from hydrogen peroxide. In test B, hydrogen peroxide (2 µL of a 9.7 M hydrogen
peroxide solution) was added to the DMPO vials of test four. When hydrogen peroxide
is considered to be the main source of free radical generation, hydrogen peroxide
should amplify free radical signals. 
Finally, saliva and sputum were investigated on the presence of free radical signals,
in order to exclude free radical contamination by these biofluids.
Results
The median duration of EBC collection was 16.5 minutes (range 13-18 minutes). As
shown in Table III, optimal capture of free radical adducts was obtained using 0.25-
0.50 mL DMPO (100 mM) and 0.5 mL condensate. Free radical adduct signals were
detected in 18 out of 21 DMPO-condensate samples of children with cystic fibrosis
and healthy controls (Table III). 
148
Chapter 6
Figure 3. Quantification of electron paramagnetic resonance spectra in exhaled breath condensate by
assessing maximal peak height in arbitrary units.
X-axis: magnetic field strength
(Gauss)
Y-axis: intensity of the electron
paramagnetic resonance
signal 
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Figure 4A. Oxygen (1:2:2:1) centered radical adduct signal in the mixture of condensate and spin trap
(DMPO).
Figure 4B. Carbon (1:1:1:1:1:1) centered radical adduct signal in the mixture of condensate and spin trap
(DMPO).
Table III. Detection of oxygen (O) and carbon (C) centered radical adduct signals in exhaled breath
condensate of children with cystic fibrosis and healthy controls.
Cystic Fibrosis Healthy Controls
O C O or C O C O or C
Test 1 1/2 0/2 1/2 0/1 0/1 0/1
Test 2 1/4 3/4 4/4 - - -
Test 3 5/5 3/5 5/5 6/6 4/6 6/6
Test 4 2/3 0/3 2/3 - - -
Total 12/14 6/7
O number of oxygen centered radical adduct signals to number of subjects
C number of carbon centered radical adduct signals to number of subjects
O or C number of free radical adduct signals to number of subjects
Total total number of free radical adduct signals to total number of subjects
DMPO: 5,5-dimethyl-1-
pyrroline N-oxide
X-axis: magnetic field strength
(Gauss)
Y-axis: intensity of the electron
paramagnetic resonance
signal 
DMPO: 5,5-dimethyl-1-
pyrroline N-oxide
X-axis: magnetic field strength
(Gauss)
Y-axis: intensity of the electron
paramagnetic resonance
signal 
Analysis of electron paramagnetic resonance spectra indicated that both oxygen and
carbon centered radicals were trapped by DMPO, as shown in Figure 4A and 4B respectively. 
Within-subject reproducibility of electron paramagnetic resonance spectra in EBC
was good in four subjects (coefficients of variation ranged from five to twelve percent)
(figure 5). However, in one subject the coefficient of variation was 87%. 
Quantitative results expressed as maximal peak height (in arbitrary units) of both
oxygen and carbon centered radicals in children with cystic fibrosis and healthy
controls had a normal distribution and are shown in figure 6. The maximal peak
heights of oxygen as well as carbon centered radical adduct signals seemed higher in
the cystic fibrosis group compared with the healthy controls. However, the difference
in oxygen and carbon centered radicals failed to reach statistical significance (p=0.828
and p=0.253 respectively, Student’s t-test). 
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Figure 5. Within-subject reproducibility of electron paramagnetic resonance spectra in exhaled breath
condensate.
Figure 6. Quantitative results expressed as maximal peak height (in arbitrary units) of both oxygen and
carbon centered radical adduct signals in exhaled breath condensate in children with cystic
fibrosis and healthy controls.
Within-subject reproducibility
was assessed in five subjects by
measuring electron paramagnetic
resonance spectra in exhaled
breath condensate that was
collected twice with 1hr time
interval. The coefficients of
variation were 87, 5, 12, 8 and
5% respectively.
The maximal peak height of
oxygen centered radical
adduct signals (oxygen) and
carbon centered radical adduct
signals (carbon) did not differ
significantly between the
children with cystic fibrosis
(CF) and healthy control group
(p=0.828 and p=0.253
respectively, t-test).
Catalase completely suppressed most oxygen centered radical adduct signals in EBC
of children with cystic fibrosis (four out of five) and healthy controls (three out of six)
(Figure 7A). On the other hand, addition of hydrogen peroxide resulted in a substantial
increase of oxygen centered radical adduct signals in EBC of children with cystic
fibrosis (two out of three) (Figure 7B). 
Saliva contained little or no free radicals (three out of four samples were negative).
It was not possible to detect free radicals in sputum (n=1) due to its viscosity. 
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Figure 7A. Suppression of oxygen centered radical adduct signal in the mixture of condensate, spin trap
(DMPO) and catalase.
Figure 7B. Amplification of oxygen centered radical adduct signal in the mixture of condensate, spin trap
(DMPO) and hydrogen peroxide.
The upper part of figure 7A shows an
oxygen centered radical adduct signal
in the mixture of condensate and spin
trap (5,5-dimethyl-1-pyrroline N-
oxide, or DMPO). The lower part of
figure 7A shows that subsequent
addition of catalase results in
suppression of the oxygen centered
radical adduct signal.
X-axis: magnetic field strength
(Gauss)
Y-axis: intensity of the electron
paramagnetic resonance signal
The upper part of figure 7B shows an
oxygen centered radical adduct signal
in the mixture of condensate and spin
trap (5,5-dimethyl-1-pyrroline N-
oxide, or DMPO). The lower part of
figure 7B shows that subsequent
addition of hydrogen peroxide results
in amplification of the oxygen
centered radical adduct signal.
X-axis: magnetic field strength
(Gauss)
Y-axis: intensity of the electron
paramagnetic resonance signal 
Discussion
The presence of oxidative stress in children with cystic fibrosis was assessed by direct
measurement of free radicals in EBC using electron paramagnetic resonance
spectroscopy. Oxygen as well as carbon centered radicals were trapped by DMPO in
EBC in children with cystic fibrosis and healthy controls. Quantification demonstrated
a difference that failed to reach statistical significance. Short-term reproducibility was
good, except in one subject. Furthermore, most oxygen centered radical adduct
signals were completely suppressed by catalase, while signal amplification by hydrogen
peroxide was observed, indicating that hydrogen peroxide is a main source for the
generation of free radicals in EBC.
Although within-subject reproducibility was good in four subjects, reproducibility
was questionable in one subject, maybe as a consequence of physical exertion
between the two tests.
Our quantitative approach using maximal peak height of an electron paramagnetic
resonance signal in EBC did not show a statistical significant difference in oxygen or
carbon centered radicals, between the cystic fibrosis children and healthy controls.
However, there was a trend towards higher maximal peak heights of both oxygen and
carbon centered radicals in the cystic fibrosis group, that may reach statistical
significance in a larger study population.
Various indirect biomarkers of oxidative stress in condensate of subjects with
chronic respiratory inflammation are known, as recently reviewed 3,14. Currently,
comparative reports on the direct measurement of free radicals in EBC are, to our
knowledge, not available. 
Oxidative stress appears to play an important role in several inflammatory lung
diseases. It is defined as an imbalance between oxidants (reactive oxygen species,
reactive nitrogen species) and antioxidants (e.g. catalase) in favor of oxidants 13.
Chronic inflammatory lung diseases, such as asthma and cystic fibrosis, are characterized
by the activation of epithelial cells and resident macrophages, and the recruitment and
activation of neutrophils, eosinophils, monocytes and lymphocytes 14. The activation of
macrophages, neutrophils and eosinophils results in the generation of reactive oxygen
species 14. Lung epithelial cells also release reactive oxygen species, and when this
occurs these substances stimulate inflammatory cells directly, thereby amplifying lung
inflammatory and oxidant events 14,21.
By virtue of their unpaired electrons, oxygen species are reactive compounds, that
cause widespread oxidative events 14. One such species, the superoxide anion, is
rapidly reduced to hydrogen peroxide by superoxide dismutase 14. The combination
of hydrogen peroxide with transition metal ions yields the hydroxyl radical 14. Reactive
oxygen and nitrogen species can also be generated intracellular from several sources,
including mitochondrial respiration, the NADPH oxidase system and xanthine/xanthine
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oxidase, leading to cell necrosis or apoptosis 14. When generated close to cell
membranes, the reactive oxygen species oxidize membrane phospholipids (lipid
peroxidation) 14. This initiates a chain reaction, which in turn leads to the generation
and accumulation of lipid peroxidation products such as malondialdehyde, F2-
isoprostanes, 4-hydroxy-2-nonenal and acrolein 14. The peroxidative breakdown of
polyunsaturated fatty acids within the membrane impairs function, inactivates
membrane-bound receptors and enzymes and increases tissue permeability and cell
fragility 14. In addition to their cytotoxic properties, lipid peroxides are increasingly
recognized as being important in redox-sensitive signal transduction pathways,
especially those activated during an inflammatory response 14,22,23.
To study the source of the formation of oxygen centered radicals, two additional
tests (test A and B) were performed. Test A shows the absence of a radical adduct
signal in the mixture condensate, catalase and spin trap (in seven out of eleven
samples), which suggests that hydrogen peroxide may play an important role in the
generation of oxygen centered radicals measured in EBC after spin trapping. Increased
concentrations of hydrogen peroxide in EBC have been demonstrated in patients with
asthma and cystic fibrosis 3. In sixteen children with cystic fibrosis, Jöbsis et al reported
increased hydrogen peroxide levels in EBC, and a significant decrease of these levels
during intravenous antibiotic treatment 24. Test B demonstrates an increased formation
of most oxygen centered radicals (in two out of three samples), after addition of
hydrogen peroxide. These amplified electron paramagnetic resonance signals suggests
that EBC may contain compounds that enable the formation of radicals from hydrogen
peroxide, such as transition metal ions and/or compounds that reduce these ions to
their Fenton active states. Griese and co-workers found higher concentrations of zinc
in EBC in cystic fibrosis patients, compared to healthy controls 25. Zinc is known as a
redox-active metal that may generate both hydrogen peroxide and hydroxyl radicals
by Fenton reaction 26.
Carbon centered radicals may originate from various sources, such as fatty acids,
alkane, ethanol or carbohydrates. However, we are not able to exclude with certainty
whether free radicals are formed in situ in the collection vial. A possible explanation for
the presence of carbon centered radicals, in the absence of oxygen centered radicals,
may be that carbon-containing molecules react with hydroxyl radicals. By consequence,
carbon containing molecules become carbon centered radicals and the former hydroxyl
radical is no longer an oxygen centered radical. Similarly, hydroxyl radicals may be
formed in situ from hydrogen peroxide in the presence of certain compounds such as
transition metals. In order to reduce the risk of in situ free radical formation, one may
develop a collecting device that allows direct contact between exhaled air and a DMPO
containing filter. Spin trapping remains highly dependent on the spin trap used and the
antioxidant status of the condensate 27. Furthermore, the outcome of electron
paramagnetic resonance results is not only influenced by the amount of free radicals
trapped by constituent compounds of the EBC and the presence of some electrolyte
ions, such as sodium and potassium, but also influenced by the spin trap-free radical
interaction (each free radical has a specific affinity for a given spin trap) 27.
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Finally, as most saliva samples were negative, free radicals in EBC do not likely result
from contamination with this biofluid. This suggests that free radicals in EBC may
originate from the lower respiratory tract, providing further support that EBC reflects
the epithelial lining fluid.
Free radicals were also present in condensate of healthy subjects. This may not be
surprising, considering that the lung normally exists in an oxygen rich environment
which makes it susceptible to oxidative stress, and considering that electron
paramagnetic resonance spectroscopy allows direct but semi-quantitative measurement
of free radicals 14,28. We did not find free radicals in three out of 21 condensate
samples, including one healthy control, one child with cystic fibrosis on longterm
prednison treatment, and one child with cystic fibrosis on antibiotics. Corticosteroids
may have an antioxidant effect by decreasing the numbers as well as the oxidative and
chemotactic responses of neutrophils, whereas antibiotics may have a certain role in
reducing oxidative stress by reducing infection and thereby lung inflammation 29.
We aimed at assessing the potential use of electron paramagnetic resonance
spectroscopy in the detection of free radicals in EBC in children with cystic fibrosis and
healthy subjects. Future studies should include a larger number of subjects and a
wider range of disease severity, with repeated measurements of conventional markers
and free radicals in EBC. 
Other disturbing factors may include counteracting effects of exercise, dietary
components, diurnal rhythm, duration of EBC collection and analysis, partial exposition
of DMPO to daylight, environmental temperature and inhaled air particles of diverse
origin 27,30,31.
As we report on a more direct and noninvasive assessment of oxidative stress, one
may speculate on clinical implications. However, the future challenge is to define the
source of free radical formation, and to extend our understanding of the discriminative
power of electron paramagnetic resonance spectroscopy in the detection of
(exacerbations of) chronic lung disease, monitoring of disease severity, and disease
progression.
We conclude that detection of free radicals in EBC of children with cystic fibrosis
and healthy subjects is feasible using electron paramagnetic resonance spectroscopy.
Furthermore, it is likely that hydrogen peroxide is crucial for the generation of oxygen
centered radicals detected in EBC. Moreover, EBC may also contain compounds that
enable radical formation.
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CHAPTER 7
BIOMARKERS IN EXHALED BREATH CONDENSATE
INDICATE PRESENCE AND SEVERITY
OF CYSTIC FIBROSIS IN CHILDREN
Robroeks CMHHT, Rosias PPR, van Vliet D, Jöbsis Q, Yntema J-BL, Brackel HJL,
Damoiseaux JGMC, den Hartog GJM, Wodzig WKWH, Dompeling E.
Pediatric Allergy and Immunology; in press.
Abstract
Chronic airway inflammation is present in cystic fibrosis. Noninvasive inflammometry
may be useful in disease management. The aim of the present cross-sectional study
in children with cystic fibrosis was to investigate: (i) the ability of fractional exhaled
nitric oxide and other exhaled inflammatory markers (exhaled breath condensate
acidity, nitrite, nitrate, hydrogen peroxide, 8-isoprostane, and Th1/Th2 cytokines) to
indicate (exacerbations of) cystic fibrosis; and (ii) the ability of these noninvasive
inflammatory markers to indicate disease severity in cystic fibrosis.
In 98 children (48 cystic fibrosis / 50 controls) exhaled nitric oxide was measured
using the NIOX®. Subsequently, exhaled breath condensate was collected and
analysed, and lung function tests were performed by means of dynamic spirometry. 
In cystic fibrosis, condensate interferon-gamma and nitrite concentrations were
significantly higher, and exhaled nitric oxide levels were significantly lower, compared
to controls (3.3 (±0.3) pg/mL, 2.2 (±0.2) µM, 10.0 (±1.2) ppb, versus 2.6 (±0.2) pg/mL,
1.4 (±0.1) µM, 15.4 (±1.4) ppb, respectively). Using multivariate logistic regression
models, the presence of cystic fibrosis was best indicated by combined condensate 8-
isoprostane, nitrite and interferon-gamma (sensitivity 78%, specificity 83%; area
under receiver operating characteristic curve 0.906, p<0.001). An exacerbation of
cystic fibrosis was best indicated by condensate 8-isoprostane and nitrite (sensitivity
40%, specificity 97%, area under receiver operating characteristic curve 0.838,
p=0.009). Most indicative biomarkers of cystic fibrosis severity were exhaled nitric
oxide, and condensate acidity (sensitivity 96%, specificity 67%; area under receiver
operating characteristic curve 0.751, p=0.008).
In this cross-sectional study in children, the combination of different exhaled
inflammatory markers could indicate the presence of cystic fibrosis disease,
exacerbation, and severity. Longitudinal data are necessary to further confirm the role
of these exhaled markers in the management of cystic fibrosis in children.
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Introduction
Cystic fibrosis is an autosomal recessive disorder, caused by genetic mutations in the
cystic fibrosis transmembrane conductance regulator protein. This results in impaired
or absent transport of chloride through cell-membranes, with impaired mucociliary
clearance, and viscous mucus in the airways. Moreover, defective mucociliary action
results in inability of the airways to clear bacteria, e.g. Pseudomonas aeruginosa 1.
Chronic airway infection, inflammation and oxidative stress are the characteristics of
cystic fibrosis disease, which are mainly due to neutrophilic immune responses 2.
Pulmonary disease is the leading cause of morbidity and mortality in patients with
cystic fibrosis 3.
Currently, monitoring of pulmonary disease in cystic fibrosis is based on clinical
features and pulmonary function tests. However, these tests may not reflect the onset,
origin or severity of airway inflammation 4. The noninvasive assessment of inflammatory
markers in exhaled breath condensate (EBC) may be a promising tool in patients with
chronic lung diseases 4-6. In cystic fibrosis, noninvasive inflammatory markers may be
helpful in the early detection of cystic fibrosis lung disease in infants, the prediction and
follow-up of an exacerbation, and the evaluation of treatment effects. 
Several research groups detected altered inflammatory markers, such as
leukotriene–B4, interleukin-6, and free radicals, in EBC of patients with cystic fibrosis,
compared to controls 7-10. Jöbsis et al showed increased exhaled hydrogen peroxide
concentrations during cystic fibrosis exacerbations 8. Recently, the presence of
interleukin-4, interleukin-10, tumor necrosis factor-alpha, and interferon-gamma was
demonstrated in EBC of patients with cystic fibrosis 10. However, study populations
were often small, and data on noninvasive markers in cystic fibrosis limited and
inconsistent. In addition, the relationships between noninvasive inflammatory markers,
and the severity or exacerbations of cystic fibrosis disease, are still unknown. Therefore,
we assessed different inflammatory markers in EBC in almost 100 children with cystic
fibrosis and controls, comparing the ability of these markers to indicate (exacerbations
of) cystic fibrosis, and/or disease severity. Because of oxidative stress and airway
inflammation, hydrogen peroxide, 8-isoprostane, and nitrite/nitrate are upregulated in
the airways of cystic fibrosis patients, and acidity is increased. Conversely, fractional
exhaled nitric oxide levels have shown to be lower in cystic fibrosis. 
The aim of the present cross-sectional study in children with cystic fibrosis was to
investigate: (i) the ability of fractional exhaled nitric oxide and other exhaled inflammatory
markers (condensate acidity, nitrite, nitrate, hydrogen peroxide, 8-isoprostane, and
Th1/Th2 cytokines) to indicate (exacerbations of) cystic fibrosis; and (ii) the ability of
these noninvasive inflammatory markers to indicate disease severity in cystic fibrosis.
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Methods 
Study subjects
We included 48 children with cystic fibrosis, and 50 control children without a history
of lung disease or atopy. Informed consent was obtained from all subjects. The study
was approved by the Medical Ethics Committee of the University Hospital of Maastricht.
Cystic fibrosis population
Children known with cystic fibrosis were recruited from the outpatient clinics. Cystic
fibrosis disease was defined as a combination of typical clinical features (persistent
pulmonary problems, meconium ileus, failure to thrive, steatorrhoe), and an abnormal
sweat test (chloride > 60mM). An exacerbation of cystic fibrosis was diagnosed by the
paediatric pulmonologist based on a significant increase in cystic fibrosis related
symptoms, and/or a decrease of at least 10% in forced expiratory volume in one
second, or forced vital capacity compared to previous measurements 11. Height and
weight were expressed as Z-scores (age and gender specific standard deviation scores).
Cystic fibrosis severity was assessed using the Shwachman-Kulczycki score.
Control population
Control children without lung disease were recruited from the outpatient clinic of the
University Hospital Maastricht. The reasons of consultation were constipation and
enuresis nocturna. All children completed the questionnaire from the International
Study of Asthma and Allergies in Childhood (ISAAC) to exclude children with a (history
of) airway or allergy complaints, or asthmatic disease 12.
Exclusion criteria
Exclusion criteria were: (i) diseases that may interfere with the results of the study (upper
airway infection, heart disease, anatomic abnormalities of the airways, and other chronic
inflammatory diseases, such as Crohns disease and rheumatoid arthritis); (ii) mental
retardation; (iii) inability to perform the EBC collection procedure; (iv) active smoking; and
(v) use of the following medication: papaverin, sodium nitroprusside, angiotensin-
converting enzyme inhibitors, oxymetazoline, L-arginine, or nitric oxide synthase inhibitors.
Design and Measurements
The design of this study was cross-sectional. At first, fractional exhaled nitric oxide
was measured. Subsequently, EBC was collected, and lung function was measured by
means of dynamic spirometry. All tests were performed within one hour.
Nitric oxide in exhaled air
Fractional exhaled nitric oxide was measured using a NIOX® chemiluminescence
analyser (Aerocrine, Solna, Sweden). Measurements were assessed according to the
recommendations of the American Thoracic Society and European Respiratory Society
for children 6. The mean nitric oxide value of the plateau reached during the last 3
seconds of exhalation, was used to obtain the fractional exhaled nitric oxide value of
that measurement 6. The mean fractional exhaled nitric oxide of three measurements
was used for analysis.
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In 14 patients with cystic fibrosis, fractional exhaled nitric oxide was measured using
the offline method, because there was not a NIOX® analyser available in these clinics.
The first 4 seconds of exhaled air were discarded and during the next 4 seconds,
exhaled air was collected in an inert balloon. Fractional exhaled nitric oxide levels were
analysed on the NIOX® chemiluminescence analyser within 8 hours 13. The exhalation
flow rate during these measurements was 50 mL/sec.
Exhaled breath condensate
EBC was collected using a home-made 50-cm double-wall borosilicate glass condenser,
continuously cooled by circulating ice water (1ºC), as described previously 5,10,14.
Subjects were asked to breath tidally for 30 minutes through a mouthpiece, while
wearing a nose-clip. The mouthpiece was connected to a two-way non-rebreathing
valve (Hans Rudolph Inc, series 1420, Kansas City,USA), which also served as a
gravitational saliva trap. In addition, children were allowed to swallow saliva during
EBC collection. 
The acidity of the EBC was measured immediately after collection (Radiometer®,
type PHM201, Radiometer Nederland BV, Zoetermeer, the Netherlands). Samples were
not deaerated 14. Subsequently, the EBC samples were frozen and stored at -80ºC in
1mL Eppendorf® tubes. 
In EBC, nitrite and nitrate concentrations were assessed using a fluorimetric assay
(Cayman Chemical, Ann Arbor, USA) 15. To measure 8-isoprostane in EBC, an enzyme
immunoassay was used (Cayman Chemical, Ann Arbor, USA), which was modified in
order to lower the detection limit from 5.0 pg/mL (80% B/B0) to 0.5 pg/mL. Standard
curves, patient samples and quality control samples of 2.5 pg/mL and 10 pg/mL, were
assayed in triplicate. The coefficients of variation of the absorption signal were
assessed. Intra-assay variation of standard curves, patient samples and quality control
samples should be less than 15%, otherwise all samples measured in that assay were
excluded and re-analysed. Finally, in all accepted samples, 8-isoprostane concentrations
were determined from mean absorption signal intensities. 
Hydrogen peroxide measurements in EBC were based on a method previously
described by Dekhuijzen et al 16. Briefly, EBC was mixed with 0.4M citrate buffer,
horseradish peroxidase solution (50U/mL), and tetramethylbenzidine (20 mM), and
incubated for 20 minutes at room temperature. Subsequently, the sample was mixed
with sulphuric acid (2M). The tetramethylbenzidine oxidation product, as a measure
of the amount of hydrogen peroxide, was determined spectrometrically at 450nm
using a Perkin Elmer UV-VIS Spectrometer Lambda 10 (Norwalk, CT, USA). 
Cytokines (interleukin-2, interleukin-4, interleukin-5, interleukin-10, tumor
necrosis factor-alpha, and interferon-gamma) were assessed in 50 µL samples of EBC
with flow cytometry (multiplexed cytometric bead array (CBA), BD Bioscience®, San
Diego, USA), as described previously 10.
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Lung function tests
Bronchodilator medication was stopped prior to lung function testing: shortacting
bronchodilators for at least 8 hours, and longacting bronchodilators at least for 36
hours. Dynamic spirometry was performed by means of the Flowscreen® (Jaeger®,
Wuerzburg, Germany). The lung function parameters were assessed according to
European Respiratory Society standards. The highest values of one of three correct
performed manoeuvres were used for analysis. Recorded parameters were: forced
expiratory volume in one second, and forced vital capacity. In addition, in the cystic
fibrosis population, residual volume, total lung capacity, and intrathoracic gas volume
were assessed by body plethysmography (Jaeger®, Würzberg, Germany). The
reversibility on a bronchodilator was determined 15 minutes after inhalation of 400µg
salbutamol. Reversibility was defined as an increase in measured forced expiratory
volume in one second of at least 9% of predicted value. 
Statistical analysis
Statistical calculations were performed using SPSS 11.5 (SPSS Inc., Chicago, USA).
Data were expressed as mean ± standard error of the mean, or as median (interquartile
range) values for normal, or not normal distributed continuous variables, respectively.
Comparison between groups was performed using the chi-square for categorical
variables, the Student’s t-tests for normal distributed parameters, and, Mann Whitney
U-test was used when the distribution of the parameters was considered not normal.
P-values < 0.05 were considered statistically significant. 
At first, the influence of separate inflammatory markers was tested in univariate
logistic regression analyses. Thereafter, the different inflammatory markers were
combined in multivariate logistic regression models with cystic fibrosis disease, cystic
fibrosis exacerbation, and cystic fibrosis severity as dependent binary variables. Age,
height, weight, forced expiratory volume in one second as per centage of predicted
value, and the forced expiratory volume in one second to vital capacity ratio were
introduced in the model as covariates, but were removed if p-values exceeded 0.10,
in order to keep the degrees of freedom as high as possible. The stepwise backward
method was applied to reduce the number of independent variables, and to assess
which inflammatory markers were most predictive: only inflammatory markers with a
p-value <0.05 were kept in the final models. Based on these models, receiver operating
characteristic curves were obtained. EBC samples with negative detections were not
considered as missings, because they actually inform us that the measurements of
inflammatory markers were below the lower detection limit. Therefore, the negative
detections were given an arbitrary value between the lower detection limit and zero.
Power analysis
The standard error of the sensitivity and the specificity of an inflammatory marker will
be less than 5%, given a population of 50 children with cystic fibrosis and 50 controls,
and an assumed sensitivity of 70%. This was considered sufficiently accurate for the
purpose of this study. 
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Results
Population characteristics
Two of the 48 patients with cystic fibrosis were older than 18 (21 and 25 years,
respectively). Children with cystic fibrosis (n=48) were older, smaller, weighed less and
had more airway obstruction compared to controls (n=50) (Table 1; p<0.05). Exacerbation
was diagnosed in 13% of the cystic fibrosis patients. 24 Patients were treated with
prophylactic antibiotics. All of these patients were receiving antibiotics orally
(trimethoprim/sulphamethoxazol 17%, azitromycin 27%, amoxicillin/clavulanic acid
4%, and flucloxacillin 2%). In addition, 11 patients received inhaled antibiotics (8 (17%
tobramycin, and 6 (13%) colistin). Therapeutic antibiotic treatment was given to the six
patients with an exacerbation (orally: azitromycin 2(4%), ciprofloxacin 2(4%),
amoxicillin/clavulanic acid 1(2%), and, intravenously: tobramycin 3(6%), ceftazidim
1(2%), piperacillin/tazobactam 1(2%)).
Collection of EBC and FeNO measurements
The mean EBC volume collected was 3.1 ± 0.2 mL and 3.0 ± 0.2 mL in the cystic
fibrosis population and control population, respectively. No side effects were reported
during or following exhaled nitric oxide measurements and EBC collection.
Detection of inflammatory markers 
Detections of inflammatory markers in EBC are shown in Table 2. Nitrite, nitrate,
hydrogen peroxide, and 8-isoprostane were measured in all EBC samples. The level of
cytokine detection in EBC ranged up to 42%, and 20% in children with cystic fibrosis,
and healthy controls, respectively. It was not possible to detect interleukin-5.
Interferon-gamma and interleukin-4 were detected significantly more often in EBC
samples of cystic fibrosis patients (42%, and 13% respectively), compared to samples
originating from healthy controls (20%, and 2% respectively; Chi-square test, p<0.05). 
Concentration of inflammatory markers
Mean concentrations of interferon-gamma and nitrite were significantly higher in the
cystic fibrosis group (3.3 ± 0.3 pg/mL, and 2.2 ± 0.2 µM, respectively) compared to
controls (2.6 ± 0.2 pg/mL, and 1.4 ± 0.1 µM, respectively; Student’s t-test, p<0.05)
(Table 2). In contrast, fractional exhaled nitric oxide was significantly lower in children
with cystic fibrosis (10.0 ± 1.2 ppb), compared to control children (15.4 ± 1.4 ppb;
p<0.05). No influence was present of inhaled corticosteroids, use of antibiotics, or
presence of atopy.
Cystic fibrosis disease 
Multivariate logistic regression models showed that EBC 8-isoprostane, nitrite, and
interferon-gamma, and forced expiratory volume in one second, were all significant
indicators for cystic fibrosis disease (Table 3). The model including exhaled markers
only, had a sensitivity of 78%, a specificity of 92%, and a area under the receiver
operating characteristic curve of 0.906 (Figure 1A).
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Table 1. Clinical characteristics of the study population*
cystic fibrosis controls
(n=48) (n=50)
age (yrs) 13.0 ± 0.6 † 10.0 ± 0.4
height (cm) 148 ± 3 142 ± 2
Z-score height # -1.0 ± 0.2 † 0.1 ± 0.2
Z-score weight || -1.0 ± 0.1 † 0.5 ± 0.2
sexe (male / female) 27 / 21 27 / 23
FEV1 % predicted 76 ± 4 † 102 ± 2
FEV1/VC (%) 77 ± 2 † 88 ± 1
TLC % predicted 104 ± 2 NA
RV % predicted 174 ± 10 NA
ITVG % predicted 123 ± 4 NA
reversibility § 23 % NA
cystic fibrosis exacerbation 6 (13 %) NA
atopy ** 17 (36 %) NA
positive sputum cultures:
- Pseudomonas aeruginosa 23 (58 %) NA
- Staphylococcus aureus 29 (60 %) NA
- Haemophilus influenzae 14 (29 %) NA
- Haemophilus parainfluenzae 3 (6 %) NA
- Aspergillus fumigatus 17 (35 %) NA
- Candida albicans 6 (13 %) NA
- Hemolytic Streptococcus group A or B 8 (17 %) NA
therapy:
- rhDNase 25 (52 %) NA
- antacids 24 (50 %) NA
- corticosteroids 13 (27 %) NA
- therapeutic antibiotics 7 (15 %) NA
- prophylactic antibiotics 24 (50 %) NA
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; ITVG, intrathoracic gas
volume; NA, not applicable; rhDNase, recombinant human desoxyribonuclease; RV, residual volume;
TLC, total lung capacity; VC, vital capacity.
* data are shown as mean ± SEM, except indicated otherwise
# standard deviation of height corrected for age and sex, according to Dutch standard values
||  standard deviation of weight corrected for age and sex, according to Dutch standard values
§ defined as an increase in FEV1 after 400 µg salbutamol of 9% of predicted or more
† significantly different from controls (p<0.05)
** defined as total IgE level exceeds 20 kU/L, and/or positive Phadiatop, and/or positive radioallergo-
sorbent test
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Table 2. Concentrations, and number of positive detections of inflammatory markers in exhaled breath
condensate.
cystic fibrosis controls 
(n=48) (n=50)
exhaled 
inflammatory detection
marker units limit N% mean ± SEM N% mean ± SEM
FeNO ppb 90 10.0 ± 1.2 ‡ 100 15.4 ± 1.4 
pH 100 6.3 ± 0.1 100 6.3 ± 0.0 
nitrite µM 0.05 100 2.2 ± 0.2 ‡ 100 1.4 ± 0.1 
nitrate µM 0.05 100 14.4 ± 2.0 100 16.5 ± 1.4 
H2O2 µM 0.1 100 2.4 ± 0.2 100 2.2 ± 0.3 
8-isoprostane pg/mL 0.5 100 4.3 ± 0.5 100 4.7 ± 0.6 
IFN-γ pg/mL 1.5 42 3.3 ± 0.3 † ‡ 20 2.6 ± 0.2 
TNF-α pg/mL 1.2 15 1.6 ± 0.1 15 1.6 ± 0.1 
IL-2 pg/mL 1.2 2 1.2 0 ND
IL-4 pg/mL 1.4 13 1.8 ± 0.1 † 2 2.0
IL-5 pg/mL 1.1 0 ND 0 ND
IL-10 pg/mL 1.1 10 1.3 ± 0.1 6 1.4 ± 0.2 
FeNO, fractional exhaled nitric oxide; H2O2, hydrogen peroxide; IFN-γ, interferon-gamma; IL, interleukin;
ND, not detectable; pH, condensate acidity; SEM, standard error of the mean; TNF-α, tumor necrosis
factor-alpha.
N%  number of positive detections, as percentage of samples above detection limit
† p<0.05  positive detections of cystic fibrosis versus controls
‡ p<0.05  concentrations of inflammatory markers in cystic fibrosis versus controls
Table 3. Multivariate logistic regression model to indicate the presence of cystic fibrosis disease.
p(-2LL) ß ± SE OR (CI 95%)
8-isoprostane 0.02 -0.08 ± 0.76 0.92 (0.88-0.98)
nitrite 0.03 0.75 ± 0.37 2.11 (1.35-3.25)
IFN-γ 0.02 0.74 ± 0.35 2.10 (1.17-2.54)
FEV1 % predicted <0.01 -0.07 ± 0.02 0.93 (0.89-0.97)
β, coefficient of the predictor variables; CI, confidence interval; FEV1, forced expiratory volume in one
second; IFN-γ, interferon-gamma; OR, odds ratio; p(-2LL), significance of change in -2 log likelihood-
ratio; SE, standard error.
Cystic fibrosis exacerbation
Six (13%) of the cystic fibrosis population had an exacerbation, based on an increase in
symptoms, and/or decrease in lung function parameters. In the sputum of these patients, the
following micro-organisms were cultured: Pseudomonas aeruginosa (100%), Staphylococcus
aureus (67%), Haemophilus influenzae (33%), Aspergillus fumigatus (83%), Candida
albicans (17%), Hemolytic Streptococcus group A or B (17%). In a multivariate analysis, 8-
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Figure 1B. Receiver operating characteristic (ROC) curve of
the multivariate backward logistic regression
model of exhaled breath condensate 8-
isoprostane and nitrite, to indicate cystic fibrosis
(CF) exacerbation.
The area under the curve is 0.838.The maximum
sensitivity is 40%, with a specificity 97%.
0 = Stable CF 
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Table 4. Multivariate logistic regression model to indicate cystic fibrosis exacerbation.
p(-2LL) ß ± SE OR (CI 95%)
8-isoprostane 0.03 -0.42 ± 0.21 0.70 (0.44-0.99)
nitrite 0.01 -1.34 ± 0.65 0.26 (0.07-0.93)
The definition of poor cystic fibrosis lung disease control was based on the presence or severity of
symptoms, and decrease in lung function parameters.
ß, coefficient of the predictor variables; CI, confidence interval; OR, odds ratio; p(-2LL), significance of
change in -2 log likelihood-ratio; SE, standard error.
Figure 1A. Receiver operating characteristic (ROC) curve of
the multivariate backward logistic regression
model of exhaled breath condensate 8-
isoprostane, nitrite and interferon-gamma, to
indicate the presence of cystic fibrosis (CF)
disease.
The area under the curve is 0.906.The maximum
sensitivity is 78%, with a specificity 92%.
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isoprostane and nitrite indicated a cystic fibrosis exacerbation (Table 4). However, sensitivity
was only 40%, with a corresponding specificity of 97% (area under the receiver operating
characteristic curve of 0.838, p=0.009) (Figure 1B). Correction for age, gender, presence of
atopy, lung function parameters, or use of antibiotics, did not influence the results.
Cystic fibrosis severity 
In this part of the analysis, the cystic fibrosis severity classes were reduced to two
groups, according to the Shwachman-Kulczycki score: group 1 (n=15) consisted of
patients with no excellent severity status, whereas group 2 (n=33) consisted of children
with an excellent status. In the multivariate logistic regression model, fractional exhaled
nitric oxide, EBC acidity, and forced expiratory volume in one second to vital capacity
ratio were significant markers to indicate cystic fibrosis severity (Table 5). The model
including exhaled markers only, had a sensitivity of 96%, and a specificity of 67% (area
under the receiver operating characteristic curve of 0.751, p=0.008) (Figure 1C).
169
Cystic fibrosis – exhaled markers
Figure 1C. Receiver operating characteristic (ROC) curve of
the multivariate backward logistic regression
model of fractional exhaled nitric oxide, and
exhaled breath condensate acidity, to indicate
cystic fibrosis (CF) lung disease severity.
Cystic fibrosis severity was classified using the
Shwachman-Kulczycki score. The area under the
curve is 0.751. The maximum sensitivity is 96%
with a specificity 67%.
0 = Not excellent CF status
1 = Excellent CF status
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Table 5. Multivariate logistic regression model to indicate cystic fibrosis lung disease severity.
p(-2LL) ß ± SE OR (CI 95%)
FeNO 0.01 -0.19 ± 0.09 0.83 (0.70-0.98)
pH 0.01 -6.04 ± 2.66 0.02 (0.00-0.44)
FEV1/VC % <0.01 0.19 ± 0.08 1.21 (1.03-1.41)
Cystic fibrosis severity was classified using the Shwachman-Kulczycki score.
ß, coefficient of the predictor variables; CI, confidence interval; FeNO, fractional exhaled nitric oxide;
FEV1, forced expiratory volume in one second; OR, odds ratio; p(-2LL), significance of change in -2 log
likelihood-ratio; pH, condensate acidity; SE, standard error; VC, vital capacity.
Discussion
This study is based on a relatively large study population of 98 children, of whom 48
children with cystic fibrosis, and simultaneous measurement of several exhaled
inflammatory biomarkers, as well as conventional (noninvasive) disease measures, in
order to allow a comparison between inflammatory markers, and to assess
relationships with cystic fibrosis exacerbation and disease severity. The presented data
show that different profiles of noninvasive inflammatory markers in exhaled air and
breath condensate are able to reflect different aspects of cystic fibrosis disease in
children with good sensitivity and specificity: (i) EBC 8-isoprostane, nitrite and
interferon-gamma concentrations were able to indicate the presence of cystic fibrosis
disease; (ii) EBC 8-isoprostane and nitrite indicated cystic fibrosis exacerbation; and (iii)
cystic fibrosis lung disease severity was assessed by fractional exhaled nitric oxide and
EBC acidity. 
To our knowledge, no comparable studies on noninvasive profiles of inflammatory
markers in children with cystic fibrosis have (yet) been published. However, several of
these markers have been studied separately. In the cystic fibrosis population, fractional
exhaled nitric oxide levels were reduced when compared with control population,
which is in accordance with available data in literature 8,17-25. Furthermore, we found
significantly higher concentrations of nitrite in EBC originating from children with
cystic fibrosis, compared to controls. These results are similar to the findings of
Formanek et al, Cunningham et al, as well as Ho, Ojoo and Tate et al in young adults
with cystic fibrosis 17-18,26-28. Lower fractional exhaled nitric oxide levels and higher
nitrite concentrations in the cystic fibrosis population may be explained by several
hypotheses 17,29. On one hand, the viscous mucus in cystic fibrosis airways may impair
diffusion of gaseous nitric oxide into the airway lumen, which may result in conversion
of nitric oxide into nitrite 18. On the other hand, decreased expression of inducible
nitric oxide synthase II in epithelial cells may result in low fractional exhaled nitric oxide
levels in children with cystic fibrosis 25,30-33.
Interferon-gamma and interleukin-4 were detected more often in EBC samples
originating from children with cystic fibrosis, and interferon-gamma condensate
concentrations were higher in this group, compared to controls. This is in accordance
with the findings of Wojnarowski et al, which demonstrated increased transcription
of interferon-gamma and interleukin-4 in bronchial biopsies from children with cystic
fibrosis, whereas normal controls did not express these cytokines 34. Immunoregulatory
effects of interferon-gamma on various cells, are extensive and diverse 35-36. Interferon-
gamma and interleukin-4 upregulate class II molecules on macrophages and dendritic
cells. Thereby, the antigen presenting capacity of epithelial and endothelial cells,
among others, is being induced 36. Moreover in cystic fibrosis, defensive mechanisms
to antigens are impaired, and by consequence, additional mechanisms need to be
addressed to resolve ongoing inflammatory processes and infections 37. Interleukin-5
was not detected in any EBC sample, which is in agrrement with the findings of
Armstrong et al in bronchoalveolar lavage fluid, and may be related to the presence
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of proteases in cystic fibrosis airways 38. In general, cytokine concentrations in EBC
were relatively low, and close to the detection limits of the assays. Previously, we
reported that interferon-gamma, interleukin-2, interleukin-4, and interleukin-10 were
detected in 8-25% of the samples originating from children with cystic fibrosis,
whereas tumor necrosis factor-alpha and interleukin-5 were not detected 10. In
literature, no other comparative data on multiplexed cytometric bead array in small
EBC sample sizes in children with cystic fibrosis are yet available.
EBC acidity, and concentrations of 8-isoprostane and hydrogen peroxide did not
differ between cystic fibrosis and control populations, which is in accordance with the
results of Jöbsis et al, and Ho et al 8,39. On the other hand, other research groups
demonstrated lower EBC pH levels and higher 8-isoprostane concentrations in children
with cystic fibrosis 40-42. This discrepancy may be attributed to the mild to moderate
cystic fibrosis severity in this study population, as, in the multivariate models, condensate
8-isoprostane was a significant indicator of cystic fibrosis disease and exacerbation,
while EBC pH significantly contributed to the indication model of cystic fibrosis severity. 
Several limitations of this study on noninvasive measurements of inflammatory
biomarkers in children have to be acknowledged. At first, the cystic fibrosis population
mainly consisted of patients with mild to moderate disease, whereas no subjects were
actually categorised into a severe disease category. Therefore, results cannot be
generalised to the latter type of patients. Secondly, not all cytokines were detected in
all EBC samples. However, the lack to detect (some) cytokines does not necessarily
implicate that they are not present, as the used detection method may lack sufficient
sensitivity, and as there is an overall agreement that cytokines are involved in the
pathophysiology of cystic fibrosis. Therefore, a sample with negative detection was
not considered as a missing value, as it actually informed us that the measurement of
an inflammatroy marker was below the lower detection limit. Thirdly, and obviously,
the clinical relevance of these findings for the individual child at long term level
remains yet to be determined. Although the presented data may suggest that the
combined use of exhaled inflammatory markers may be helpful in the management
of cystic fibrosis disease, longitudinal study designs are needed to assess whether
these markers are able to: (i) indicate the early onset of cystic fibrosis lung disease in
young children, (ii) detect exacerbations in an early stage, and (iii) monitor disease
exacerbations and treatment effects.
Finally, the presented findings emphasise the importance of evaluating different
profiles of different exhaled inflammatory markers, for their ‘synergistic’ ability to
reflect different aspects of chronic lung disease, as current disease management is
mainly based on symptoms and deterioration of lung function parameters, which may
not appropriately reflect ongoing inflammatory processes, and as a single inflammatory
marker may not be able to properly reflect (an aspect of) an evolving chronic
inflammatory process. In future, inflammatory markers in EBC may be a valuable
additional tool to detect and monitor inflammatory activity in patients with cystic
fibrosis, which ultimately may improve quality of live in children with cystic fibrosis. 
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In conclusion, this cross-sectional study in children demonstrated that different profiles
of noninvasive inflammatory markers, such as condensate 8-isoprostane, nitrite,
interferon-gamma, acidity, and fractional exhaled nitric oxide, were able to indicate
the presence of cystic fibrosis disease, disease exacerbation, and/or cystic fibrosis lung
disease severity, with good sensitivity and specificity. Longitudinal data are necessary
to further confirm the role of these exhaled markers in the management of cystic
fibrosis in children.
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NEW METHOD TO COLLECT EXHALED BREATH
CONDENSATE, AND TO ASSESS AIRWAY
INFLAMMATION IN WHEEZING PRESCHOOL CHILDREN
Rosias PPR, Robroeks CM, van de Kant KD, Rijkers GT, Zimmermann LJ, van Schayck
CP, Heynens JW, Jöbsis Q, Dompeling E.
Submitted
Abstract
Exhaled breath condensate is a promising noninvasive method to assess respiratory
inflammation in adults and children. So far, condensate collection is mainly feasible in
children aged 4 years and over, and condensate analysis is hampered by insufficiently
sensitive bioassays. We hypothesised that a new optimised glass condenser, combined
with an ultrasensitive multiplexed assay, enables adequate collection, and cytokine
measurements in exhaled breath condensate in preschool children. 
To assess feasibility and efficacy of a new method of exhaled breath condensate
collection in 70 nonsedated preschool children; and to assess cytokine concentrations
in condensate (interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10,
interleukin-12p70, interleukin-13, tumor necrosis factor-alpha) in preschool children
with atopic asthma, recurrent viral wheeze, and healthy controls. 
The overall success rate of condensate collection was 83%. Median condensate
volume was 400µL. The detection of cytokines was succesful in 95-100% of samples.
In the asthmatic group, tumor necrosis factor-alpha concentrations were significantly
decreased, and the ratio’s of interleukin-5 to tumor necrosis factor-alpha, and
interleukin-13 to tumor necrosis factor-alpha were higher, compared to nonasthmatic
children.
Noninvasive assessment of cytokines in exhaled breath condensate in preschool
children is possible, by using a new optimised glass condenser system in combination
with the ultrasensitive multiplexed liquid bead array analysis. This new method may
help to discriminate between wheezing phenotypes in these children.
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Introduction
Preschool wheezing is reported in no less than 30% of children, and may indicate a
trivial cold, as well as an ongoing chronic lung inflammation, such as asthma 1-2.
Atopic asthma is associated with a cytokine pattern compatible with predominant
activation of the T-helper cell type 2 mediated immune response 3. However, in the
developing preschool child, accurate assessment of different wheezing phenotypes is
currently difficult 1-8. Moreover, proper diagnosis is hampered by the current lack of a
reliable routine technique to assess different types of respiratory inflammation in
preschool children. 
Ideally, such a technique would be noninvasive, rapid and easy to perform, without
any risks, successful at any age, standardised, sensitive, specific and highly reproducible.
The collection of exhaled breath condensate (EBC) is a noninvasive technique to obtain
direct samples from the lower respiratory tract, without disturbing an ongoing
inflammation 9-11. In children, analysis of EBC reveals the presence of various types of
inflammatory biomarkers, including cytokines 9-15.
General methodological recommendations on EBC collection are published 11. So
far, the collection of EBC was mainly feasible in children aged four years and over 11,16.
In preschool children, feasibility is substantially hampered by the need for procedural
sedation, or, in nonsedated preschool children, by relatively too long EBC sampling
times (from a toddler’s point of view). Also, suboptimal condensate analysis due to
the use of immunoassays with questionable reproducibility, that often require relatively
too large sample volumes, contributes to this problem 10,17-21.
Recently, the efficacy of different open-ended EBC collection systems was
compared, and a condenser with silicone or glass coating was found to be more
efficient for the measurement of 8-isoprostane or albumin in exhaled breath
condensate, than EcoScreen®, aluminum, polypropylene or Teflon™ 17.
Taken together, this has led us to make the following methodological adjustments
for the purpose of this study: (i) the collection of EBC using an optimised closed glass
condenser system; and (ii) the simultaneous measurement of cytokines in the resulting
EBC by means of xMAP® technology, an ultrasensitive multiplexed liquid bead array
that requires only small sample volumes. We hypothesised that the combination of
these methodological adjustments enhances the feasibility and efficacy of EBC
collection and analysis in preschool children with and without wheezing. 
Therefore, the aims of the present study were: (i) to assess the feasibility and
efficacy of EBC collection in nonsedated preschool children, using a modified, closed,
glass condenser, and (ii) to assess cytokine profiles (interleukin-4, interleukin-5,
interleukin-6, interleukin-8, interleukin-10, interleukin-12p70, interleukin-13, and
tumor necrosis factor-alpha) in EBC using multiplexed xMAP® technology in preschool
children with different wheezing phenotypes.
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Methods
Study subjects
Eligible preschool children were recruited at the paediatric outpatient department of
the Maasland Hospital of Sittard and the University Hospital of Maastricht. According
to parent-completed questionnaires, medical documents, and information of the
responsible paediatric pulmonologist, children were allocated to one of the following
study groups:
1. The doctor’s diagnosed atopic asthma group characterised by: (i) recurrent
wheezing, (ii) not ‘exclusively’ triggered by viral infections, (iii) with a documented
history of a favourable corticosteroid effect, (iv) positive family history of atopy in
the first degree (parent or sibling with astma, hay fever, food allergy, or eczema),
and (v) atopy (positive Phadiatop or radioallergo-sorbent test class≥2, and/or
elevated blood level of total immunoglobulin-E,). Current corticosteroid
maintenance therapy was not an obligatory criterion.
2. The viral-triggered  recurrent wheeze group characterised by: (i) recurrent
wheezing, (ii) ‘exclusively’ triggered by viral infections, (iii) without a documented
history of steroid therapy, or with documented history of no favourable
corticosteroid effect, and (iv) without corticosteroid maintenance therapy in the
preceding three months. Lack of atopy was not an obligatory criterion.
3. The healthy control group characterised by: (i) the absence of recurrent wheezing,
and (ii) without a history of corticosteroid maintenance therapy. Lack of atopy was
not an obligatory criterion.
4. The unclassifiable recurrent wheeze group consisted of infants and toddlers with
recurrent wheezing, but not eligible for the asthmatic or viral wheeze group. They
participated only in the feasibility study.
Overall exclusion criteria were cardiac disease, anatomic or congenital defects of
the airways or lungs, syndromes, systemic disease, and/or mental retardation.
Presumed inability to use a face mask did not preclude participation into this study.
Subject characteristics are shown in Table 1.
Exhaled breath condensate collection
This cross sectional study design comprised one attempt, between wheezing episodes,
to collect EBC in a preschool child. Precedingly, parents received thorough instructions
on the collection procedure by one of the coaching childhood asthma nurses, and
were asked to bring along the child’s favourite cartoon, cd-song, booklet, and/or
puppet.
EBC was collected using a modified closed glass condenser system that was developed
in close collaboration with the Department of Instrument Development Engineering &
Evaluation of the Maastricht University (patent number EP 07102586). The EBC collection
system consisted of an inclined and closed glass condenser with a tube length of 90cm
(to enlarge the condensation surface to 1046cm2), a downwards moveable plunger (to
optimise condensate recovery from the inner wall of the condenser), with tangential and
axial breath flow channels (to turbunately direct the tidal breath flows towards the cooled
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Table 1. Characteristics of 70 preschool children, allocated to one of the four study groups, based on
parent-completed questionnaires and available medical documents.
Study group Asthma Viral Control Unclassifiable
Number 23 22 20 5
Age in months A 31 (19) C 28 (16) C 13 (18) C 25 (15)
range 11-47 5-47 2-41 14-47
Male / female ratio 13 / 10 17 / 5 12 / 8 2 / 3
Weight in kg A 14 (3) D 13 (2) D 11 (5) D 12 (3)
Z-score weight A 0 (1.4) 0 (2.5) 0 (1.1) 0 (1.0)
Height in cm A 95 (14) 94 (17) 85 (23) 92 (15)
Z-score height A 0.0 (1.5) -0.3 (2.1) 0.5 (2.1) -1.0 (2.0)
Elevated IgE / Pos RAST B 23 (100) 4 (18) 0 (0) 2 (40)
Current use of steroids B 15 (65) - - 5 (100)
Inhaled steroid dose B 400 (100) - - 400 (200) 
Asthma, doctor’s diagnosed atopic asthma group; Control, healthy control group;
Elevated IgE, elevated blood level of total immunoglobulin-E; Pos RAST, positive radioallergo-sorbent
test ≥ class 2; Unclassifiable, unclassifiable recurrent wheezing group; Viral, viral-triggered recurrent
wheezing group.
Amedian (interquartile range); Babsolute number (percentage); Cp = 0.012 (multiple comparisons,
Hochberg correction); Dp = 0.046 (multiple comparisons, Hochberg correction).
Figure 1. Schematic representation of the new closed glass condenser system, that enabled condensate
collection in preschool children before and after breath recirculation.
1. inclined and closed glass condenser,
and downwards moveable plunger with
tangential and axial breath flow
channels.
2. swan-neck tubing, two-way
nonrebreathing valve, and face mask
with separated nose and mouth cavity.
3. entrance of inspired room air
4. cooling unit consisting of a counter-
current circulating ice-water pump 
5. removable glass sample vial, to
collect exhaled breath condensate
6. heated (at 37ºC) tubing, to guide the
residual noncondensed exhaled breath
7. humidity sensor and heated (at 37ºC)
inert Tedlar™ gas sample bag
8. small ventilator system to recirculate
the residual noncondensed exhaled
breath back into the condenser system.
inner condenser wall), and a unique breath recirculation system, heated at 37°C (Figure
1). The breath recirculation system consisted of heated tubing (to guide the residual
noncondensed exhaled breath, and to avoid condensation outside the condenser tube),
a humidity sensor, a heated inert Tedlar™ gas sample bag (to collect all residual
noncondensed exhaled breath), and a small ventilator system to recirculate the residual
noncondensed exhaled breath back into the cooled condenser system (to allow secondary
condensation of exhaled breath) (Figure 1).
The child exhaled tidally, as long as possible, through a face mask which separated
exhaled air from nose and mouth cavity, and with two-way nonrebreathing valve (8900
pediatric sizes oro-nasal masks, Hans Rudolph Inc., Kansas City, Missouri, USA),
connected to the glass condenser system by means of a swan-neck tubing (serving as
gravitational saliva trap). During this condensation process, the formerly lost
noncondensed exhaled breath was separately being collected in the gradually inflating
inert Tedlar™ gas sample bag. When the child ceased the procedure, EBC was collected
by pushing the plunger downwards. Subsequently, the plunger was pulled up again,
and the separately collected exhaled breath was recirculated from the Tedlar™ gas
sample bag back into the condenser system, to perform a secondary breath
condensation. The recirculation was stopped when the degree of humidity was ≤ 22%.
To improve the toddler’s coping with distress from the unfamiliar procedure, they
were distracted while breathing tidally through a facemask. We primarily combined
strict parental cooperation, with an age appropriate cartoon, that was already started
prior to entrance. In case of imminent failure to cope, a more active strategy was used
on parent’s advice, including children’s stories, puppetry, and/or children’s songs. 
EBC collection was defined successful when at least 60µL condensate was
produced, comprising the minimal required volume of 50µL to perform one
multiplexed cytokine analysis, and an additional 10µL to compensate for loss due to
sample handling. 
After each procedure, the nondisposable parts of the condenser were
disconnected, rinsed repeatedly with bi-distilled water, and subsequently dried at
room air for at least 24 hours.
Condensate sample processing
Immediately after collection, condensate samples were snap-frozen at -78°C using dry
ice and stored at -80°C. Analysis was performed within three months from sampling
time. Cytokines in EBC were measured in duplicate using a liquid bead array multiplexing
system or xMAP® technology (Luminex Corporation, Austin, USA). Multiplex
immunoassay was performed as described previously, to measure the following cytokines
(with corresponding lower limits of detection): interleukin-4 (1.2 pg/mL), interleukin-5
(1.2 pg/mL), interleukin-6 (2.4 pg/mL), chemokine interleukin-8 (2.9 pg/mL), interleukin-
10 (2.3 pg/mL), interleukin-12p70 (1.2 pg/mL), interleukin-13 (1.0 pg/mL), and tumor
necrosis factor-alpha (1.3 pg/mL) 22-24. Measurement and data analysis were performed
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using the Bioplex 100 system and Bioplex Manager software version 3.0 (Bio-Rad
Laboratories, Hercules, CA). All multiplex immunoassays were performed in 96 well
format 1.2µm filter bottom plates (Millipore, Amsterdam, The Netherlands) and a 12
point standard curve in duplicate was included on every plate. In order to minimise
interassay variation, positive and negative control samples were included. 
In earlier experiments, the short-term intrasubject variability of cytokine
measurements in EBC was determined in 59 older children (18 asthmatics, 21 children
with cystic fibrosis, and 20 healthy controls), aged 6 to 16 years. The coefficient of
variation was 17.9% for interleukin-4, 11.9% for interleukin-5, 13.0% for interleukin-
6, 6.1% for interleukin-8, 14.9% for interleukin-10, 26.9% for interleukin-12p70,
22.6% for interleukin-13, and 15.8% for tumor necrosis factor-alpha 25.
Statistics
Statistical calculations were performed using SPSS 11.5 (SPSS Inc, Chicago, USA).
Normally distributed data were expressed as mean and standard error. The Student’s
t-test was used to test for differences among dependent, paired or repeated samples.
Pearson’s correlation coefficients were used to assess the degree of association
between two normally distributed variables. Analysis of variance (ANOVA) was used
to test for differences among normally distributed variables for more than two study
groups. 
Not normally distributed data were expressed as median with interquartile ranges
(IQR). The Wilcoxon signed rank test was used to test for differences among not
normally distributed paired data, whereas the Mann-Whitney U test was used for
unpaired data. Spearman’s rank correlation coefficients were used to assess the
degree of association between two not normally distributed variables. The Kruskal-
Wallis test was used to test for differences among non-normal variables for more than
two study groups. The Hochberg correction for multiple comparisons was applied. The
Chi-square test was used to evaluate the distribution of categorical variables (number
of occurrences) in four study groups.
Power Calculation
Assuming a success rate of 80%, the standard error of feasibility is 5.1% using n=60
subjects. This was considered sufficiently accurate for the purpose of this study.
Ethics
The study was approved by the Medical Ethics Committee of the University Hospital of
Maastricht and the Maasland Hospital Sittard. All parents gave written informed consent.
Results
Feasibility of EBC collection
A total number of 70 preschool children participated. Feasibility of the new EBC
collection method in preschool children is shown in Table 2. 
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Before breath recirculation, the median duration of EBC collection was 10 minutes
(IQR 9), the median EBC volume was 200µL (IQR 270), and the success rate was 64%
in these preschool children. After breath recirculation, the median EBC volume was
225µL (IQR 495). 
In total, the median EBC volume was 400µL (IQR 450). The success rate of EBC
collection was 83% in these preschool children, but differed significantly between the
four study groups (p<0.001, Chi square). 
In the healthy group, the median duration of EBC collection was 6 minutes, and median
EBC volume before breath recirculation was zero µL, whereas both were significantly
decreased compared to the asthmatic and viral wheeze group (p<0.031, ANOVA). 
A younger age was significantly correlated with less duration of EBC collection
time (R=0.481, p<0.001, Spearman correlation coefficient). A duration of EBC
collection time of 10 minutes or more, was associated with successful EBC collection
before breath recirculation.
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Table 2. Feasibility of exhaled breath condensate collection, before and after breath recirculation (BR), in
70 preschool children.
Study group Asthma Viral Control Unclass. p value
Number 23 22 20 5 -
Age A 31 (19) C 28 (16) C 13 (18) C 25 (15) -
Before BR
Duration A 11 (9) D 12 (6) D 6 (6) D 14 (1) 0.004 F
Volume A 200 (250) E 300 (280) E 0 (245) E 300 (100) 0.031 F
Success rate B 15 (65) 20 (91) 6 (30) 4 (80) -
After BR
Volume A 367 (620) 340 (362) 130 (417) 575 (287) 0.385 F
Total 
Volume A 300 (500) 410 (400) 295 (357) 800 (150) 0.351 F
Success rate B 17 (74) 21 (95) 15 (75) 5 (100) <0.001 G
After BR, after breath recirculation; Age, in months; Asthma, doctor’s diagnosed atopic asthma group;
Before BR, before breath recirculation; Control, healthy control group; Duration, duration of
condensate collection in minutes; Success, exhaled breath condensate collection was defined
successful when at least 60 µL of condensate was yielded; Total, before and after breath recirculation;
Unclass., unclassifiable recurrent wheezing group, excluded for statistical analysis for reasons of
disproportionality; Viral, viral-triggered recurrent wheezing group; Volume, condensate volume in µL.
Amedian (interquartile range); Babsolute number (percentage); Cp = 0.012 (multiple 
comparisons, Hochberg correction); Dp ≤ 0.012 (multiple comparisons, Hochberg correction);
Ep = 0.039 (multiple comparisons, Hochberg correction); F analysis of variance (ANOVA); Gchi square
test.
Table 3 shows the distractive measures used during EBC collection. Four children
refused to start due to sudden anxiety, associated with insufficient parental stimulation
and/or recent ear-nose-throat surgery (adenoidectomy, and/or tonsillectomy, and/or
myringotomy with insertion of tympanostomy tube). Distraction was mainly achieved
by combined parental cooperation and cartoon watching. The Hans Rudolph face
mask was applied in 60 children, whereas five preferred the babyhaler® and one the
nebuchamber® face mask. Two collection procedures were not successful due to
leakage of exhaled breath from defective Tedlar™ gas sample bags. No adverse effects
on respiration, nor other side-effects, were seen during the collection procedures.
Cytokine measurements before and after breath recirculation
Table 4 shows the detection and concentration of interleukin-4, interleukin-5, interleukin-
6, interleukin-8, interleukin-10, interleukin-12p70, interleukin-13, and tumor necrosis
factor-alpha in EBC collected before, as well as after breath recirculation, in 45 preschool
children. The detection of cytokines in EBC was successful in 95 to 100% of the collected
50µL condensate samples. There was no statistical difference between cytokine
concentrations before and after breath recirculation (p>0.117, Wilcoxon).
Cytokines in subgroups with and without wheeze
For further cytokine analysis between the different study groups, the separately collected
condensate samples before as well as after breath recirculation in each subject, were
considered as one donor series. Between the asthmatic (n=17), viral wheeze (n=21) and
healthy (n=15) group, the median cytokine concentrations of interleukin-4, interleukin-
5, interleukin-6, interleukin-8, interleukin-10, interleukin-12p70, and interleukin-13 did
not differ (data not shown), whereas the median concentration of tumor necrosis
factor-alpha was significantly decreased in the asthmatic group (median 38.8pg/mL in
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Table 3. Distractive measures for preschool children during the exhaled breath condensate collection
procedure.
Study group Asthma Viral Control Unclass. total (%)
Number 23 22 20 5 70 (100)
Success 17 21 15 5 58 (83)
Not started 1 1 2 0 4 (6)
Distraction by:
Parent 19 17 17 4 57 (86)
Cartoon 20 14 11 5 50 (76)
Book 10 5 5 4 24 (36)
Puppet 5 3 2 0 10 (15)
Song 0 6 2 0 8 (12)
Asthma, doctor’s diagnosed atopic asthma group; Control, healthy control group; Success, exhaled
breath condensate collection was defined successful when at least 60 µL of condensate was yielded;
Unclass., unclassifiable recurrent wheezing group; Viral, viral-triggered recurrent wheezing group.
asthma, 42.9pg/mL in viral wheeze, and 40.9pg/mL in healthy controls, respectively)
(p=0.030, Kruskal Wallis). A weak correlation existed between age and cytokine
concentrations (-0.120 < R < 0.392, Spearman).
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Table 4. Detection (%) and concentration (pg/mL) of cytokines in exhaled breath condensate collected
before and after breath recirculation (BR) in 45 preschool children.
EBC before BR         after BR           p value C
% A pg/mL B % A pg/mL B
IL-4 100 2.1 (0.7) 100 2.2 (0.9) 0.346
IL-5 98 16.7 (1.6) 97 16.7 (1.6) 0.278
IL-6 96 3.3 (0.9) 95 2.9 (0.4) 0.611
IL-8 100 3.9 (1.0) 100 4.4 (1.1) 0.117
IL-10 98 4.7 (0.7) 100 4.7 (0.5) 0.455
IL-12p70 100 3.4 (0.4) 100 3.4 (0.3) 0.301
IL-13 100 8.5 (1.8) 100 8.5 (1.4) 0.603
TNF-alpha 96 40.9 (5.8) 95 40.9 (6.1) 0.746
after BR, after breath recirculation; before BR, before breath recirculation; EBC, exhaled breath
condensate.
Adetection in percentage; Bmedian concentration (interquartile range) in pg/mL; CWilcoxon signed rank
test.
Table 5. Cytokine profile in exhaled breath condensate in 53 doctor’s diagnosed atopic asthmatic (AA) and
nonasthmatic (nonA) preschool children.
EBC AA nonA p-value B
Number 17 36 -
TNF-alpha A 38.8 (4.3) 41.7 (3.4) 0.019
IL-5 / TNF-alpha A 0.45 (0.05) 0.40 (0.06) 0.032
IL-13 / TNF-alpha A 0.24 (0.06) 0.20 (0.03) 0.049
IL-4 A 2.1 (0.6) 2.0 (0.7) NS
IL-5 A 17.1 (2.0) 16.9 (1.6) NS
IL-6 A 3.2 (0.7) 3.1 (0.7) NS
IL-8 A 4.1 (1.0) 4.0 (0.5) NS
IL-10 A 4.7 (1.0) 4.9 (0.5) NS
IL-12p70 A 3.5 (0.7) 3.4 (0.2) NS
IL-13 A 8.8 (1.5) 8.5 (1.8) NS
AA, doctor’s diagnosed atopic asthma group; EBC, exhaled breath condensate; nonA, nonasthmatic
preschool children consisting of the viral-triggered recurrent wheezing group and healthy group; NS,
not significant.
Amedian (interquartile range); BMann Whitney U test.
In atopic asthmatic children, inhaled corticosteroids did in general not influence
cytokine levels in EBC, with one exception: tumor necrosis factor-alpha concentrations
were significantly lowered in children with inhaled corticosteroid therapy, compared
to steroid naïve children (median 37.1pg/mL versus 41.7pg/mL, respectively) (p=0.013,
Mann Whitney U).
When asthmatic and nonasthmatic (viral wheeze and healthy) children were
compared, tumor necrosis factor-alpha concentrations in the asthmatic group (median
38.8pg/mL, IQR 4.3) were significantly decreased versus nonasthmathic children
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A
Tumor necrosis factor-alpha concentra-
tion in EBC was significantly decreased
in the AA group (median 38.8pg/mL,
IQR 4.3), compared to the nonA group
(median 41.7pg/mL, IQR 3.4) (p=0.019,
Mann Whitney U test).
B
The interleukin-5 to tumor necrosis
factor-alpha ratio in EBC was
significantly increased in the AA group
(median 0.45, IQR 0.05) compared to
the nonA group (median 0.40, IQR
0.06) (p=0.032, Mann Whitney U test).
C
The interleukin-13 to tumor necrosis
factor-alpha ratio in EBC was
significantly increased in the AA group
(median 0.24, IQR 0.06) compared to
the nonA group (median 0.20, IQR
0.03) (p=0.049, Mann Whitney U test).
Figure 2A- 2B-2C. Th2/Th1 cytokine profiles in exhaled breath condensate (EBC) in doctor’s diagnosed
atopic asthmatic (AA) and nonasthmatic (nonA) preschool children.
AA, doctor’s diagnosed atopic asthma group; EBC, exhaled breath condensate; IL, interleukin;
IQR, interquartile range; nonA, nonasthmatic preschool children consisting of the viral-triggered
recurrent wheezing group and healthy group; Th,T-helper cell; TNF-α, tumor necrosis factor-alpha.
(median 41.7pg/mL, IQR 3.4) (p=0.019, Mann Whitney U) (Table 5, Figure 2a). The
ratios of interleukin-5 to tumor necrosis factor-alpha, and interleukin-13 to tumor
necrosis factor-alpha in the asthmatic group (median 0.45, IQR 0.05, and median
0.24, IQR 0.06, respectively) were significantly higher compared to nonasthmatic
children (median 0.40, IQR 0.06, and median 0.20, IQR 0.03, respectively) (p=0.032,
and p=0.049, respectively, Mann Whitney U) (Table 5, Figures 2b-2c). 
Discussion
We demonstrated the feasibility and efficacy of EBC collection and analysis in preschool
children with and without wheezing, using a novel closed glass condenser with breath
recirculation system, and using multiplexed liquid bead array: (i) the overall success
rate of the new EBC collection method was 83%, with a median EBC volume of
400µL; (ii) the detection of cytokine profiles in 50µL EBC was successful in 95 to 100%
of the collected samples; (iii) similar cytokine concentrations were found in EBC
collected before as well as after breath recirculation; and (iv) in the atopic asthmatic
group tumor necrosis factor-alpha concentrations in EBC were significantly decreased,
whereas interleukin-5 to tumor necrosis factor-alpha, and interleukin-13 to tumor
necrosis factor-alpha ratio’s were significantly increased, compared to preschool
children with viral wheeze and healthy controls.
We simultaneously introduced novel techniques to optimise the condensation
process (Figure 1), and to improve small condensate sample analysis, in nonsedated
preschool children with and without recurrent wheezing. Cumulatively, this new
collection method with breath recirculation resulted in an overall success rate of 83%,
compared to 64% when using the ‘usual’ (before breath recirculation) procedure.
Overall, the median total volume of EBC was 400µL in this study. In the literature,
Moeller et al proposed a method to collect, both orally and nasally, a median EBC
volume of 282µL, using two disposable Plastipack syringes, in tidal breathing infants,
however, during sedated sleep and without assessment of markers in the collected
condensate 19. Griese et al presented a nasal polypropylene collection system with air
suction pump, to measure hydrogen peroxide and 8-isoprostane, and reported 85µL
min-1 of nasally collected EBC in healthy children aged 4 weeks to 18 years, however,
with contamination by nasal secretions 26-27. The correlation between age and duration
of EBC collection is in accordance with the significantly increased volume of collected
EBC with age, reported by both Griese et al, and Moeller et al 19,25. Irrespective of the
duration of EBC collection, breath recirculation allowed condensation of the totally
exhaled breath volume within the closed glass system, in contrast to maximally 30%
using the open-ended nasal suction system of Griese et al 26-27. Hence, our concept
of breath recirculation enabled not only the collection of an increased volume of EBC,
but also, in the younger toddlers, with limited cooperation in time (often less than 10
minutes), breath recirculation was often crucial to yield a minimal but sufficient
volume of condensate. 
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Furthermore, cytokine concentrations in EBC collected before and after breath
recirculation did not differ significantly, demonstrating that concentrations were not
affected by the breath recirculation process, and illustrating an efficiency to generate
additional and equivalent condensate.
In the literature, vastly different, nonstandardised EBC collection techniques are
available, including the immersion of plastic tubing in an ice-filled bucket, a double-
wall glass distilling column with counter-current ice-water pump, an ice-filled and
double-chambered glass container, the commercial EcoScreen® (Erich Jaeger GmbH,
Hoechberg, Germany), RTube™ (Respiratory Inc., Charlottesville, Virginia, USA), and
Turbo-Deccs (ItalChill, Parma, Italy) 9-11,28-29. All systems are based on the principle of
constantly cooling exhaled air, whereas the handheld plastic RTube™, placed in a pre-
cooled sleeve, is highly susceptible to (higher) ambient temperatures during collection
9-11,30. Moreover, these systems have an open ended and relatively short measured
design, resulting in the variable loss of noncondensed exhaled breath, as condensation
does not immediately occur, and/or does not continue once the condensation surface
is completely saturated.
Additionally, exhaled biomarkers may be lost in different EBC sampling systems,
due to adhesive interactions between condenser coatings and exhaled biomarkers
17,31. Therefore, Tufvesson et al proposed to coat the EcoScreen® collection surfaces
with bovine serum albumin and Tween-20, to measure cytokines and eicosanoids,
respectively 31. However, they reported possible false-positive eicosanoid results, and
the need of vacuum-centrifugation prior to analysis 31. Recently, we compared six
condenser systems, and found a glass or silicone condenser more efficient, both in
vitro and in vivo, for the recovery of 8-isoprostane and albumin in EBC, compared to
aluminium, polypropylene, Teflon and the EcoScreen® condenser 17.
In ventilated neonates, Cheah et al described a polyvinylchloride tubing, immersed
in wet ice, to collect EBC, however, with insufficient sensitivity to detect hydrogen
peroxide 18. Other techniques for EBC collection in ventilated infants, children and
young adults, have recently been proposed 32-33.
Multiplexed liquid bead array was used to measure cytokines more accurately in
only 50µL sample volumes of EBC. The detection level of cytokines was high, ranging
from 95 to 100%. Multiplexed liquid bead array is based on flow cytometry and
microspheres (with faster and more reproducible liquid reaction kinetics, than solid
planar assays), and allows multiplexing of up to 100 assays within one sample 22.
Reasons to introduce this technique were: (a) lack of sensitivity of conventional
enzyme-linked immunosorbent assays to detect cytokines in 200 to 500µL EBC 34; and
(b) variable level of simultaneous cytokine detection by cytometric bead array, ranging
from 0 to 25%, in 50µL EBC in children 13, and from 3 to 100%, in 1000 to 2000µL
lyophilised EBC in adults 35-37. When compared with conventional assays, multiplexed
immunoassays are highly sensitive and specific, detect bioactive and inactive molecules,
are rapid (hours instead of day(s)), have good (but not yet excellent) precision with
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coefficients of variation ranging from 10 to 15%, are not interfered by drugs, have a
simple protocol, require small sample volumes, and allow simultaneous detection 22.
In preschool children with different wheezing phenotypes, the central issue consists
of finding a noninvasive measure to identify underlying (persisting) airway disease,
such as atopic asthma. In contrast to preschool children with viral wheeze and healthy
children, atopic asthma is characterised by a predominantly T-helper cell type 2
mediated chronic eosinophilic airway inflammation 1,3,6. Statistical analysis revealed a
significantly decreased tumor necrosis factor-alpha in EBC in the atopic asthmatic
group, compared to viral wheeze and healthy controls. Steroid-treated atopic asthmatic
children had lowered levels of tumor necrosis factor-alpha in EBC. This is in accordance
with studies on bronchial biopsies in atopic asthmatic inflammation showing
significantly decreased levels of tumor necrosis factor-alpha after eight weeks of
budesonide treatment 38.
As supported by the findings of Shahid et al, who reported increased levels of
interleukin-4 and decreased interferon-gamma in EBC in asthmatic children, the ratio’s
of interleukin-5 to tumor necrosis factor-alpha, and interleukin-13 to tumor necrosis
factor-alpha in EBC were significantly increased in the asthmatic group, compared to
nonasthmatics, although the difference between these fractions of interleukin-5 and
interleukin-13 to tumor necrosis factor-alpha were mainly due to the lowered levels
of tumor necrosis factor-alpha in EBC in asthmatic preschool children 15.
The phenotypic classification in this study was performed on basis of parentally
reported symptoms, a documented reaction on (inhaled) corticosteroids, medical
records, and information of the responsible paediatric pulmonologist. Although a
certain asthma diagnosis cannot be proven in this age group, a reasonable accuracy
can be obtained using simple, clinically based parameters 39. It is likely that children
of the asthmatic group had allergic asthma on basis of recurrent wheezing that was
not ‘exclusively’ viral triggered, a documented positive steroid response, the presence
of allergic sensitisation in these children, and a positive family history of atopy in the
first degree. On the other hand, we acknowledge that the presence of atopy in four
children in the viral wheeze group may have influenced cytokine concentrations.
Similarly, upper airway contamination through the use of facemasks without separated
nose and mouth cavity, may have been another possible confounding factor in six
children. Age was not a confounder in this study, as cytokine concentrations were not
significantly related to age. This is particularly important as a difference of age existed
between the healthy children and the children with wheeze (Table 1). Further
evaluation of repeated cytokine profile measurements in distinct wheezing phenotypes
is warranted.
Finally, we speculate that the proposed method of EBC collection may open a new
window of opportunities in pediatric research, as it may allow noninvasive
inflammatory profiling in nonsedated preschool children.
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In conclusion, we demonstrated the feasibility and efficacy of a novel closed glass
condenser with breath recirculation system to collect EBC in nonsedated preschool
children with and without wheezing illness, irrespective of the duration of EBC
collection. Multiplexed liquid bead array enabled more accurate cytokine measurement
in only small EBC sample sizes. In atopic asthmatic preschool children, tumor necrosis
factor-alpha concentrations in EBC were significantly decreased, whereas the ratio’s
of interleukin-5 to tumor necrosis factor-alpha, and interleukin-13 to tumor necrosis
factor-alpha were significantly increased, compared to nonasthmatic children.
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General Discussion
The front cover of this thesis reminds us that in the eighth century before Christ,
Homeros has written the Odyssey, an epic poem telling of the wanderings of Odysseus,
a greek heroe of the Troyan war and king of Ithaca.1 It took Odysseus ten long years
to return to his homeland and to finally regain the heart of his beloved queen
Penelope.1 The methodological development of exhaled breath condensate (EBC)
collection and analysis, the subject of this thesis, is also to some extend a telling of
the long voyage we have made, instead of a clearcut report of stepwise proceedings,
before our destination came into sight. In this way, the heart of Penelope consists of
accurate diagnosis and customised care based on noninvasive techniques for all
children with chronic respiratory inflammation.
9.1. What is exhaled breath condensate ?
In 1980, the pilot article on EBC entitled ‘Surface-active properties of the exhaled air
condensate, a new method of studying lung function’, was published in Russian by
Sidorenko et alia.2 The perestroika reforms and the policy of glasnost hastened the
end of the former Soviet Union in 1991.3 Soon after, EBC was rediscovered as a bi-
phasic technique implicating, at first, the cooling of exhaled breath to collect the
condensate, and, secondly, the analysis of the collected condensate.4 EBC contains
respiratory droplets with volatile and (mainly) nonvolatile macromolecules that are
released from the epithelial lining fluid of the airways, and that, subsequently, are
‘drowned’ in an excess of water vapour.4-5 There is evidence that abnormalities in EBC
composition may reflect biochemical changes of the airway lining fluid.4 Moreover,
the guiding and cooling of exhaled breath into a breath condenser system appears to
constitute a noninvasive, rapid and relatively easy to perform method, as well as a
technique that may be used repeatedly as it does not interact with the ongoing
(patho)physiological processes in the airways, which, by consequence, may guarantee
a high degree of safety to the subjected individual.6
9.2. Why should we study EBC ?
In this section we substantiate the further methodological development of EBC
collection and analysis, as argued in chapter 1.
Evidence-based medicine is the ‘gold standard’ for clinical practice and treatment
guidelines, and is largely dependent upon distinct disease phenotypes.7-8 However,
daily clinical reality confronts us with a natural diversity of complaints, which often
reflects various dimensions of a broad spectrum of diseases.9-10 Heterogeneity is the
hallmark of chronic respiratory inflammation, especially in growing children.10-17
However, current management guidelines are mainly based on symptoms and
pulmonary function tests, and do not succeed in achieving optimal disease control.18-
19 This is, at least in part, due to the lack of a tailored individual approach, especially
in the younger child.18-19
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Moreover, current conventional disease measures have some important limitations.
There are many discrepancies between: (i) subjectively reported and objectively
assessed airway symptoms; (ii) pulmonary function tests reflecting airflow limitation;
and (iii) direct or indirect markers of airway inflammation, such as bronchoalveolar
lavage fluid or bronchial challenge tests, respectively. Endobronchial biopsy,
bronchoalveolar lavage and sputum induction are relatively difficult direct measures
of airway inflammation and not suitable for routine use in clinical pediatric practice.
Pulmonary function tests and sputum induction require more than minimal
cooperation of a child, and thus, success rate substantially declines in children aged
six to seven years or less. In general, procedures in favour of children should be
suitable at any age, rapid and easy to perform, requiring only minimal cooperation,
as well as harmless and painless, and thus, by definition, should never be invasive or
semi-invasive. As chronic respiratory disease expression is heterogeneous, it seems
only logical that noninvasive specific single markers (indicating diagnosis, disease
control and/or airway inflammation), have to be assessed at an individual level.
Moreover, if generally applied, a set of various markers is more likely to be useful in
larger populations. 
Therefore, it is crucial to define additional noninvasive markers of inflammation, in
particular in children with chronic respiratory disorders, that can be applied in clinical
practice over a wide range, that may be specific for the evaluation and monitoring of
certain disease patterns, including early disease events, and/or response to treatment,
and that may give relevant information on the individual child. One such noninvasive
marker, nitric oxide, was discovered in human exhaled breath by Gustafsson et alia in
1991.20 Exhaled nitric oxide fraction is a marker of eosinophilic asthmatic
inflammation.21 Only recently, in 2005, the first randomised controlled trial in asthmatic
children on titrating inhaled corticosteroids using exhaled nitric oxide was published.22
Compared to current disease measures, and in particular exhaled nitric oxide, the
noninvasive collection and analysis of EBC offers some theoretical advantages
comprising: (i) an EBC collection procedure that may require only uncontrolled tidal
breathing, instead of constant expiratory flow rates (with or without the use of
dynamic flow restrictors);21 (ii) the potential of EBC to reveal the presence of multiple
nonvolatile biomarkers, that play a role in the pathophysiology of various respiratory
disorders, in contrast to only one specific volatile substance such as nitric oxide; and,
subsequently, (iii) the potential to be useful in discriminating and/or monitoring of
more than one inflammatory lung disease in subjects of all ages. Therefore, the
development of EBC methodology may ultimately result in a promising new tool to
measure various markers of chronic respiratory disease, especially in preschool children. 
9.3. Pearls and pitfalls of EBC
In this section we separately discuss our findings, as presented in chapter 1.6, chapter
2 and chapter 4.1, because these insights, in their very essence, were formative to our
further research efforts.
200
Chapter 9
In chapter 1.6, we presented the methodology of EBC, corresponding to our
knowledge at that time, and we found it to offer challenging new perspectives for
the diagnosis and management of various inflammatory lung diseases, of particular
interest for paediatric respiratory medicine. Moreover, EBC procedures are well
tolerated, and even safe in children, aged four years and above, with and without
asthma exacerbation.6
Subsequently, we proceeded with a systematic elaboration from a pediatric point
of view, presented in chapter 2, of the pearls and pitfalls of each single aspect of EBC
methodology, comprising the collection, preservation and analysis of EBC. We
identified many confounding factors that were, in general, attributable to the lack of
a standardised collection technique and procedure, as well as to the lack of specific
and highly sensitive analytical techniques.
By consequence, we did not wish to overstate the apparent simplicity of EBC.
Moreover, we were triggered off by, on one hand, the constant flux of reports on
highly variable marker concentrations in condensate in clinical studies using more or
less inappropriate assays, and, on the other hand, by the various methods of EBC
collection, as systematically reviewed in chapter 2. 
Hence, we put forward that these two key issues (id est variable marker concentrations
in EBC, and various methods of EBC collection) might very well be mutually linked, at
least in part, and until proven otherwise, as argued in chapter 4.1. All the above has led
us to direct our research efforts primarily towards optimising the condensate collection
system for the measurement of a given type of biomarker, prior to any standardisation at
all, rather than focussing on pure clinical ‘hit-and-run’ EBC trials, that usually provide only
limited cross sectional data in relatively small populations, with only median group
differences, using very different techniques, including assays with inappropriate lower
detection limits and poor reproducibility. On the other hand, we could not neglect the
fundamental reasons why we were and still are involved in research on EBC. In fact, we
ultimately want to develop a new and noninvasive tool to assess chronic respiratory
inflammation, especially in preschool children. Thus, we simultaneously performed two
clinical trials, although one may argue their early or preliminary status.
We now invite the interested reader to join us in systematically evaluating four
topics on EBC that are addressed by this thesis, although there inevitably exists some
overlap: (i) cross sectional studies in children with asthma and cystic fibrosis (chapter
9.4), (ii) development of a new condenser system (chapter 9.5), (iii) new sensitive
techniques for the detection and measurement of biomarkers in EBC (chapter 9.6),
and (iv) application of new techniques in preschool children (chapter 9.7). 
9.4. Cross sectional studies in children
In this section we will mainly discuss our findings in two – early – cross sectional,
clinical studies, presented in chapter 3 and chapter 7, in children with asthma and
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cystic fibrosis, respectively. In this – early – perspective, we have put on trial our
knowledge on EBC at that time, in order to further direct and adjust our research
planning.
9.4.1. A cross sectional study in children with asthma
In chapter 3, we presented a cross sectional clinical trial in a relatively homogenous
and well-controlled population of 23 asthmatic children and 9 healthy controls. New
exhaled markers, comprising exhaled nitric oxide, exhaled carbon monoxide,
condensate acidity (pH) and cytokines (in casu interleukin-6, interleukin-8, tumor
necrosis factor-alpha, soluble tumor necrosis factor-alpha receptor 75, soluble
intercellular adhesion molecule-1), as well as albumin and C-reactive protein in EBC,
collected using a cooled borosilicate glass distilling column, were compared with
conventional disease measures, such as lung function parameters and the asthma
control questionnaire of Juniper. 
At first, it was shown that, conventional specific solid-phase enzyme-linked
immunosorbent assays, in particular designed for use in blood- and/or bronchoalveolar
lavage fluid-samples (with lower limits of detection ranging from 20 to 50 pg/mL),
were not sensitive enough to detect interleukin-6, interleukin-8, tumor necrosis
factor-alpha, soluble tumor necrosis factor-alpha receptor 75, and C-reactive protein
in 200 to 500µL of EBC. On the other hand, ultrasensitive enzyme immunoassays were
only able to detect albumin in two out of 32 EBC samples (with a lower limit of 8
ng/mL), and were not able to detect soluble intercellular adhesion molecule-1 in EBC
(with a lower limit of 3 ng/mL). Thus, conventional and even ultrasensitive solid-phase
enzyme immunoassays were not able to smoothly detect small proteins in condensate
samples, mainly due to lower detection limits that were not suitable for use in this
‘new’ water vapour-dominated medium. Huszar et alia compared two types of (similar)
immunoassays to measure thromboxane A2 concentrations in EBC collected with the
commercially available EcoScreen® condenser.23 They reported vastly different absolute
values, due to intrinsic analytical problems associated with these assays.23 Similarly, 30-
fold differences in condensate levels of interleukin-4 in asthmatic children were found
using different enzyme immunoassays, as well as different condenser systems.24-25 On
the other hand, Leung et alia also used ultrasensitive sandwich enzyme immunoassays,
and reported detectable and reproducible measurements of growth factors (in casu
macrophage-derived chemokine, thymus and activation regulated chemokine,
epidermal growth factor, AA isoform of platelet-derived growth factor, and vascular
endothelial growth factor) and cytokines (in casu tumor necrosis factor-alpha and
interleukin-4) in EBC collected in asthmatic children with the RTube™ condenser.24,26-
27 Detectable levels were ranging from 27 to 100 per cent.24 In children with cystic
fibrosis, Bodini et alia found interleukin-8 detectable using a similarly ultrasensitive
immunoassay in 90 per cent of EBC samples collected with a glass condenser.28
However, these authors did not report the volume of EBC that was required to
perform each measurement.24,26-28 It may be clear that these conventional
immunoassays are not yet optimal for routine use in EBC.
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Secondly, our childhood asthma study had shown that not-deaerated condensate pH
was significantly lowered in the asthmatic group, compared to controls, whereas this
was not found using deaerated condensate pH. At that time, the methodology of
condensate pH measurements was quite controversial, and even provoked a fierce
polemic in literature whether to deaerate EBC samples or not.29-37 Meanwhile, this
particular acid issue has been extensively addressed by several other research groups.38-
47 Condensate pH is not stable due to the presence of ambient and exhaled carbon
dioxide.48-49 Therefore, deaeration or gas standardisation involves the bubbling a
carbon dioxide-free gas through the EBC sample for several minutes, to remove
carbon dioxide and bicarbonate from EBC, and to rise and stabilise EBC pH.48-49
Nowadays, the American Thoracic Society / European Respiratory Society Task Force
on EBC states that gas standardisation is useful when samples cannot be assayed
immediately, when one is not interested in exhaled carbon dioxide levels, or when the
condensate pH is expected to be particularly acidic.48-49
Thirdly, we reported a discordant pattern of generally low correlations between
measures of airway inflammation, clinical parameters of disease severity, and physiological
variables such as spirometric assessment of airway calibre. These few positive findings are
likely related to the very absence of any methodological EBC standardisation, including
the use of inappropriate analytical techniques, and/or to the relatively homogenous and
well-controlled study population. However, it is also plausible that this may have been a
first subtle indication that the measurement of airway inflammation does reflect some
unmet aspects of chronic respiratory disease. Airway inflammation is not the same as
subjectively reported airway symptoms, nor is it the same as pulmonary function tests
that only reflect airflow limitation. Hence, this may suggest an additional value of exhaled
measures of inflammation, for the noninvasive management of childhood asthma.
Nevertheless, a rapid and ill-considered implementation of EBC in clinical trials may
be not more than walking on thin ice. Recently, this was demonstrated, again, in a
prospective study in 40 children with stable asthma eligible for inhaled steroid
reduction.50 In this study, the authors report that EBC measurements of nitrite/nitrate
levels and cysteinyl leukotrienes proved to be disappointing clinical tools, although
they add that their results cannot be taken to suggest that EBC has no role in the
monitoring of childhood asthma.50 However, some alternative and plausible
methodological explanations have not been highlighted by this study, such as the use
of a specific solid-phase enzyme immunoassay to measure cysteinyl leukotrienes, with
a relatively high lower-limit of detection of 15.0 pg/mL, designed for application in
other mediums, but not EBC.50 Moreover, the authors mentioned they had to make
arbitrary choices of what to measure due to the small volumes of condensate obtained
by the commercially available EcoScreen® condenser, indicating an inefficient
condensation process, or the need of large sample volumes required for analysis.50
9.4.2. A cross sectional study in children with cystic fibrosis
In chapter 7, we explored the ability of different exhaled inflammatory markers,
including exhaled nitric oxide, condensate pH, nitrite, nitrate, hydrogen peroxide, 8-
203
General Discussion
isoprostane, and various T helper-1 and T helper-2 cytokines, such as interferon-
gamma, tumor necrosis factor-alpha, interleukin-2, interleukin-4, interleukin-5 and
interleukin-10 in EBC, to discriminate between a large cohort of 48 children with
cystic fibrosis and 50 healthy controls in a cross sectional study design. Furthermore,
we used multiplexed cytometric bead array, as previously described by our research
group, to measure several cytokines, simultaneously, in EBC collected using a cooled
borosilicate glass distilling column.51
The cross sectional cystic fibrosis study showed that multiplexed detection of
cytokines in only 50µL of EBC was possible, using cytometric bead array. This technique
consists of a series of spectrally discrete particles that can be used to capture and
quantitate soluble analytes (in casu cytokines).52-53 The analyte is then measured by
detection of a fluorescence-based emission and flow cytometric analysis.52-53 In short,
cytometric bead array generates data that are comparable to enzyme linked immuno
sorbent assays, but in a multiplexed or simultaneous fashion, and obtains more results
from a single small sample.52-53 In the cystic fibrosis study, interleukin-5 was the only
nondetectable cytokine in EBC, compared to several nondetectable cytokines in our
first report on cytometric bead array (tumor necrosis factor-alpha and interleukin-5
were nondetectable in children with cystic fibrosis, whereas interleukin-2, interleukin-
4 and interleukin-5 were nondetectable in healthy control children).51 The lack to
detect any interleukin-5 is in agreement with the findings of Armstrong et alia in
bronchoalveolar lavage fluid, and may be related to the presence of proteases in cystic
fibrosis airways.54-55 The lack to detect (some) cytokines does not necessarily implicate
that they are not present, as the detection method may lack sufficient sensitivity. In
the cystic fibrosis study, the levels of detection of the other cytokines (interferon-
gamma, tumor necrosis factor-alpha, interleukin-2, interleukin-4 and interleukin-10)
ranged up to 42, and 20 per cent in children with cystic fibrosis, and healthy control
children, respectively, compared to 25 and 14 per cent in our first report.51
Significantly more detections of interferon-gamma and interleukin-4 were found
in EBC in children with cystic fibrosis compared to controls. Moreover, cytometric bead
array did require only a small EBC sample size, as mentioned above, and in contrast
to other reports, as noted below.56-58
In literature, no comparative data on cytometric bead array in EBC in children are
(yet) available. On the other hand, in adults with acute lung injury or chronic obstructive
pulmonary disease, cytometric bead array has also been described for the
measurement of interleukin-1-beta, interleukin-6, interleukin-8, interleukin-10, tumor
necrosis factor-alpha and interleukin-12p70 in EBC, collected with the EcoScreen®,
and only after lyophilisation (or freeze-drying) of 2000µL EBC and cryopreservation.56-
57 The reported levels of cytokine detection in these subjects ranged from 37 to 100
per cent.57 Recently, Matsunaga et alia also reported the use of a membrane protein
array to measure 40 different cytokines and chemokines in 1000µL EBC in adult
asthmatics using the EcoScreen®, and found relative cytokine levels in 3 to 27 per cent
of the samples.58 Interleukin-4, interleukin-8, interleukin-17, tumor necrosis factor-
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alpha, regulated on activation normal T-cell expressed and secreted (RANTES),
interferon-gamma-inducible protein 10, transforming growth factor-beta, and
macrophage inflammatory protein 1-alpha and 1-beta were significantly upregulated
in asthmatics compared with healthy controls.58 Matsunaga et alia refer to a
confirmation of good correlations between the relative levels obtained by using this
method and the actual levels obtained by means of quantitative assays.58-59 In 22
adults, Schumann et alia reported the detection of erythropoietin and tumor necrosis
factor-alpha in EBC collected using the EcoScreen®, in 68 and 59 per cent,
respectively.60 However, they did not report further details on the required volume of
EBC, nor on sample processing.60
Furthermore, in the cross sectional cystic fibrosis study, the concentrations of
interferon-gamma and nitrite in EBC were significantly increased, whereas exhaled
nitric oxide levels were significantly decreased in the cystic fibrosis group, compared
to controls. These results are in accordance with available data in literature on nitric
oxide,61-70 nitrite (assessed in young adults with cystic fibrosis),62-63,71-73 as well as
interferon-gamma (assessed in bronchial biopsies).74 Several hypotheses may explain
lowered exhaled nitric oxide levels and higher nitrite concentrations in cystic fibrosis,
including: (i) impaired diffusion of gasseous nitric oxide into the airway lumen due to
viscous mucus in the cystic fibrosis airways, which in turn may result in conversion of
nitric oxide into nitrite;63,75 (ii) decreased expression of inducible nitric oxide synthase
II in epithelial cells;70,76-80 and (iii) increased arginase activity in cystic fibrosis airways.81
Hence, we provided evidence for the discriminating ability, between children with
cystic fibrosis and healthy controls, of three separate, exhaled inflammatory markers.
Obviously, the clinical relevance of these findings for the individual child at long-term
level remains yet to be determined. The concentration of hydrogen peroxide in EBC
did not differ between children with cystic fibrosis and controls, which is in accordance
with other reports.61,82 Also, condensate pH and the concentration of 8-isoprostane
in EBC did not significantly differ between these study groups, which may be attributed
to the mild to moderate cystic fibrosis severity in the study population. On the other
hand, Montuschi et alia found significantly increased 8-isoprostane concentrations in
EBC in 19 adult patients with cystic fibrosis, compared to normal subjects,83 whereas
Carpagnano et alia found significantly lowered condensate pH in children with cystic
fibrosis, than in healthy controls, and a further decrease in 10 children with cystic
fibrosis exacerbation, compared to 10 stable cystic fibrosis patients.84
Using multivariate logistic regression models, a diagnosis of cystic fibrosis was best
indicated by 8-isoprostane, nitrite and interferon-gamma in EBC. This particular profile
of combined exhaled inflammatory markers, was able to discriminate children with
cystic fibrosis from healthy controls, with an acceptable ratio of sensitivity (78 per cent)
to specificity (92 per cent), and an area under the receiver operating characteristic
curve of 0.906. An exacerbation of cystic fibrosis was best indicated by 8-isoprostane
and nitrite, with a sensitivity of 40 per cent, a specificity of 97 per cent, and an area
under the receiver operating characteristic curve of 0.838. Most indicative biomarkers
of cystic fibrosis severity were exhaled nitric oxide and condensate pH, with a sensitivity
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of 96 per cent, a specificity of 67 per cent, and an area under the receiver operating
characteristic curve of 0.751. In literature, to date, no comparable data are available.
However, to clearly state, these indicative profiles do not at all intend to be an
alternative assessment of cystic fibrosis diagnosis, as this would be almost redundant
and even out of the question. In our opinion, such disease discriminating profiles of
exhaled markers have to be identified, prior to any longitudinal clinical study on the
noninvasive monitoring of chronic respiratory disease. Moreover, this study illustrates
that the combination of various noninvasive markers into several specific profiles, may
indicate different aspects of chronic respiratory disease. Hence, these combined
noninvasive markers may even provide additional information, in contrast to each
marker separately. Exempli gratia, in cystic fibrosis exhaled nitric oxide levels are
usually low, whereas nitric oxide may indicate disease severity when combined with
condesate pH. This interesting ‘synergisitic’ effect warrants further exploration in a
longitudinal setting.
In summary, it may be clear that the need for additional improvement of EBC
methodology, prior to longitudinal clinical studies, was still incontestable.
9.5. Development of a new condenser system
In this section we will chronologically describe, in four phases, the development of a
new breath condenser system, based on findings originating from chapter 4.2, chapter
5 and chapter 8.
9.5.1. Phase 1: the Babel confusion
In the methodological review, presented in chapter 2, we provided an overview of the
vastly different techniques to collect EBC, at that time. Most widely used designs
included imersion of a Teflon-lined tubing in an ice-filled bucket, and a double-wall
borosilicate glass distilling column connected to a counter-current ice-water pump.
Commercially available systems included the lamellar Teflon-like EcoScreen® condenser
(Erich Jaeger GmbH, Hoechberg, Germany) and the hand-held disposable
polypropylene RTube™ breath condensate collector (Respiratory Inc., Charlottesville,
Virginia, USA). The EcoScreen® conducts exhaled air through a lamellar condenser
with a sample collection vial inserted into an electrical cooling cuff. This design has
been associated with deposition of frozen condensate on its inner lamellar walls.
Likewise, immersed plastic tubing was even associated with complete obstruction of
the collection lumen. Most of these condenser systems are connected to a two-way
non-rebreathing valve and a mouth piece, whereas the RTube™, a portable hand-held
condensate collector which consists of a re-usable and precooled aluminium sleeve
that is placed over the outside of a disposable polypropylene vertical condensation or
collection tube, is connected to one-way valves and a mouth piece. Recently, the
thermostatically controlled polyethylene Turbo-Deccs (ItalChill, Parma, Italy) has joined
this list.85 All systems are based on the principle of constantly cooling exhaled air,
whereas the handheld plastic RTube™, placed in a pre-cooled sleeve, is highly
susceptible to (higher) ambient temperatures during EBC collection.86 Hence, the
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confusing variety of physical characteristics associated with each specific condenser
design constitutes one of the main obstacles for a smooth development of a
standardised EBC sampling device.
9.5.2. Phase 2: the condenser coating study
As stated in chapter 4.1, we argued that the variability of biomarker concentrations
may be associated, at least in part, and until proven otherwise, with the various
designs of EBC collection. This culminated in the so-called coating study, as presented
in chapter 4.2, and investigated the influence of different adhesive properties of inner
condenser coating surfaces (in casu glass, silicone, aluminium, polypropylene, Teflon
and the EcoScreen® condenser) on the measurement of eicosanoids (in casu 8-
isoprostane) and proteins (in casu human albumin) in condensate. We have shown
that a condenser with a glass coating was more efficient for the measurement of these
molecules in EBC, both in vitro as well as in vivo, when compared with other coatings,
including the commercially available and Teflon-like EcoScreen® condenser. 
The reported in vivo detectability and concentrations of 8-isoprostane in EBC in
healthy subjects, were in line with available, but scarce data in literature.87 Moreover,
when reviewing literature, according to an identical assay (enzyme or radio-
immunoassay), and different condenser coatings, also higher 8-isoprostane
concentrations were reported using a glass condenser compared with the EcoScreen®
condenser.83,87-100
On the other hand, the reported isoprostane condensate recovery percentages in
vitro were high and did not differ significantly between the condenser coatings. This
may be a reflection of the higher overall mean condensate recovery of isoprostane
(100 per cent) in contrast to albumin (52 per cent), which may in turn illustrate a
different behaviour of these molecules during the expiratory phase of the EBC
collection, as molecules with a higher molecular weight (id est 354 Dalton versus up
to 80.000 Dalton, for 8-isoprostane and albumin, respectively) may experience more
difficulties in their transition from respiratory fluid droplets and exhaled air, into the
condensate. Conversely, an isoprostane overload in the in vitro experiments seems
unlikely, when considering that the absolute amount in the condensate sample vials
must have been very close to the concentrations found in vivo, as an isoprostane test
solution of 42 pg/mL was nebulised. This may indicate that the nebuliser set-up was
producing isoprostane aerosols that have been more effectively condensed as
compared to the real EBC in vivo, and/or that the upper out of range plateau zone of
the immunoassay was reached.
We also report in this study, a limited number of positive albumin detections in
vivo, which in turn is in agreement with (i) the relatively few positive studies, at that
time, on cytokines or proteins in EBC versus several positive reports on 8-isoprostane
and leukotrienes in EBC; and with (ii) the methodological concerns raised by Tufvesson
et alia on evaporation, loss of biomarkers in the condensate collection system and low
biomarker concentrations in EBC (as further discussed).101
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A possible plausible explanation for the superiority of glass coatings is mainly related
to the fact that water acts as a bipolar vehicle, whereas the pH of exhaled breath
ranges from 6.50 to 7.80, and the isoelectrical point of human albumin is situated at
pH 4.80.102 In other words, at higher pH values (such as reported in EBC) albumin acts
as a negatively charged molecule in exhaled breath, that may be repulsed by the
negatively charged glass condenser wall, and thus, may promote the recovery of
albumin in EBC. In contrast, the same negatively charged albumin molecule may be
attracted by aluminium metal ions that are positively charged, and thus, may hamper
the recovery in EBC. Also, 8-isoprostane acts in an extremely hydrophobic manner, but
will stick to neutral surfaces (such as Teflon) in the presence of aqueous solutions, to
lipids and to detergents.
Furthermore, we acknowledge that variability of biomarker concentrations in EBC
may, in part, be due to reported intrinsic problems of different immunoassays (as
already discussed).23-25 Thus, to actually comprehend the possible impact or relevance
of our finding, the reproducibility of the measurement of 8-isoprostane (or other
eicosanoids) and proteins such as cytokines, should be additionally evaluated in vivo
by using different condenser coatings as well as a reliable ultrasensitive analytical
method (this issue will be addressed in the next chapter). 
We believe that borosilicate glass, which is readily available and easy to use, should
be considered as a more appropriate, instead of inferior, basic material for condenser
systems than the Teflon-coated EcoScreen®, at least for the measurement of
eicosanoids and small proteins in EBC. Hereby, not only offering new and more
perspectives to further develop the condensate collection system, but also illustrating
that future guidelines for EBC standardisation should be prone to include the most
valid condenser coating(s) to collect condensate and subsequently measure a specific
disease marker.
Up to date, three other studies on the potential influence of sampling systems on
biomarkers in the EBC have been published.86,101,103 Tufvesson et alia proposed a
novel method to collect EBC using the EcoScreen® condenser of which all collection
surfaces previously had been coated with bovine serum albumin (1 per cent) and
Tween-20 (0.01 per cent), when measuring cytokines and eicosanoids, respectively.101
However, they also reported some major limitations, as (i) the preceeding coating
procedure lasts 30 minutes, (ii) the Tween-20 coating may lead to false-positive
(eicosanoid) results, and (iii) a 5 to 10-fold concentration of the condensate sample
was necessary, by vacuum-centrifugator, prior to analysis.101 Soyer et alia compared
two commonly used commercially available EBC collection systems, the RTube™ and
EcoScreen® condensers.86 They found that there was no difference for the
measurement of acidity, but the concentrations of cysteinyl leukotrienes and eotaxin
were significantly higher in samples collected with the EcoScreen®, than with the
RTube™.86 Soyer et alia attributed these differences mainly to (i) the susceptibility of
pre-cooled RTube™ sleeves to (increased) ambient temperatures over the
recommended time course of a collection maneuvre, whereas the highest
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temperatures were measured at the one-way valve, near the mouth, however (ii) they
also stated that differences in the materials could affect sample recovery.86 Recently,
Prieto et alia compared the RTube™ and EcoScreen®, and reported that condensate
pH values are dependent upon the collection device used.103
9.5.3. Phase 3: a new condenser concept emerges
The next step in our search for a more reliable condenser device, was to introduce a
newly developed glass condenser system, as presented in chapter 5. Briefly, the
condensation surface was enlarged using a glass condenser tube length of 90 cm,
condensate recovery was optimised using an inclined condensation tube with a
downwards moveable condensate sweeping plunger, and exhaled breath flows were
turbinately directed towards the cooled inner condenser wall by the plunger’s multiple
tangential and axial breath channels (Figure 1). 
In this study, 30 healthy adult subjects were chosen in order to eliminate possible
confounding factors attributable to heterogenous disease expression and/or variability
of disease control. Each subject was asked to perform four tests at different points in
time, to assess within-day, between-day and between-week reproducibility of
condensate volume, and of the measurements of hydrogen peroxide, 8-isoprostane,
interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-8, interleukin-10,
interleukin-13, and tumor necrosis factor-alpha (using a new technique for the
detection of cytokines, as will be further discussed in chapter 9.6). Each of these four
tests consisted of four sequential EBC collections, during 15 minutes, using ad random
different types of condenser systems (the new optimised glass condenser, a silicone
condenser, the former glass condenser, and the EcoScreen®).
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Figure 1. Description of the new, optimised glass condenser system, as presented in chapter 5.
1. inclined glass condenser with a tube length of
90 cm (to enlarge the condensation surface),
and downwards moveable plunger (to optimise
condensate recovery from the inner condenser
wall), with tangential and axial breath channels
(to turbinately direct the tidally exhaled breath
flows towards the cooled inner condenser wall)
2. swan-neck tubing (serving as gravitational
saliva trap) and two-way nonrebreathing valve,
connected to a mouthpiece
3. entrance of inspired room air
4. cooling unit consisting of a counter-current
circulating ice-water pump
5. removable, cooled glass sample vial (to collect
exhaled breath condensate)
We demonstrated that the newly developed optimised glass condenser yielded
significantly more condensate volume (2025µL), compared to the silicone, (former)
glass and EcoScreen® condensers (525µL, 712µL, and 1237µL respectively), suggesting
both an improved condensation process, and an increased opportunity to perform a
broad spectrum of analyses using the new optimised condenser. Reproducibility of
EBC volume, expressed by means of percentage of coefficient of variation, was
comparable for the new condenser and EcoScreen® (ranging from 11 to 20 per cent,
and from 9 to 19 per cent, respectively), but was significantly better compared to the
silicone and (former) glass condenser (ranging from 20 to 37 per cent, and from 21
to 30 per cent, respectively). Hence, the optimised glass and EcoScreen® condenser
were both significantly associated with less variation in the generated EBC volume,
compared to the other condensers. Hereby, reducing a possible confounding influence
of the variable quantity of EBC collected over a given time, and even within individuals.
In EBC collected with the new glass condenser system, significantly more positive
hydrogen peroxide, 8-isoprostane, interleukin-2, interleukin-4, interleukin-5,
interleukin-13, and tumor necrosis factor-alpha detections were found, supporting an
improved sampling of EBC. Moreover, 8-isoprostane concentrations were significantly
increased in EBC yielded by the new condenser, compared to the other three
condensers, which is in accordance with the findings in the former coating study. On
the other hand, reproducibility of hydrogen peroxide, 8-isoprostane and cytokine
measurements in EBC, expressed by means of percentage of coefficient of variation,
was equally variable for all condenser types, suggesting no significant influence of the
type of condenser coating on reproducibility of biomarker measurements in EBC in
healthy adults. In literature and to date, no formal study addressing this issue has been
published, although biomarker reproducibility using other analytical techniques has
been reported,104-106 and/or could not be calculated due to small number of
subjects.87,107-108
Variations in biomarker measurements in EBC may be attributed to variations in
the dilution and/or quality of condensate, that is influenced by different collection
techniques and procedures, sample processing and storage conditions, and/or
sensitivity of the analytical techniques used.107 The levels of the highly volatile hydrogen
peroxide in EBC are susceptible to (yet) uncleared methodological issues that may be
attributed to: (i) different cooling temperatures during collection;109 (ii) a circadian
rhythm of exhaled hydrogen peroxide levels;110 (iii) the different methods of
measurement with widely varying values for both healthy individuals and patients with
respiratory disorders, with most of these values being close to the lower limits of
detection;82,87-88,104-105,111-124 (iv) evidence of hydrogen peroxide flow dependency, as
nontidal breathing or lower controlled exhalation flows lead to significantly higher
hydrogen peroxide levels in EBC, when compared with higher controlled flows, and
as tidal breathing during EBC collection incorporates multiple different flows in each
breath;115 and (v) the high level of chemical reactivity of hydrogen peroxide with
salivary contamination, and exhaled nitrogen oxides and ammonia, forming various
other compounds, including hydroxylamine, peroxynitrite and nitrate, by which
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hydrogen peroxide levels in EBC decline over time in storage, and by which it is likely
that (some) hydrogen peroxide is consumed even during the time of collection.48-
49,119,125-127 Isoprostanes are relatively stable end-products of in vivo arachidonate
peroxidation, and are measured in EBC by immunoassay, that may be influenced by
crossreactivity with closely related substances.107 We used commercially available
enzyme immunoassays, that are very sensitive but lack in specificity, to measure 8-
isoprostane in 100µL of EBC, instead of radioimmunoassays that now have been
qualitatively validated for these measurements, by reverse phase high performance
liquid chromatography, as described by Montuschi et alia.128-129 However, the use of
both enzyme immunoassays and radioimmunoassays may be associated with cross
reactivity of antibodies.106 On the other hand, Cap et alia have used gas
chromatography/mass spectrometry to quantify exhaled eicosanoids (in casu
leukotrienes).130 Although the specificity of mass spectrometry detection ensures an
unequivocal determination of the analysed substances, gas chromatography requires,
in contrast to liquid chromatography, derivatisation procedures and corresponding
sample pre-treatment for nonvolatile compounds.130 Therefore, to avoid more sources
of errors, Gonzalez-Reche et alia recently presented a validated method for the
simultaneous determination of arachidonic acid metabolites in 1000µL of EBC by
liquid chromatography-electrospray ionisation tandem mass spectrometry, although
this method still included an automated sample enrichment step.106 Other
confounding factors may be age, diets rich in antioxidants, and smoking habits.107
Our findings on biomarker reproducibility were not altered by expressing the
results as intraclass correlation coefficients or standard deviations, instead of
coefficients of variation. Biomarker levels were assessed in condensate originating
from healthy adults, and thus, may have been more pronounced in a steroid naïve
population with documented chronic respiratory inflammation, and comparable levels
of disease control. In diseased subjects, one may expect increased mean
concentrations, and lowered coefficients of variation.
To recapitulate, the proposed new glass condenser had an improved condensation
process and condensate recovery, using an inclined and enlarged condensation
surface, with a condensate sweeping plunger, having tangentially and axially guiding
breath flow channels. These improvements resulted in significantly increased EBC
volumes and biomarker detections, including higher 8-isoprostane EBC levels,
demonstrating a significant influence of the condenser system, in favour of the new
optimised glass condenser. However, reproducibility of biomarker measurements in
EBC in healthy adults was not influenced by the type of condenser. 
9.5.4. Phase 4: the new condenser system
Finally, we introduced, in chapter 8, a new method for the collection of EBC, before
and after breath recirculation, and demonstrated its feasibility in 70 preschool children,
aged 4 years or less, with and without wheezing illness. Furthermore, we used the
same analytical technique as previously mentioned to measure cytokines in the
collected EBC (as will be further discussed in chapter 9.6 and 9.7).
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Preschool children, and in particular toddlers, do not simply intend to follow any instruction
(to breath tidally into a facemask with separated nose and mouth cavity) unless they are
willing to cooperate. Also, if toddlers tend to cooperate, they often do not sustain their effort
for a relatively long time (initially condensation of exhaled breath often takes at least 5 to 10
minutes depending on the available condensation surface), as their willingness to cooperate
may rapidly disappear, and/or as they can be distracted by anything at all. The collection of
EBC in preschool children requires short sampling times. However, these are not always
offered by the currently used and less efficient condensers, with open ended and relatively
short-measured designs. These condensers are characterised by the loss of a highly variable
amount of noncondensed exhaled breath, as condensation does not immediately occur,
and/or does not continue to occur once the condensation surface is completely saturated. In
addition, exhaled biomarkers may be lost in different EBC sampling systems, due to adhesive
interactions between condenser coatings and exhaled biomarkers, as already discussed.
Furthermore, EBC collection in preschool children is also hampered by suboptimal condensate
analysis, associated with techniques that require relatively large volumes of EBC, and by
consequence, necessitate again a prolongation of sampling times. For all the above reasons,
a modification of the glass condenser was mandatory, in such a way that the condensation
process was optimised with a high efficiency-to-time ratio. Hence, we were searching a
design that would allow maximal condensation of all the exhaled breath that was gathered,
whether in only a few minutes or after a prolonged period of time.
In short, the glass condenser system as previously described in chapter 5 (with
enlarged condensation surface, inclined and optimised condensate recovery with
plunger, and turbinately directed breath flow channels), was now closed and
connected to a unique heated (at 37 degrees Celsius) breath recirculator system
(Figure 2). The breath recirculation system itself consists of heated tubing (to guide
the residual noncondensed exhaled breath, and to avoid condensation outside the
condenser tube), a humidity sensor, a heated inert Tedlar™ gas sample bag (to collect
all residual noncondensed exhaled breath), and  a small ventilator system (to recirculate
the residual noncondensed exhaled breath back into the condenser system for
secondary condensation of exhaled breath).
The child exhaled tidally, as long as possible, through a face mask, with separated
nose/mouth cavity, and two-way nonrebreathing valve, that was connected to the
glass condenser system. During this condensation process, the formerly lost
noncondensed exhaled breath was separately being collected in a gradually inflating
inert Tedlar™ gas sample bag. When the child ceased this procedure, EBC was
collected by pushing downwards the plunger. Subsequently, the plunger was pulled
up again, and the separately collected exhaled breath was recirculated, from the
Tedlar™ gas sample bag, back into the condenser system, to perform a secondary
breath condensation, until the degree of relative humidity was less than 22 per cent.
This new concept of EBC collection before and after breath recirculation, allowed
condensation of the totally exhaled breath volume, whether gathered after only a few
minutes of EBC collection, or after a prolonged period. Moreover, the concept enabled
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the collection of significantly more EBC volume compared to the ‘usual’ (before breath
recirculation) procedure, whereas, in toddlers with limited cooperation in time (and
more often seen in the healthy group that was relatively unknown with the use of
face masks), breath recirculation was often crucial to yield minimal but sufficient
condensate volume. The cumulative nature of these methodological modifications
resulted in an overall success rate of 83%. Furthermore, the main issue was whether
the concentration of cytokines, measured in the collected EBC, was affected by the
recirculation process or not. We demonstrated that all cytokine concentrations in EBC
collected before and after breath recirculation, were comparable and did not differ
significantly. Hence, illustrating the efficiency of the breath recirculation system in
generating an additional amount of equivalent condensate.
In literature, some attempts have been described to collect EBC in infants.117,131
Griese et alia presented a nasal collection system, that consisted of two serially
connected polypropylene tubes and an electrical air suction pump, for the
measurement of hydrogen peroxide and 8-isoprostane.131-132 However, they reported
difficulties related to contamination with nasal secretions, and to the collection of only
20 to 30 per cent of the totally exhaled breath volume.131-132 Cheah et alia described
a bedside method for the collection of EBC, based on polyvinylchloride tubing, that
was immersed in a column of wet ice, for the measurement of hydrogen peroxide in
neonates who were ventilated or receiving nasal continuous positive airway
pressure.117 However, they reported insufficient sensitivity to use their system for the
detection of exhaled hydrogen peroxide.117 Recently, Moeller et alia proposed, a
feasible and safe method to collect EBC, both orally and nasally, in tidally breathing
infants.133 However, this method required sedated sleep, and was described without
the assessment of any marker in the collected condensate.133 Last but not least, other
techniques for the collection of EBC from ventilated patients, including infants,
children and young adults, have recently been proposed.134-135
In our study, successful EBC collection was associated with an optimal distraction
of the preschool children. We primarily combined strict parental cooperation (86 per
cent), after preceding instructions by the coaching childhood asthma nurse, with an
age appropriate cartoon (76 per cent), that was already started prior to entrance. In
case of imminent failure to cope, a more active strategy was used on parent’s advice,
including children’s stories (36 per cent), puppetry (15 per cent), and/or children’s
songs (12 per cent). Distraction was mainly hampered by insufficient parental
stimulation and/or a history of ear-nose-throat surgery. 
In literature, a variety of different distractors have been used for non-
pharmacological pain or distress management in children of all ages, including
watching cartoons,136-138 using party blowers,139 looking through kaleidoscopes,140
blowing bubbles,141-142 non-procedural talk,143 listening to short stories,144 humour,145
listening to music,146 puppetry,147-148 and virtual reality glasses.149-150 The management
of a child’s distress does not equal pain management. However, the latter may provide
some hints to improve the child’s coping with distress due to a noninvasive and
213
General Discussion
painless  but unfamiliar procedure, such as the collection of EBC, in particular in
preschool children. In literature, distraction performed by mothers has been reported
to be an effective analgesic factor.143-144 Moreover, children state that just having their
parents present provides the most comfort when in pain, and they will recall that they
were not left alone on a stressful occasion.136,151 Cohen et alia found that 4 to 6 year
old children watching a popular cartoon series felt less pain, whereas Cassidy et alia
found that watching television during an immunisation injection was not effective in
reducing pain in a group of 5 year old children.137-138 Mason et alia suggested that a
passive strategy, such as watching television, may be more effective than an active
one, such as distraction with an interactive toy, for decreasing pain, because children’s
distress interfered with their ability to interact with the distractor.144
Hence, we introduced a novel, highly efficient, closed concept that enabled the
collection of EBC, both before and after breath recirculation, and yielded sufficient as
well as equivalent condensate in the ‘diagnostically-nearly-unaddressed’ population
of (nonsedated) preschool children with or without wheezing illness.
9.6. New sensitive techniques for the detection and measurement of
biomarkers in EBC   
In this section we will discuss our findings, mainly related to the analysis of EBC to
measure cytokines, and free radicals (as markers of oxidative stress), using new
sensitive techniques as applied in chapters 5 and 8, and chapter 6, respectively.
9.6.1. Cytokines in EBC
9.6.1.1. Why and how we tried to detect cytokines in EBC
Cytokines are intercellular immune regulatory peptides involved in the orchestration of
many different aspects of local and/or systemic inflammatory processes, including tissue
repair, and thus, cytokines are associated with various chronic respiratory disorders, as
indicated in chapter 1. This also implicates that these mediators constitute interesting
research targets as the changing level of different cytokines, or in other words specific
profiles of cytokines, may reflect parallel changes at certain stages in specific types of chronic
respiratory inflammation. Furthermore, cytokines are low molecular weight proteins (ranging
from 4.000 to 50.000 Dalton), that may be able to shift or migrate from the intrapulmonary
compartment into the airway lumen, and, thus, may be exhaled, as suggested by two
incidental reports, at that time, on their detection in EBC in children.25,71 Cunningham et
alia reported the detection of the pro-inflammatory interleukin-8 in EBC in 30 per cent of
children with clinically stable cystic fibrosis.71 Shahid et alia reported significantly increased
mean levels of interleukin-4 and decreased mean levels of interferon-gamma in asthmatic
children, compared with healthy controls, whereas lower levels of interleukin-4 were found
under corticosteroid treatment.25 Hence, we were primarily interested in the detection of
these small proteins in EBC in children, but at the same time, we were also very aware of
the difficulties that we were facing, as our review (presented in chapter 2) had also made
clear that EBC methodology was significantly hampered by the lack of specific and highly
sensitive analytical techniques. In the early childhood asthma study, presented in chapter 3,
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it was shown that conventional and even ultrasensitive specific solid-phase enzyme
immunoassays were not able to sufficiently detect cytokines in EBC (chapter 9.4 above).
Subsequently, a new technique, multiplexed cytometric bead array, was used in the early
cystic fibrosis study, presented in chapter 7, and allowed the simultaneous measurement of
several cytokines in only small condensate samples (chapter 9.4 above). However, the level
of cytokine detection still did not reach 50 per cent, as already discussed.
Therefore, we were unremittingly pursueing amelioration. Moreover, all the above
may only illustrate the very importance of rapidly transfering novel developments of
‘nano-molecular’ analytical technology, into the field of condensate-related research. 
9.6.1.2. Multiplexed liquid bead array and the measurement of cytokines
in EBC
In chapter 5, we not only investigated the in vivo reproducibility of different biomarkers
in EBC using four different condenser types (including the new open glass condenser),
but we also introduced a novel technique to, both more rapidly and precisely, detect
and measure several cytokines simultaneously. Luminex’s xMAP technology is a liquid
bead array multiplexing system, built on proven, existing technology, including
traditional chemistry, flow cytometry, microspheres (characterised by liquid reaction
kinetics that are faster and more reproducible, than with solid planar assays), laser
technology and digital signal processing, that are combined in a unique way and allow
multiplexing of up to 100 unique assays within a single sample.152-153
When compared with conventional bioassays and solid-phase enzyme
immunoassays, multiplexed immunoassays are highly sensitive (a few pg/mL), allow
quatitative detection (in contrast to semiquantitative bioassays), have high specificity,
detect bioactive as well as inactive molecules, have a growing analytical range
(cytokines, phosphoproteins, antibodies), are rapid (hours instead of day(s)), have
good (but not yet excellent) precision (coefficients of variation range from 10 to 15
per cent), are not interfered by drugs, have a simple protocol, require small sample
volumes, allow simultaneous detection, and can be applied for multiple species (not
only human).153 However, the initial set-up time is consuming and expensive.153
Cytokines were simultaneously measured by means of xMAP’s technology in small
EBC sample volumes of 50 µL. All cytokines (id est interleukin-2, interleukin-4,
interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin-13, and tumor
necrosis factor-alpha) were now detectable in EBC, compared to our early studies
based on cytometric bead array with 1 to 4 not detectable cytokines in EBC.51 The
overall level of cytokine detection using multiplexed liquid bead array was 46 to 97
per cent, whereas the detection level using cytometric bead array was less than 50
per cent in similarly small EBC samples in children,51 and 3 to 100 per cent in large
1000 to 2000 µL lyophilisated EBC samples in adults.56-58,60
In EBC collected with the new (open) glass condenser, significantly more detections
of interleukin-2, interleukin-4, interleukin-5, and interleukin-13, and tumor necrosis
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factor-alpha were found, compared to the other condenser types. However, cytokine
concentrations in EBC in healthy adults, and reproducibility of these cytokine
measurements expressed as coefficients of variation (ranging from 5 to 78 per cent),
did not significantly differ and were equally variable for all types of condenser (as
previously discussed). 
In chapter 8, the same multiplexed liquid bead array technique was applied for the
measurement of cytokines in 50 µL of EBC collected with the new closed glass
condenser, before and after breath recirculation, in preschool children with and
without wheezing illness. Also in this study, all cytokines (id est interleukin-4,
interleukin-5, interleukin-6, interleukin-8, interleukin-10, interleukin 12p70,
interleukin-13, and tumor necrosis factor-alpha) were detectable in EBC, and the level
of cytokine detection in EBC ranged from 95 to 100 per cent.
Hence, we believe that optimisation of EBC collection, using the new glass
condenser(s), and optimisation of EBC analysis, using rapid multiplexed xMAP
measurement of cytokines in small EBC sample sizes, may all together open a window
of opportunities, even in strained collection procedures, such as in young or dyspnoeic
subjects (with less sustained efforts to cope with sampling procedures), by allowing
the search for, and identification of, particular profiles of different exhaled markers,
involved in the regulation of chronic respiratory inflammation, for diagnostic and
monitoring purposes.
On one hand, we acknowledge the fact that the introduction of novel analytical
technique may be considered as a major confounding factor, as this technique still
awaites further investigation of the reproducibility, sensibility, specificity and validity
of its generated data on cytokines in EBC. For this purpose, the Standards for Reporting
of Diagnostic Accuracy (STARD) initiative provides recommendations, including a
checklist and flow diagram, towards complete and accurate reporting on diagnostic
accuracy.154-156 On the other hand, we ultimately do not see an alternative approach
other than the one proposed, to gradually introduce such novelties, because the first
step, in our opinion, will always consist of establishing an accurate and rapid analytical
technique, prior to any application in longitudinal clinical trials.
9.6.2. Free radicals in EBC
Oxidative stress, defined as an imbalance between oxidants (such as reactive oxygen
species) and antioxidants (such as vitamin C) in favour of oxidants, also appears to play an
important role in several inflammatory lung diseases.107,157 Hence, in our search for the
application of new analytical techniques in EBC, we were also interested in the assessment
of free radicals, that are considered the most direct markers of oxidative stress.107,157
In the study, as presented in chapter 6, we used the most direct method to assess
oxidative stress status in vivo in children with cystic fibrosis and healthy control
children. This study did demonstrate the feasibility of electron paramagnetic resonance
spectroscopy to directly and semi-quantitatively detect free radicals, in casu both
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oxygen- and carbon-centered radicals, in 500µL of EBC. We found a trend towards
higher maximal peak heights of oxygen- as well as carbon-centered radicals in EBC in
children with cystic fibrosis, compared to healthy controls. However, this difference
did not reach statistical significance, and may be attributed to the small study
population, and/or to the fact that also a normal lung exists in an oxygen-rich
environment that makes this lung also susceptible to oxidative stress. 
On the other hand, we found that this direct and nearly online technique required
quite sophisticated equipement and personel, which makes it not readily available for
practical use in a clinical setting. 
We also examined the possible source of these free radicals. The findings of this
study suggested that hydrogen peroxide is likely crucial for the generation of oxygen
centered radicals, and that EBC may also contain compounds that enable in situ
radical formation. Furthermore, free radicals do not likely result from salivary
contamination, and thus, may originate from the lower respiratory tract. By
consequence, this may provide further support that the content of EBC reflects the
ongoing processes in the epithelial lining fluid.
Recently, Carraro et alia reported the application of metabolomics in the analysis
of EBC, in asthmatic children.158 Metabolomic analysis, by means of high resolution
1H nuclear magnetic resonance spectroscopy and multivariate statistical methods,
provides biochemical profiles of low molecular weigth proton-containing endogenous
metabolites in biological fluids, without requiring any preselection of measurable
analytes, and allows both the detection of known metabolites as well as the prediction
of unknown metabolites and novel biomarkers.158 Discrimination between asthmatic
children and healthy controls, using the combination of exhaled nitric oxide and
forced expiratory volume in one second had a success rate of 81 per cent, whereas
selected nuclear magnetic resonance signals, corresponding to acetylated and to
oxidized compounds, had a success rate of 86 per cent.158
9.6.3. The measurement of other inflammatory markers in EBC
Although we were primarily focused on the measurement of cytokines and free radicals
in EBC, from a condensate analytical point of view, we concomitantly measured other
inflammatory markers in EBC, including hydrogen peroxide, nitrite, nitrate, condensate
acidity, and 8-isoprostane. However, due to the increasing complexity of our own
research efforts, and due to the fact that several other research groups have addressed
or still investigate the methodology of these specific markers in EBC, we chose to
incorporate the recommendations and workshop proceedings published by the American
Thoracic Society & European Respiratory Society Task Force on EBC,48-49,159 or to take
into account, if possible, new and relevant methodological findings, as listed below.
9.6.3.1.The measurement of hydrogen peroxide in EBC
Superoxide anions (O2
.-) are rapidly reduced to hydrogen peroxide (H2O2) by superoxide
dismutase in several cell types.48,107 In the respiratory system, hydrogen peroxide may be
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released both from inflammatory and structural cells, including neutrophils, eosinophils,
macrophages and epithelial cells.48 The most frequently used methods of measuring
hydrogen peroxide in EBC are the colorimetric and fluorimetric assays, that are based on
the ability of hydrogen peroxide to react with suitable substrates.48 Hydrogen peroxide
is assayed by colorimetry using horseradish peroxidase-catalysed oxidation of
tetramethylbenzidine, as described by Gallati and Pracht.107,160 Using the colorimetric
method, most groups have reported 0.1µM as detection limit.48 The fluorimetric
technique, described by Ruch et alia, uses the reaction substrates 3,3’,5,5’-
tetramethylbenzidine, p-hydroxyphenylacetic acid, scopoletin, phenolsulphonphthalein,
luminol 5-amino-1,2,3,4-tetrahydrophthalazine-1,4-dione or homovanillic acid.107,161
Using the fluorimetric method, the lower limit of detection is 0.1µM, although in one
study this was lowered to 0.0005µM using automated flow injection to detect the
fluorescence of the reaction product.48,113 Recently, an optimisation of this technique by
increasing the buffering capacity of the reaction mix, has been published.105 Hydrogen
peroxide, being highly volatile, evaporates rapidly and therefore, could be trapped by
adding the substrates to the EBC immediately after sample collection and kept frozen
until analysis.107 New techniques, such as online or real-time measurements using
sensitive biosensors have been developed, although the imprecision in the low range is
still high (28 per cent), but declines with higher concentrations of hydrogen
peroxide.104,107
Data on hydrogen peroxide vary considerably, and most of them are even close to
the lower limit of detection.48 Therefore, concern has been raised regarding the
reproducibility of the colorimetric assay, and the use of more sensitive methods is
advised.48,119-123 Furthermore, as already discussed in chapter 9.5, the levels of the
highly volatile hydrogen peroxide in EBC are susceptible to (yet) uncleared
methodological issues that may be attributed to a possible circadian rhythm,110 flow
dependency,115 rapid chemical reactivity,119,125-127 and susceptibility to different cooling
temperatures.109 Day-to-day intra-subject coefficient of variation was 43 per cent in
healthy subjects,48 whereas we reported, in chapter 5, overall coefficients of variation
ranging from 22 to 29 per cent. 
9.6.3.2.The measurement of nitrogen oxides and related products in EBC
Nitrite (NO2
-) and nitrate (NO3
-) are nitrogen redox forms that are present in the
epithelial lining fluid of the human respiratory tract.48,107 The term nitrogen oxides
(NOx) incorporates these two ions, as well as other oxides of nitrogen.48,107
Nitrite and nitrate have been detected in EBC by using spectrophotometric assays
(Griess reaction), a fluorimetric method (2,3-diaminonapthalene (DAN) reaction),
chemiluminescence assays, or ion chromatography followed by conductivity
measurement.48,71-72,162-174 The reported detection limit of the DAN assay is 0.1µM,
and that of the Griess reaction is higher.48 The chemiluminescence technique is
sensitive in the nanoM range.48 Caution must be taken when interpreting nitrite
assays, as the compound cannot be considered stable at low pH, and even at neutral
pH.48 Nitrate is considered stable, whereas its levels tend to be roughly 5 to 10 fold
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higher than nitrite levels, although this may vary in part because of changes in airway
oxidative conditions.48 Most combined nitrite/nitrate assays rely on the formation of
nitrite from nitrate.48 In this respect, enzymatic reduction was found to be better for
nitrate determination in EBC, than cadmium reduction.48,166
Nitrogen oxides are present on every laboratory surface, including glassware and
pipette tips.48 Readily diffusible ambient nitric oxide becomes oxidised and
contaminates surfaces rapidly.48 Therefore, great precautions should be taken to avoid
sample contamination.48 It is necessary to thoroughly rinse with highly pure water, any
material that might come in contact with EBC, including devices used for collection,
processing and assaying EBC.48
The reaction of nitric oxide and superoxide anions in the airways leads to the
formation of peroxynitrite (ONOO-), which is a highly reactive oxidant species.48,107
Peroxynitrite reacts with tyrosine residues of proteins to form the stable product
nitrotyrosine, that may be detected with specific antibodies, using a specific enzyme
immunoassay with a detection limit of 3.9 ng/mL.48,175 However, commercial enzyme
linked immunosorbent assays presumably quantify proteins nitrated at more than one
site, rather than single amino acids.48 Likely this means that nitrotyrosine levels mainly
consist of nitrated proteins.48
Nitrosothiols (RS-NOs) are formed by interaction of nitric oxide or nitrite with
gluthatione or other thiol containing molecules.48,107,176-177 Nitrosothiols can be
measured by colorimetric assay, based on the cleavage reaction of nitrosthiols releasing
nitric oxide, which is then oxidised to nitrite and detected by the assay.48 The detection
limit is 0.025µM.48 A more sensitive method is chemiluminescence analysis after
reduction to nitric oxide in copper-cysteine or by ultraviolet light.48
There are no reported data on day-to-day intra-subject coefficient of variation of
nitrogen oxides.48
9.6.3.3. The measurement of condensate acidity (pH)
Airway pH homeostasis is maintained by a balance of different buffer systems and the
production and release of acids and bases in the airways.48 The acidity of EBC can be
readily measured with pH electrodes and indicator dyes.31,39,48,178 Gas standardisation
(with a carbondioxide-free gas, such as argon and nitrogen) is recommended to
stabilise pH of EBC, as already discussed in chapter 9.4.42,44,48 There is a debate as to
whether orally collected EBC pH reflects acidification of the lower airways, because of
high ammonia content of the mouth.35-37,40,47-48,179-180 The pH of deaerated EBC is not
affected by hyperventilation, duration of collection, duration or manner of storage (up
to two years), and oral versus endotracheal collection.38,48,178 Recently, normative data
for dearated EBC pH in all ages have been published,43 as well as in a prospective
population-based birth cohort of 630 children.45 Reported day-to-day intra-subject
coefficient of variation of deaerated EBC pH is 4.5 per cent, and 5 per cent using non
deaerated EBC pH.41,48,178
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9.6.3.4. The measurement of 8-isoprostane in EBC
8-Isoprostane, a stable prostaglandin-like product, is formed from arachidonic acid by the
nonenzymatic action of reactive oxygen species, and, therefore, it is suggested to be a
proprotional marker of oxidative stress.48,107 Commercial enzyme immunoassays are used
to measure 8-isoprostane in EBC, with a detection limit of 3.9 pg/mL.48,107 The assay was
validated directly by gas chromatography / mass spectroscopy showing high correlation
between added known amounts of 8-isoprostane and the concentration measured with
the assay.48,128 However, reproducibility remains contradictory.48,107 Enzyme immunoassays
may give false values owing to the presence of closely related substances in biological fluids
that may potentially interfere with the assay.107 The potential disadvantage of measuring
isoporstanes is that they are unstable at room temperature or on ice, and rapidly degrade
ex vivo.107 Agents such as lipid peroxidation inhibitors and metal chelators may be added
prior to freezing to stabilise (F2-)isoprostanes.107 A more sensitive and specific method to
assay isoprostane in EBC is gas chromatography / mass spectroscopy.48 Recently, Gonzalez-
Reche et alia presented a validated method for the simultaneous determination of
arachidonic acid metabolites in 1000µL of EBC by liquid chromatography-electrospray
ionisation tandem mass spectrometry, as already discussed in chapter 9.5.106 There are no
reported data on day-to-day intra-subject coefficient of variation whereas we reported, in
chapter 5, overall coefficients of variation ranging from 26 to 48 per cent in healthy adults.48
9.6.3.5. The measurement of prostaglandines and thromboxanes in EBC
Aracidonic acid, released from the cell wall by phospholipase A2, is converted to
prostaglandin endoperoxides by cyclo-oxygenase.48 Endoperoxides are then converted
to prostaglandins, prostacyclin and thromboxane A2.48,181 Thromboxane A2 is rapdily
converted to thromboxane B2, a chemically stable but biologically inactive metabolite,
that can be measured.48
Prostaglandin E2 and thromboxane B2 can be measured by enzyme immunoassay
and by radio immunoassay.48,128,182-185 The specificity of prostaglandin E2
measurement by radio immunoassay has been validated by reverse phase high
performance liquid chromatography.48,128 The detection limit for thromboxane B2 is
13 pg/mL for the enzyme immunoassay, and 13.6 pg/mL for the radio immunoassay.48
Higher thromboxane B2 values were found by radio immunoassay, which is likely
attributable to the 100 per cent crossreactivity of this assay (but not the enzyme
immunoassay) with 2,3-dinor-thromboxane B2.48 The detection limit for prostaglandin
E2 is 8 pg/mL using the enzyme immunoassay.48 There are no reported data on day-
to-day intra-subject coefficient of variation.48
9.6.3.6. The measurement of leukotrienes in EBC
The cysteinyl-leukotrienes (leukotriene C4, leukotriene D4, and leukotriene E4) are
released from inflammatory cells of the airways, in particular mast cells and eosinophils,
and play a role in asthmathic airway inflammation.48,186 Leukotriene B4 is formed from
arachidonic acid as a result of enzymatic hydrolysis of leukotriene A4, a potent
activator of neutrophils and a proinflammatory mediator.48,187 Leukotrienes can be
measured by enzyme immunoassay with detection limit of 15 pg/mL and 4.4 pg/mL,
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respectively.48 The specificity of the immunoreactivity of the leukotriene B4 enzyme
immunoassay was confirmed by using reverse phase high performance liquid
chromatography.48,188 The correlation coefficient for two repeated leukotriene B4
measurements was 0.76.48,188 Reported day-to-day intra-subject coefficient of
variation for leukotriene B4 is 2 per cent in a small group of healthy subjects.48,189
9.6.3.7. The measurement of other markes of oxidative stress in EBC
Aldehydes (malondialdehyde, 4-hydroxyhexanal, 4-hydroxynonenal, hexanal, heptanal
and nonanal) are lipid peroxides which reflect oxidant-induced damage.48,107,190
Conversely, reduced glutathione reflects the antioxidant capacity.48,191 Aldehydes were
detected in EBC using liquid chromatography-tandem mass spectroscopy which had a
detection limit for different aldehydes between 0.31 and 1.07 nM.48,190,192 Glutathione
was determined by high performance liquid chromatography with fluorescence detection,
with a detection limit of 2.0 nM.48,193 Reported day-to-day intra-subject coefficients of
variation for different aldehydes are between 12 and 20 per cent.48,193 There are no
reported data on day-to-day intra-subject coefficients of variation on EBC glutathione.
When interpreting the results obtained for markers of oxidative stress, it should be borne
in mind that malondialdehyde is not a specific product of lipid peroxidation.107 Although
the levels of malondialdehyde and isoprostanes correlate well in vitro, there is 25.000
times more malondialdehyde as compared to isoprostanes, and the in vivo levels of
isoprostanes are 28-fold higher than those of malondialdehyde.107 The level of oxidative
biomarkers in EBC can be affected by diet, smoking, diurnal variation and age.107
9.6.3.8. The measurement of adenosine in EBC
Adenosine is formed during the degradation of adenosine triphosphate (ATP) and has
a wide range of effects in the respiratory system through its specific receptors.48,194
Adenosine can de determined by high performance liquid chromatography, and has
been validated for EBC.48,195,196 The detection limit is 2 nmol/L.48 There are no reported
data on day-to-day intra-subject coefficient of variation, whereas mean intra-day
coefficient of variation is 10 per cent in healhty subjects.48,196
9.6.3.9. The measurement of ammonia in EBC
Ammonia (NH4
+) produced during the urease hydrolysis and/or glutaminase activity in
the airways may have important functions, including pH regulation.29,48 Ammonia is
a volatile compound, and collection temperature and duration influences its level in
EBC.48 Ammonia can be readily measured spectrophotometrically in EBC.29,48 Most of
EBC ammonia arises from the mouth.5,48,182,197 Mean intra-day coefficient of variation
is 60 per cent, with a broad range from 10 to 180 per cent.48
9.6.3.10. The measurement of other molecules in EBC
EBC contains other molecules that can provide important information, such as p53
mutation,198-199 deoxyribonucleinic acid,4,200 hepatocyte growth factor,201 erythropoietin,60
vitronectin, and endothelin-1.202 EBC collection may also be useful for rapid detection of
infectious processes in the lung using polymerase chain reaction technology, such as
tuberculosis.48,200,203
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9.6.3.11. Dilution factor of EBC
The importance of a dilution factor is still being debated, and based on the assumption
that the ratio of liberated solutes to exhaled water vapour is variable.48 A so called
222
Chapter 9
Table 1. State of the art on biomarkers in EBC, including condensate pH, in children with asthma or cystic
fibrosis.
Biomarker in EBC Asthma CF Reference
Hydrogen peroxide ⇑ ⇑ 61,124,209
8-isoprostane ⇑ (-) 92,93,95,99,129
Prostaglandin E2 = (-) 93
Cysteinyl-leukotrienes = / ⇑ (-) 50§,92,95,99,129,189,210*-212
Leukotriene B4 = / ⇑ ⇑ 26,28,99,189,212,213
Nitrite = / ⇑ ⇑ 46,50§,71,72
Nitrotyrosine ⇓ / = / ⇑ = 214‡,215,216
Interleukin-4 ⇑ (-) 24,25
Interleukin-8 (-) ⇑ 28,71
Interleukin-10 = = 51
Interferon-gamma ⇓ / = = 25,51
TNF-alpha = (-) 24
PDGF, VEGF, EGF = (-) 24
MDC ⇑ (-) 26,27
Eotaxin ⇑ (-) 26
Aldehyde ⇑ (-) 193
Glutathione ⇓ (-) 193
Metabolomics † ⇑ (-) 158
Ammonia ⇓ (-) 212,219
Condensate pH ⇓ / = ⇓ 28,45-46,84,217-219
EBC exhaled breath condensate
CF cystic fibrosis
TNF-alpha tumor necrosis factor-alpha
PDGF platelet-derived growth factor
VEGF vascular endothelial growth factor
EGF epidermal growth factor
MDC macrophage-derived chemokine
⇑ significantly increased compared to healthy children
⇓ significantly decreased compared to healthy children
= no significant difference compared to healthy children
(-) no paediatric data
* levels in asthma decreased if treated with montelukast
§ levels in asthma unchanged compared with asthma exacerbation 
† oxidised and acetylated compounds
‡ levels in asthma decreased after treatment with inhaled corticosteroids
dilution factor can be determined from each EBC sample by determining the
concentration of a substance in EBC, which has a well known concentration in sera
and diffuses through the cell membranes, but is not produced in the alveoli or
airways.48 Such a dilution marker would make it possible to calculate the real airway
level of determined mediators in EBC.48 Many attempts have been made.5,197,204-207
The most simple of these is the measurement of conductivity of lyophilised EBC
samples.206 Recently, this method was used by Baker et alia to develop the noninvasive
measurement of breath glucose concentrations.208 These were obtained by multiplying
condensate glucose concentrations by calculated dilution factors (estimated by dividing
serum total cation concentration by condensate total cation concentration).208 They
reported an elevated breath-to-blood glucose ratio in adult patients with cystic
fibrosis, compared to healthy patients and diabetes mellitus patients.208
In Table 1, we provide a state of the art on the current measurements of biomarkers
in EBC, including condensate pH, in children with asthma and cystic fibrosis.
Finally, we want to emphasize again that EBC constitutes a very different matrix than
those employed in ‘conventional‘ research and current clinical practice, and that various
potential biomarkers (yet) have been detected in this exciting matrix. Furthermore, it may
be clear that each of these biomarkers has its own physical, pathophysiological,
biochemical, electrical, and/or even quantum-physical characteristics. Thus, this very
diversity itself is of vital importance to its potential value in noninvasive inflammometry,
but simultaneously, it is the main complicating factor in a smooth and stepwise
advancement of research efforts. 
9.7. Application of new techniques in preschool children
Finally, in chapter 8, we not only demonstrated the feasibility of a novel method to
collect EBC in 70 nonsedated preschool children with and without wheezing illness
(Figure 2). Also, we assessed EBC cytokine profiles, by multiplexed liquid bead array,
in probably atopic asthmatic and nonasthmatic preschool children, and found
significantly discriminating T-helper 2 to T-helper 1 cytokine ratios in EBC.
In children, wheezing is reported in no less than 30 per cent during the first three
years of life.9 In preschool children, wheeze is poorly characterised, and may indicate
a trivial viral cold, as well as an ongoing chronic lung inflammation.9,220 On one hand,
exclusively viral-triggered wheeze accounts for about two-third of wheezy children,
and is characterised by acute episodes associated with viral (upper) respiratory tract
infections.9,220 Between episodes, viral wheeze is not associated with eosinophilic
airway inflammation, which has important therapeutic implications.9 These children
have a good prognosis since 60 per cent will stop wheezing by the early school
years.221 Transient, viral-triggered wheeze is not related to atopy and allergic
conditions, whereas maternal smoking during pregnancy, premature birth and low
birth weight are known risk factors.11 On the other hand, atopic asthma is associated
with a cytokine pattern compatible with predominant activation of the T-helper 2
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Figure 2. Description of the new glass condenser system and exhaled breath condensate collection
procedure. The new system enabled condensate collection in preschool children before and after
breath recirculation.
Description of the new condenser system:
1. inclined and closed glass condenser with a tube length of 90 cm (to enlarge the condensation surface), and
downwards moveable plunger (to optimise condensate recovery from the inner wall of the condenser), with tangential
and axial breath channels (to turbunately direct the tidal breath flows towards the cooled inner condenser wall) 
2. swan-neck tubing (serving as gravitational saliva trap) and two-way nonrebreathing valve, connected to a
face mask with separated nose and mouth cavity (8900 pediatric sizes oro-nasal masks, Hans Rudolph Inc.,
Kansas City, Missouri, USA)
3. entrance of inspired room air
4. cooling unit consisting of a counter-current circulating ice-water pump 
5. removable glass sample vial (to collect exhaled breath condensate)
6. heated (at 37ºC) tubing (to guide the residual noncondensed exhaled breath, and to avoid condensation
outside the condenser tube)
7. humidity sensor and heated (at 37ºC) inert Tedlar™ gas sample bag (to collect all residual noncondensed
exhaled breath)
8. small ventilator system to recirculate the residual noncondensed exhaled breath back into the condenser
system (to allow secondary condensation of exhaled breath)
Description of the new EBC collection procedure:
The child exhaled tidally, as long as possible, through a face mask, with separated nose/mouth cavity, and two-
way nonrebreathing valve (2), that was connected to the glass condenser system (1). During this condensation
process, the formerly lost noncondensed exhaled breath was separately being collected in a gradually inflating
inert Tedlar™ gas sample bag (6-7). When the child ceased this procedure, EBC was collected by pushing
downwards the plunger (1). Subsequently, the plunger was pulled up again (1), and the separately collected
exhaled breath was recirculated (8), from the Tedlar™ gas sample bag (7), back into the condenser system (1),
to perform a secondary breath condensation, until the degree of humidity was ≤ 22%.
mediated immune response,222-223 and is characterised by chronic interval symptoms,
with often an atopic personal or family history.9 Moreover, asthma is a heterogeneous
disease, and diagnosis is hampered by features of the developing child undergoing
(lung)growth, immune maturation and environmental influences.12-13,15
Furthermore, accurate diagnosis is hampered by the current lack of a reliable routine
technique to assess different types of respiratory inflammation in preschool children.
Hence, these confounding issues make it hard to classify a wheezing phenotype
in preschool children unequivocally. 
By consequence, the central issue, in preschool children with different wheezing
phenotypes, consists of finding a noninvasive measure to identify and discriminate
underlying (persisting) airway disease, such as atopic asthmatic airway
inflammation,222-223 from nonasthmatic states, such as recurrent viral wheeze and
healthy children.9,15 Accordingly, statistical anaylsis revealed several significant
differences between probably atopic asthmatic and nonasthmatic preschool children:
tumor necrosis factor-alpha concentrations in EBC were significantly decreased,
whereas the ratios of interleukin-5 to tumor necrosis factor-alpha and interleukin-13
to tumor necrosis factor-alpha in EBC were significantly increased in the probably
atopic asthmatic group, compared to nonasthmatics. This is in accordance with the
results of Shahid et alia, who reported an increased ratio of interleukin-4 to interferon-
gamma in EBC in asthmatic children, aged 4.5 to 17 years.25 These findings may
provide evidence for early skewing of the T-helper 2 to T-helper 1 balance in favour
of an allergy-promoting T-helper 2 response.222-223
Although an accurate and firm asthma diagnosis cannot be proven in this young
paediatric age group, a reasonable accuracy can be obtained using simple, clinically
based parameters, as demonstrated by Castro-Rodriguez et alia.224 They developed
two clinical indices for the prediction of asthma, based on the Tucson Children’s
Respiratory Study.224 A stringent index included frequent wheezing during the first
three years of life, and either one major risk factor (parental history of asthma or
eczema), or two out of three minor risk factors (eosinophilia more than 4 per cent,
wheezing without colds, and allergic rhinitis).224 A loose index required any wheezing
during the first 3 years of life, plus the same combination of risk factors described
previously.224 Children with a positive loose index were 2.6 to 5.5 times more likely to
have active asthma between ages 6 and 13, than children with a negative loose index.
Risk of having subsequent asthma increased to 4.3 to 9.8 times, when a stringent
index was used.224 Furthermore, they reported that 59 per cent of children with a
positive loose index, and 76 per cent of those with a positive stringent index had active
asthma in at least one survey during the school years.224 Over 95 per cent of children
with a negative stringent index never had active asthma between ages 6 and 13.224
Therefore, the phenotypic classification of probably atopic asthmatic preschool
children, in our study, was carefully assessed on basis of parentally reported symptoms
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including recurrent wheezing that was not ‘exclusively’ viral triggered, a documented
positive response on (inhaled) corticosteroids, and medical records and information of
the responsible paediatric pulmonologist on the presence of allergic sensitisation in
these children, and a positive family history of atopy in the first degree. Hence, it is
likely that these children had ‘true’ allergic asthma. Furthermore, support for an
accurate asthma diagnosis comes from the significantly elevated T-helper 2 to T-helper
1 ratios in the probably atopic asthmatic group, compared to the nonasthmatic
children in this study. 
In conclusion, we demonstrated the feasibility of a novel method to collect EBC in
preschool children, and subsequently assessed significantly elevated ratios of T-helper
2 to T-helper 1 cytokines in EBC in probably atopic asthmatic preschool children,
compared to nonasthmatic preschool children.
9.8. What do we add ? 
In this thesis, we described the development of EBC into a feasible and highly efficient,
noninvasive method to assess, in children of all ages, various biomarkers of
inflammation and oxidative stress. EBC is a bi-phasic technique implicating the cooling
of exhaled breath to collect the condensate, and subsequently, the analysis of the
collected condensate. 
The first part of this thesis focused on EBC collection. Initially, condensate was
collected using a wide diversity of condenser designs (as reviewed), including a
borosilicate glass distilling column, as used in two - early - cross sectional studies in
children, aged 5 years or more, with asthma and cystic fibrosis, respectively.
Subsequently, we demonstrated that a borosilicate glass condenser was more efficient
to measure 8-isoprostane and albumin in EBC, compared to five other condenser
types. We mainly attributed this signifcant difference to distinct adhesive interactions
between the inner condenser coatings and the exhaled biomarkers. Accordingly, glass
was used as basic material to further optimise the condensation process. Hence, we
presented an open glass condenser system with enlarged condenser surface, improved
condensate recovery using an inclined condenser tube setting and a condensate
sweeping plunger, with several tangential and axial breath flow channels to guide
exhaled breath towards the cooled inner condenser wall (as shown in Figure 1). We
demonstrated, in healthy adults, that the open glass condenser not only yielded
significantly more EBC volume, but was also associated with more detections of
hydrogen peroxide, 8-isoprostane, and several cytokines in the collected EBC, than
other condenser types. Succeedingly, the condenser system was modified for use in
preschool children. For this purpose, the glass condenser was closed with an unique,
heated (at 37 degrees Celsius), breath recirculation system, in such a way that the
formerly lost noncondensed exhaled breath was separately being collected in a
gradually inflating inert Tedlar™ gas sample bag (as shown in Figure 2). When the
child ceased the ‘usual’ EBC collection procedure, the separately collected exhaled
breath was recirculated, from the gas sample bag, back into the condenser system, to
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perform a secondary breath condensation. This new concept of EBC collection before
and after breath recirculation, allowed condensation of the totally exhaled breath
volume, whether gathered after only a few minutes of EBC collection, or after a
prolonged period. Moreover, this concept enabled the collection of significantly more
EBC volume compared to the ‘usual’ (before breath recirculation) procedure, whereas
in toddlers with limited cooperation in time, breath recirculation was often crucial to
yield minimal but sufficient condensate volume (to analyse for biomarkers).
Cumulatively, the success rate was 83 per cent in preschool children with and without
wheezing illness. Furthermore, we demonstrated that all cytokine concentrations in
EBC, collected before and after breath recirculation, were comparable, which
illustrated the efficiency of the new method of EBC collection in preschool children.
The second part of this thesis focused on EBC analysis. Initially, an increasing number
of biomarkers were detected (or not) in EBC, using a wide diversity of conventional
assays (as reviewed). Incidental reports on detected biomarkers included hydrogen
peroxide, nitrogen oxides, eicosanoids, (three) cytokines, and aldehyde/gluthatione (as
reviewed). EBC consists of respiratory droplets with volatile and (mainly) nonvolatile
macromolecules that are released from the epithelial lining fluid of the airways, and than
‘drowned’ in an excess of water vapour. Moreover, many different condenser designs
were in use, and most conventional assays were not appropriate for use in this new
medium as they were lacking sufficient sensitivity. Not surprisingly, biomarker
reproducibility was often poor, and sometimes even highly questionable. Several research
groups addressed these issues for specific biomarker measurements mainly by
introducing analytical modifications, and/or by exploring in various study populations.
Meanwhile, we demonstrated a significant interaction between the method of EBC
collection and its subsequent analysis, and found glass condensers more efficient (as
stated above). Also, we focused on the measurement of cytokines, as potentially highly
interesting markers of airway inflammation in EBC, and on free radicals, as ‘almost’
direct markers of oxidative stress. On one hand, we tried to detect cytokines in large
EBC samples by means of conventional specific assays, however without successful
cytokine detection. Subsequently, we used multiplexed cytometric bead array to measure
simultaneously different cytokines in small EBC samples, and reached a level of detection
of nearly 50 per cent, in five out of six assayed cytokines. Succeedingly, we were able
to increase the cytokine detection level at 95 to 100 per cent, in all (eight) assayed
cytokines, by introducing multiplexed liquid bead array. On the other hand, we were also
interested in markers of oxidative stress in EBC. We demonstrated the presence of free
radicals in EBC by means of electron paramagnetic resonance spectroscopy, although
this procedure is not likely suitable for future routine use. However, the presence of these
free radicals in EBC may provide some further evidence for its reflection of the airway
lining fluid.
The final part of this thesis focused at the clinical application of EBC. The cross
sectional childhood asthma study showed low correlations between single exhaled
inflammatory markers and conventional asthma measures. In children with cystic
fibrosis, other exhaled inflammatory markers, including exhaled nitric oxide, were
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differently combined into several specific profiles, and were able to indicate diagnosis,
exacerbation, and (to a lesser extent) disease severity, though confirmation in a
longitudinal context is needed. In preschool children with and without different
wheezing phenotypes, the new closed glass condenser with breath recirculation
system, and multiplexed liquid bead array were used to assess T-helper 1 and T-helper
2 cytokine profiles in EBC. Hence, we demonstrated – noninvasively – significantly
elevated T-helper 2 to T-helper 1 cytokine ratios in probably atopic asthmatic preschool
children, compared to nonasthmatic children.
In summary, the noninvasive methodology of EBC collection and analysis has
developed into a feasible and highly efficient method, that enabled noninvasive
inflammometric profiling in nonsedated preschool children with different wheezing
phenotypes. We believe that noninvasive inflammometric profiling will contribute to
an improvement of diagnosis and customised care in children of all ages with chronic
respiratory disease, whereas this inevitably will generate new insights that may
ultimately lead to alter some of the previously agreed disease management strategies.
9.9. What may or should be ?
Obviously, the need for a standardised EBC methodology is incontestable.48-49,159
Although substantial progress has been made by improving and adapting the
condenser system, as well as by introducing new ultrasensitive analytical techniques,
some issues still remain unresolved and await proper investigation, as listed below.
More than ever, the joint American Thoracic Society & European Respiratory Society
Task Force on EBC should diversify research efforts according to these issues, and
coordinate multicentre research groups respectively.
(i) the origin and physiology of EBC
(ii) biomarker-tailored EBC collection method(s) and procedure(s)
(iii) subject-tailored EBC collection method(s) and procedure(s)
(iv) international consensus for methodological standardisation
(v) identification of biomarker profiles in different respiratory disorders
(vi) application in longitudinal noninvasive inflammometric clinical trials
(vii) validation of biomarker profiles through correlation with conventional direct
measurements of inflammation, pulmonary function tests, and symptoms
(i) The anatomical origin and (patho)physiology of EBC remains to date largely
unknown. Increasing insights in the mechanisms regulating the formation of EBC, including
the exact anatomical sites of EBC particle formation, the influence of temperature,
exhalation flow, salivary contamination,225 and respiratory physiology itself,226-228 as well
as the so-called ‘dilutional’ effects of water vapour on the content of EBC, including a
possible marker of solubility,5,197,208,229-230 may contribute to an improvement of the EBC
collection procedure resulting in adequate sample acquisition, and may clarify whether
measurements should be standardised according to dilution, and/or expired breath volume,
or not. Hence, these understandings may contribute to improved reproducibility. 
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(ii) A biomarker-tailored EBC collection method and procedure implicates, at
least, that for each type of marker the most valid condenser system is used, as well
as the implementation of ‘nano-molecular’ analytical techniques that offer the best
sensitivity and reproducibility. We advise the use of glass condensers to measure
cytokines and 8-isoprostane in EBC. Furthermore, we advise the use of multiplexed
liquid bead array to measure cytokines in EBC. However, it is not yet possible to give
such recommendations for the measurement of other markers, as the possible
influence of condenser coating and analytical technique are yet unknown.
(iii) A subject-tailored EBC collection method and procedure should be further
modified for use in all ages, including newborns, as well as for use in ventilated
subjects, including prematurely born infants prone to bronchopulmonary dysplasia.
(iv) International consensus for methodological standardisation of a particular
EBC methodology and procedure for a given type of biomarker may be achieved
through integration of both biomarker-tailored and subject-tailored EBC methodology.
(v) Identification of potentially specific and useful profiles of noninvasive
biomarkers, measured in EBC and/or exhaled air, in different respiratory diseases. The
combination of several noninvasive markers may provide additional information, as
shown in the cross sectional cystic fibrosis study. Exempli gratia, Battaglia et alia
reported the association of FeNO and 8-isoprostane in EBC, with small airways
function assessed by the single breath nitrogen test, in steroid-naïve mild adult
asthma, suggesting that these combined markers reflect small airway inflammation,
and favouring for them a complementary role to spirometry in the monitoring of
asthma.231
Also, this disease profile identification step may include a more general approach
using factor analysis, which can help to reduce a large number of disease features, in
casu biomarkers in EBC and other conventional or new disease measures, into a
relatively small number of independent factors, and thus, grouping associated or
correlated features.26 Factor analysis is essentially free of a predetermined hypothesis
on any interrelated features (or biomarkers), and thus, factor analysis can be viewed
as a hypothesis generating tool.26 
Subsequently, cluster analysis may be used to detect clusters among a sample of
individuals.9,232 Cluster analysis encompasses a number of different algoritms and
methods for grouping objects of similar kind into respective categories.232 A general
question facing many researchers, is how to organise observed data into meaningful
structures. Cluster analysis is an exploratory data analysis tool which aims at sorting
different objects into groups in a way that the degree of association between two
objects is maximal if they belong to the same group and minimal otherwise.232 Given
the above, cluster analysis can be used to discover structures in data without providing
an explanation or interpretation.232
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We deal with clustering in almost every aspect of daily life.232 Exempli gratia, the way
food and beverage are displayed in supermarkets. Also, according to the modern
taxonomical system employed in biology, man belongs to the primates, the mammals,
the amniotes, the vertebrates, and the animals.10,232 Note how in this classification,
the higher level of aggregation the less similar are the members in the respective
class.232 Cluster analysis is not as much a typical statistical test as it is a collection of
different algorithms that put objects into clusters according to well defined similarity
rules.232 Cluster analysis methods are mostly used when we do not have any a priori
hypotheses, but are still in the exploratory phase of our research.232 In a sense, cluster
analysis finds the most significant solution possible.232 In general, whenever one
needs to classify a mountain of information into manageable meaningful piles, cluster
analysis is of great utility.232
Hence, cluster analysis may detect clusters of correlated disease features,
comprising biomarkers in EBC and other conventional or new disease measures,
among a sample of individuals.9,26,232-235 Succeedingly, the utility of these clusters can
be evaluated in clinical practice, which may accordingly lead to refining of the disease
model or profile.9,26,232-235
(vi) Application of exhaled biomarker profiles in longitudinal noninvasive
inflammometric clinical trials. This requires the establishment of normal variations and
age-dependent reference ranges in healthy control children, and an evaluation of the
best sensitivity and specificity for each profile of biomarkers in healthy children and
children with respiratory disease. 
As correlation analysis in cross sectional observations cannot prove either the
presence or the direction of causality, longitudinal clinical studies need to evaluate
these different profiles of markers in the monitoring of various respiratory disorders.
This includes an evaluation of their potentially predictive value for response to
treatment, and exacerbation or relapse of disease, as well as their correlations with
exhaled nitric oxide, pulmonary function tests and other conventional measures of
disease control, such as symptom score, usage of rescue medication and quality of life
questionnaires. 
Ultimately, this may lead to the inclusion of noninvasive inflammometric profiling
into specific management guidelines, and thus, enable future individualised
therapeutic strategies.
(vii) Validation of biomarker profiles through correlation with direct measurements
of inflammation, including induced sputum, bronchoalveolar lavage and endobronchial
biopsies. Recently, Fireman et alia demonstrated a differential pattern of inflammation
assessed by induced sputum eosinophil count and colorimetric measurement of
hydrogen peroxide in EBC in adult patients with obstructive compared to restrictive
lung diseases and persistent cough.236 Moreover, Fireman et alia reported no detectable
levels of hydrogen peroxide in EBC in subjects with interstitial lung disease, in contrast
to adults with obstructive lung disease, hence suggesting evidence for the specificity
of hydrogen peroxide measured in EBC, which is mainly derived from the airways or
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bronchial compartment, and only to a lesser extend from the alveolar compartment.236
Jackson et alia reported no correlation between markers (in casu 8-isoprostane,
hydrogen peroxide, total nitrogen oxides, acidity, total protein, total phospholipid and
keratin) in EBC and bronchoalveolar lavage, in 49 adult patients undergoing
bronchoscopy for diverse reasons, including lung transplantation.237 Gessner et alia
reported no siginificant correlations between cytokine levels (in casu interleukin-1-beta,
interleukin-6, interleukin-8, interleukin-10, interleukin-12p70 and tumor necrosis
factor-alpha) in bronchoalveolar lavage fluid and EBC in a limited population of 14
adult subjects with an acute exacerbation of chronic obstructive pulmonary disease,
requiring bronchoalveolar lavage for microbiological reasons.57 On the other hand, Lex
et alia reported, in a subgroup of asthmatic children who were not treated with
montelukast (but with high doses of inhaled and/or systemic steroids), a significant
relationship between cysteinyl leukotrienes in EBC and reticular basement membrane
thickening in endobronchial biopsies.210 Obviously, these findings are highly intrigueing,
whether positive or negative, however, we strongly insist upon cautious interpretation
in view of the many currently not (yet) standardised aspects of EBC methodology. To
state once more, the need for standardised EBC methodology is incontestable, and
should primarily and urgently be addressed using a coordinated multicenter approach.
Finally, we also want to point out that trained household dogs were able to detect
biopsy-confirmed lung and breast cancer with 0.99 and 0.88 specificity, respectively.238
Currently more than 500 trace compounds in exhaled breath are known as volatile
organic compounds (VOCs).239 Volatile organic compounds can be produced anywhere
in the body, and are transported via the bloodstream, and exhaled through the
lung.240 Therefore, looking at a set of volatile organic compounds may enable
recognition and monitoring of different complex processes in the body.239 However,
to date, huge variations exist between results of different studies, due to lack of
standardisation, and associated technical problems of sampling and (automated and
real time) analysis.239-242
Thus, noninvasive inflammometric profiling may ultimately encompass the
assessment of various biomarkers in EBC, with concomitant volatile organic compounds,
and may lead to the routine use of individual breathograms that may guide customised
management strategies in chronic respiratory disorders and beyond …  
9.10. Epilogue
To recapitulate, Penelope’s heart may not yet have been conquered entirely, but this
thesis offers at least an improved EBC methodology, and thus, a spark of new
perspectives for the management of both the younger as well as the older children with
chronic respiratory inflammation. Methodological standardisation of EBC collection
and analysis remains a prerequisite, and future investigations will demonstrate whether
accurate diagnosis and customised care for all children with chronic respiratory
inflammation can be achieved by additional routine noninvasive inflammometric
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profiling. In that way, EBC may prove to be the mythological Ianus bifrons,1 the old
roman god with two foreheads or faces, as shown on the back cover of this thesis, and
often depicted with two keys, one closing the gateway of the past, the other one
opening the gateway of the future …
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